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Abstract 
Peripheral nerve trauma remains a major cause of morbidity, healthcare expenditure, and social 
disruption, largely because the death of up to 50% of primary sensory neurons ensures that sensory outcome 
remains overwhelmingly poor despite major advances in surgical technique. Hence the principal aim of this 
project was to identifY novel, clinically applicable strategies for the prevention of sensory neuronal death 
after peripheral nerve injury. 
After a defined unilateral sciatic nerve transection in the rat, a novel triple staining technique was 
employed in order to enable the detection of neuronal death in L4 & L5 dorsal root ganglia by light 
microscopic morphology, and TdT Uptake Nick-End Labelling (TUNEL). Optical disection was then used to 
quantifY neuronal loss from statistically unbiased estimates of the number of surviving neurons. 
Neuronal death was demonstrated to begin within 24 hours of injury and to peak 2 weeks later, 
while neuronal loss plateaued 2 months after axotomy, and 39.2% of neurons died overall. Thus the most 
relevent experimental timepoints at which to examine the effects of putative neuroprotective strategies are 2 
weeks and 2 months after axotomy, until which time a window of opportunity exists for therapeutic 
intervention. 
The principal that sensory outcome might be related to the delay between injury and nerve repair 
was confirmed by the fact that although surgical nerve repair reduced neuronal death 2 weeks after axotomy, 
the neuroprotective benefit depended upon how soon after injury the nerve was repaired. Even immediate 
repair did not entirely eliminate neuronal loss, confirming the need for an adjuvant therapy. Hence the effect 
of two promising agents with established clinical safety records was examined. N-acetyl-cysteine (NAC) is a 
clinically proven glutathione substrate with antioxidant, and anti-mitotic properties. Systemic treatment 
caused a dose-dependent improvement in neuronal morphology, a significant reduction in the number of 
TUNEL positive neurons 2 weeks after axotomy (p<0.05), and 2 months after axotomy it was found to have 
reduced neuronal loss from 35% to only 3% (p<0.001). L-acetyl-carnitine (LAC) is a physiological peptide 
integral to mitochondrial aerobic glycolysis that was found to be even more neuroprotective than NAC, since 
after LAC treatment no neuronal loss was detected 2 months after axotomy (no treatment 35% loss; high-
dose LAC -4% loss, p<O.OOl). 
LAC was also found to promote peripheral nerve regeneration (p<0.05) independently of its effect 
upon neuronal survival, suggesting an additional role in the treatment of chronic peripheral nerve 
pathologies. This was confmned by a small clinical trial using immunohistochemical quantification of 
cutaneous innervation in nucleoside analogue related distal symmetrical polyneuropathy (DSP) in HN 
disease. Innervation was found to be reduced in established DSP, but after 6 months of oral LAC treatment 
(l500mg b.d.) substantial increases were found (up to 599% for some fibre types). Small sensory (C, A8) 
fibres showed the greatest response to treatment, and innervation with some fibre types returned to the same 
level as that found in asymptomatic HN negative controls. 
Given its demonstrated neuroprotective potential, and ability to promote peripheral nerve 
regeneration in both experimental and clinical settings, LAC is proposed as the first agent clinically suitable 
for the adjuvant pharmacotherapy of peripheral nerve trauma. If current clinical trials are successful, then 
LAC may also have potential in spinal cord and traumatic brain injury, and in a wider range of 
neurodegenerative disorders with dysfunctional mitochondrial bioenergetic aetiologies. 
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Chapter 1. Introduction 
No adult with a major nerve transection has ever attained normal sensibility. 
De Medinacelli & Seaber 
1.1 The Clinical Problem: Sensory Outcome After Peripheral Nerve Trauma 
In Europe the incidence of peripheral nerve trauma is estimated at 111000, although 
there is considerable local variation depending upon the preponderance of heavy industry 
and mechanised agriculture. This means that throughout Europe approximately 300,000 
peripheral nerve injuries occur each year, of which ~60,000 are in the U.K. Peripheral 
nerve injuries are typically sustained by adults of working age, many of whom are skilled 
manual workers, and injuries may vary from the relatively minor (e.g. isolated distal digital 
nerve in the non-dominant hand) to the functionally devastating (e.g. brachial plexus 
avulsion in the dominant limb). 
Surgical repair remains the defmitive treatment, but despite considerable advances 
in surgical technique 1-7 cutaneous innervation does not return to normal 8, and clinically 
the sensory outcome remains sufficiently poor 5,6,9 that "despite the application of 
meticulous techniques to peripheral nerve repair, no adult with a major nerve transection 
has ever attained normal sensibility" 10 " ... and normal restoration of function after 
significant nerve injury remain unattainable ideals" 7. This is the case even in the best of 
scenarios, outcome is even worse in complex nerve injuries 5,11, and in those requiring 
nerve grafting 2,5,11,12 or a significant delay before repair 4,5,11,13,14. Sensory outcome also 
impacts adversely upon motor outcome, particularly in fine manipulative work 15, since 
adequate proprioceptive feedback is a vital component of normal motor control 16. 
Otherwise minor injuries, such as small lacerations, can therefore cause extreme 
disability if they injure a nerve, and may result in loss of employment and dependence 
upon others. As a result, peripheral nerve trauma is a significant cause of morbidity, 
healthcare expenditure, social disruption and lost employment 6. In order to identify the 
factors underlying the poor sensory outcome of peripheral nerve injuries, it is necessary to 
consider the normal structure of the peripheral nervous system, and the ways in which its 
various components react to injury and repair. Although a variety of factors are implicated 
5,17,18, it is likely that the single most important determinant of poor sensory outcome is the 
extensive primary sensory neuronal death that occurs (cf. 1.4), since quality of sensation is 
dependent upon the number of innervating neurons and the size of their receptive fields 
17,19 
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1.2 Peripheral Nerve Injury, Repair & Regeneration 
Most peripheral nerve injuries are caused by direct mechanical trauma, whether by 
crush injury (causing ischaemia and interruption ofaxoplasmic flow), transection (partial / 
complete), traction, or avulsion 20-24. Other mechanisms include thermal injury, 
neurotoxins 5,21, metabolic disorders 25, and as a complication of drug therapy 26. 
Nerve transection is accompanied by haemorrhage, retraction of the nerve trunk 
due to its intrinsic elasticity, and mushrooming of neural contents from the cut ends. An 
inflammatory reaction occurs causing fibrin deposition, scarring, and release of neurotoxic 
cytokines such as TNFa. Intra-neural fibrosis begins within the endoneurial sheaths of the 
distal nerve stump 28-35 days after transection 11, reducing their calibre and impeding any 
subsequent regeneration. Marked fibrosis occurs within 3-6 months of injury, and is 
complete by 12 months in the rat 27,28. Endoneurial tube diameter is reduced to 26% of 
control one year after transection 27, and after 2 years to only 1 % in man 11. 
Peripheral nerve injuries may be defined as proximal or distal, or by their 
anatomical site and mechanism. Injuries are clinically graded as "neuropraxia", 
"axonometsis", or "neurometsis" as progressively more disruption ofthe normal neural 
anatomical structure occurs 20, or into Grades 1-5 ifmore detailed consideration of the 
fascicular disruption is made 21,29. Nerve repairs can also be classified by technique and 
timing, and the temporal classification given by Green 11 has been adopted in this thesis. 
Primary repairs are those performed within 48 hours of injury, early secondary repairs 
between 2 days and 6 weeks after injury, and late secondary repairs between 6 weeks and 6 
months after injury. 
Current clinical management of peripheral nerve injuries remains based upon direct 
microsurgical nerve repair by either epineurial or fascicular suture, with autologous nerve 
grafting reserved for those injuries that cannot be repaired without undue tension 5,6. Axons 
begin to sprout 17 after a delay of around 3-14 days 5,11 after peripheral nerve injury and 
repair, during which time the perikaryal injury response occurs 30,31 (el 1.3). Nerve fibres 
grow by sprouting ~50-1 00 neurites that advance through the repair site only to be pruned 
down to around 5 neurites per parent axon when the endoneurial tubes of the distal stump 
are reached 17. Neurite growth is facilitated by contact guidance from matrix proteins 32 
and cellular adhesion molecules, such as those found upon Schwann cells 33. Neurotropic 
guidance up the concentration gradients of nerve growth factor (NGF), leukaemia 
inhibitory factor (LIF), glial derived neurotrophic factor (GDNF), and other diffusible 
molecules also causes preferential neurite growth into the distal stump 34,35. Axons 
regenerate at around 0.25mm1day when crossing the repair site, and then at 1-8.5mmlday 
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in distal stump. The rate of regeneration is inversely proportional to distance from the cell 
body 11, but an overall figure of Imm1day is widely accepted in clinical practice 5. 
Target organs atrophy during the period of denervation, but the sensory organs fare 
somewhat better than muscle 11. In the skin Merkel's discs disappear by 35 days in the cat 
36, Meissner's corpuscles persist for 6 months before degenerating 22, and although 
Pacinian corpuscles atrophy, they survive for at least 10 months in the rat 37. The extent of 
target sensory organ reinnervation after peripheral regeneration is difficult to quantify and 
few studies exist, however clinically it is clear that after any nerve repair the functional 
outcome is markedly worse than normal, and that outcome is even worse after chronic 
injuries. These injuries correspond to those which require a diagnostic delay 6 or which 
cannot be repaired early due to co-morbidity 11, and to nerve repairs which fail, in which 
case the need for re-operation is often not discovered for many months 5,6. There is also 
some correlation with proximal injuries in long nerves undergoing primary repair, since 
there is a considerable delay until regenerating axons reach the periphery and the distal 
segment therefore remains chronically denervated 17. This is also the scenario in chronic 
die-back neuropathies such as those found in diabetes and in nucleoside analogue reverse 
transcriptase therapy (NRTI) associated distal symmetrical polyneuropathy (DSP), which 
is the commonest form of neuropathy in HIV disease 26. 
Outcome is even worse in chronic nerve injuries, not only as a result of denervation 
atrophy but also because, after eventual repair, axonal regeneration to the target organs is 
impaired. In clinical practice it has long been recognised that, when compared to primary 
repair, the outcome is markedly worse if nerve repair is significantly delayed 5,11,17, 
particularly with delays of6-12 months or more 17,38,39. Fibrosis and narrowing in the 
endoneurial sheath 40,41 were cited as the cause of poor regeneration 5,11,28 since it was 
assumed that "that the regenerative capacity ... [of individual neurons] ... is maintained as 
long as cell death does not occur" 42. However this assumption may be false, given the 
changes in neurotrophin secretion and receptor profiles of neurons and Schwann cells 40,43, 
and experimental evidence exists for such a loss of regenerative capacity in the rat 13 and 
rabbit 41. 
Despite occasional reports of the return of some function after delays of up to 22 
years 3,11,21 it is now clear that primary repair gives the best outcome 44,45, and the general 
consensus is that the timing of nerve repair should be as follows 6,11. Nerves are repaired 
primarily where possible, however early secondary repair may be more appropriate when 
tissues are significantly devitalised, contused, or contaminated, and in the case of a 
complex wound requiring other bony or soft tissue repair. Late secondary repair after a 
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delay of up to 4 months is appropriate for certain wounds caused by high velocity 
projectiles. Also, it may be appropriate to wait up to 3 months in closed injuries where it is 
uncertain whether neurometsis has occurred, in order to exclude a more simple injury not 
requiring surgery. 
In the rat, complete loss of regenerative capacity has been demonstrated through 
denatured muscle grafts after more than 56 days delay, and any delay impaired myelination 
13. In the distal stump conditions for regeneration begin to deteriorate after 10 weeks, 
Schwann cells begin to atrophy after 20 weeks, to disappear after 30 weeks, and by 50 
weeks there is severe Schwann cell atrophy, and endoneurial fibrosis 28. Mean fascicular 
area falls by 39% after 3 months, 64% after 6 months, and 79% after 12 months, with 
comparable reductions in endoneurial tube diameter 27. Glial Growth Factor (GGF) 46 is the 
principal neuregulin controlling the interaction between Schwann cells and ingrowing 
axons 17,47,48, and after delays of more than 2 months distal stump Schwann cells begin to 
lose expression of c-erbB2&4 43 making them unresponsive to GGF 43. Neurons also lose 
expression of the regenerative neuropeptide GAP-43, and ifrepair is delayed by 2 months 
or more then the amount of axonal ingrowth into the distal stump found 28 days later is 
approximately half that found after an immediate repair 43. 
It is evident that in the rat, with delays of greater than 2 months before nerve repair, 
regenerative capacity diminishes coincident with increased endoneurial fibrosis and a 
decrease in Schwann cell numbers and neurotrophin responsiveness. Similar changes 
within the endoneurium, and in the number and morphology of distal stump Schwann cells 
have been documented in human nerves 8-53 months after injury 40. 
1.3 Cellular Events After Nerve Injury 
Axonal injury briefly exposes the intracellular compartment to the extracellular 
milieu 49, until calcium dependent restoration ofaxolemmal continuity occurs 50 and the 
axon retracts proximally, to the next node of Ran vier in myelinated nerves 11,28,47, as part of 
the process of soma tofu gal axonal atrophy 35. Distal to the injury axons undergo Wallerian 
degeneration 5,11,47, detach from their myelin sheath 47, and are phagocytosed by 
macrophages and activated Schwann cells 27,47,48,51. The Schwann cells recycle myelin 
proteins and cholesterol under the influence of Apolipoprotein E from activated invading 
macrophages 51, and in the rat sciatic nerve the whole process is completed within one 
month 27. 
The axotomised neurons display a stereotyped perikaryal injury response pattern, 
termed chromatolysis 52, which involves Nissl body displacement 5,11,30,31,47, nuclear 
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condensation and peripheralisation 30,31,53, and perikaryal swelling that ftrst occurs after 1 
day, and then recurs after 8-11 days 31, Metabolically active mitochondria accumulate 
within the cell body 53, central processes retract 54, and by 4 days after axotomy the cell has 
shrunk 30,55 to 113 of its normal volume 55, Conversely, some neurons develop a grossly 
dilated~ vacuolated morphology that has been ascribed to a regenerative phenotype 56,57, 
Profound changes occur in the DRG neuron phenotype as seen by alterations in 
mRNA transcription 58-63, protein synthesis 64-69, growth factor and cell receptor profIles 
43,47,48,61,70-74, the secretion of neuropeptides and neurotrophic factors 47,67,68,70,72,75,76, and in 
the cells' electrophysiological properties 77,78, Axonal transport ofneuropeptides 61 and 
structural proteins 69,79 is altered, more so by a transection than a crush injury 80, Given the 
important role of target-derived neurotrophic factors in neuronal survival and regeneration 
7,17,47,81,82 it is of note that after injury NGF, GDNF, neurotrophin-3 (NT-3), and BDNF are 
retrogradely transported to sUbpopulations of cells with differing mean diameters 47,83,84, 
The receptor-mediated uptake and retrograde transport ofLIF by a separate subpopulation 
of small diameter neurons 47,85,86 increases 84,87, and an increased range ofDRG neurons 
markedly increase their uptake and retrograde transport of ciliary neurotrophic factor 
(CNTF) 84,88, 
Similarly, glial cells are also affected by a peripheral nerve injury, NGF, LIF, 
GDNF, and GGF receptor (p185erbB2/neu) mRNA is upregulated in the nerve trunk 
48,58,69,87,89, while glial cells in the DRG also upregulate GDNF mRNA after chronic nerve 
transection 89, Schwann cells increase NGF, BDNF, NT4 and LIF secretion 47,48,51,69,87, and 
damaged ones are an important source of CNTF 48,69,88, Intimately related to the axons in 
normal peripheral nerves, Schwann cells are essential for the guidance and support of 
regenerating axons after injury 17,48,90,91, and following axotomy those in the distal stump 
shrink away from the endoneurium to form solid columns, the "Bands ofBungner" 27,40, 
Some will also die 27 by apoptosis 92, particularly if denervation is prolonged 27, After an 
initial period of proliferation, and upregulation of c-erbB2&4 (parts of the GGF receptor 
complex) 43 under the influence of macrophage derived IL-1 47,51,69, Schwann cells begin to 
atrophy, and become unresponsive to GGF due to loss of c-erbB2&4 expression after 2-6 
months of denervation 43, Schwann cells appear to require axonal contact for prolonged 
survival 27,40, and profound atrophy and cell death occurs 20-50 weeks after denervation 28, 
Secretion of IL-1 by both resident and invading macrophages is vital for Schwann 
cell activation and proliferation 69, and macrophage invasion appears to be essential for 
Wallerian degeneration 51, Macrophages in the DRG are also activated by peripheral nerve 
injury 93, and this has been shown to promote nerve regeneration in vivo 94 and vitro 95, 
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1.4 Axotomy Induced Cell Death Within the Dorsal Root Ganglia 
It has been recognised since the early 1900's that experimental nerve injuries lead 
to primary sensory neuronal death 57,96,97, and more recently this has been confmned by the 
demonstration of DNA fragmentation within individual neurons in vivo 92,98-102, It is now 
apparent that a considerable proportion of all neurons in the sensory pool will die 17,47,103, 
with estimates ranging from 7 to 50% 55,57,98,102,104-110 depending upon the exact nature of 
the experimental model. A similar magnitude of sensory neuronal loss has also been found 
to occur in higher mammals 111,112, for example neuronal loss after permanent division of 
the radial nerve was ~40% in the cat 113, and 27% in the macaque monkey 114, A similar 
loss has also been demonstrated clinically in post-mortem studies 115, and sensory neuronal 
death does appear to correlate with loss of sensory function since a significant loss of 
functioning sensory units has been demonstrated electrophysiologically 19, 
Neuronal loss appears to be less after crush injuries or when the transected nerve is 
immediately co-apted 116,117, However these findings may merely represent an effect upon 
horseradish peroxidase transport rather than cell death 117, and the effect of the timing of 
nerve repair upon neuronal death has not been fully investigated despite its obvious clinical 
significance, 
It has been proposed that proximal injuries are more likely to induce neuronal death 
than distal ones, This certainly seems to be the case for motomeurones, which die only 
after very proximal lesions 17, but the evidence is less clear for sensory neurons which are 
far more sensitive to the effects of peripheral axotomy 47, Ygge did demonstrate a 27% loss 
ofL4-6 DRG neurons after sciatic nerve transection in the thigh, as opposed to 7% loss 
after a lesion in the calf 118, however the sciatic nerve contains afferent fibres from 
approximately 19,000 neurons in the thigh 119, but from only ~5,000 in the calf 116, Since 
neuronal loss is calculated as a percentage of the total number of neurons in the ganglia, 
the fourfold difference in loss may largely be due to the distal lesion having axotomised 
only a quarter of the number of neurons injured by the proximal lesion, This would imply 
that a substantial proportion of the primary sensory neurons whose axons project to the 
level of even a very distal injury might die after axotomy, suggesting that sensory neuronal 
death might be critical to the clinical sensory outcome of injuries even as distal as digital 
nerve transections, 
Although sensory neuronal death has been clearly demonstrated to occur, its 
timecourse has not been fully described, and yet the time course is of crucial clinical 
importance since it would allow a therapeutic window to be defined during which attempts 
could be made to reduce neuronal death, Using in-situ end labelling (ISEL) Groves et al 98 
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did demonstrate the presence of dying neurons 7 days after sciatic nerve division in the rat, 
but there are no studies using earlier timepoints in the adult. Similarly, despite most 
authors having failed to demonstrate any neuronal loss until 7 days after axotomy, 
Vestergaard et al did fmd a 6% loss at 4 days, rising to 19% after 8 days 55 so it remains 
uncertain exactly how soon after peripheral nerve injury neurons begin to die. Nor is it 
clear how long the period of cell death lasts. Although the only studies that employed 
sufficiently long timepoints have not shown any significant difference between the loss 
found 1-2 months after injury and that found after 6-12 months 98,107,108, they either lacked 
sufficient timepoints for an accurate determination of when neuronal death ends 107, or 
used small groups 98,108, and non-stereological counting techniques 108. 
In determining the timecourse of neuronal death it is important to understand the 
ways in which cell death can be detected and quantified, and what aspect of neuronal death 
each marker demonstrates (Figure 1.1). Although the calculation of neuronal loss 
quantifies the number of neurons that have died up until that timepoint, complete 
involution does not occur for some hours in vitro 120-122 and an unspecified time in vivo 123 
after the start of the cell death cycle. Evidence of individual cell death, whether 
morphological or DNA fragmentation, is therefore more appropriate for determining the 
onset of cell death after axotomy, as well as being more sensitive for detecting low rates of 
cell death, since the normal biological variation in neuronal numbers may also mask very 
small losses. 
Until recently the interpretation of neuron counts was further complicated by the use of 
assumption based counting techniques that are "statistically biased", meaning that the 
mean of all possible estimates will tend away from the true value 124. Although serial 
reconstruction counts are the gold standard technique, they are impractical in ganglia 
which contain tens of thousands of neurons, and so methods for estimating the number of 
neurons have been developed instead. The simplest of these is profile counting, whereby 
one counts the number of neurons ("profiles") present in a sample of sections from the 
ganglion, and multiplies the mean value by the total number of sections. Since large 
neurons have profiles in more sections than small neurons, they are more likely to be 
counted, and so the count is likely to be a biased 125 overestimate 126. To combat this 
problem various systems were developed, such as those of Abercrombie 127 and 
Konigsmark 128, that involve measuring the size distribution of a sample of neurons in 
order to obtain a correction factor. However these factors do not fully take account ofthe 
non-spherical shape of cells or their anisotropic orientation and distribution within the 
ganglia 129, and so the only way to obtain a truly accurate correction factor would be to 
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measure every neuron in the ganglion 129, yet that would be a serial reconstruction. 
Estimates obtained using profile counts and correction factors must therefore involve 
assumptions about the shape of cells, and the homogeneity of their distribution throughout 
the ganglia. Since these assumptions have now been demonstrated to be untrue 126,129, the 
counts are "biased" in the statistical sense that the mean of all possible estimates tends 
away from the true value 130. The techniques are also imprecise, since variations of over 
40% 125 have been found in the counts obtained from individual ganglia using these 
techniques 131, and authors using these techniques have quoted figures for the number of 
neurons in normal rat L5 DRG's that range from 2,000 to 15,000 132• They are also 
inaccurate since they reliably gave an incorrect estimate of the number of neurons in a 
known population of neurons 126. 
In order to overcome these problems, design-based stereo logical techniques have 
been developed 129. These are time-efficient 130, do not require any assumptions about the 
tissue being quantified, and are rapidly becoming the standard tools for quantitative 
morphological study of biological systems, although this has recently been questioned on 
the grounds that the anisotropic arrangement of neurons within the nervous system, and the 
effects of section shrinkage may result in inaccuracies 133. However when the technique is 
correctly applied, with adequate, systematic random sampling, it is efficient, theoretically 
sound, and has been empirically validated against serial reconstruction counts ofDRG 
neurons 125,134,134. The correct use of systematic random sampling obviates any bias arising 
due to the non-homogenous distribution of cells within the tissue 124, and the rules used 
with the counting systems ensure that counting is performed within three dimensions 124. 
Hence every cell has an equal chance of being counted irrespective of its size, shape, or 
orientation 124,129. Stereo logical counting techniques, such as the physical and optical 
disector 125, therefore permit "statistically unbiased" counting, whereby the mean of all 
possible estimates will tend infmitely toward the true value 130. Counts are therefore 
accurate 129, as long as certain rules are adhered to 129,135. The optical disector technique 
ought to be superior to the physical, since it is more time-efficient 136 and avoids 
underestimates due to tissue sectioning artefacts and lost caps 124,131,136. Although 
precision is proportional to the amount of sampling performed, biological variation rapidly 
outweighs the benefit of increased sampling, and so counting remains time-efficient 129. 
As a marker of DNA fragmentation, terminal deoxyribonuc1eotidyl transferase 
(TdT) uptake nick-end labelling (TUNEL) is a reliable marker of neuronal death 92,99,100, 
particularly when combined with Hoechst 33342 counterstaining 137,138 and microwave 
tissue permeabilisation 139. Although TUNEL was initially proposed as a specific marker 
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Figure 1.1 Detecting Primary Sensory Neuronal Death After Peripheral 
Axotomy 
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The cell death cycle is shown schematically for axotomised primary sensory 
neurons. Neuronal death within dorsal root ganglia can be detected by 3 main 
ways. DNA fragmentation is the earliest sign of a cell's irreversible commitment to 
die, and can be detected by techniques such as TUNEL. Morphological evidence of 
neuronal death can then be sought at the light, or electron microscopic level, using 
the features described above. Finally, by subtracting the number of neurons present 
in an axotomised ganglion from that in normal control ganglia, the total number of 
neurons that have died and involuted completely can be quantified. This is termed 
the "neuronal loss." 
I, 
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for apoptosis 140, positive staining has subsequently been found in necrosis 141,142, and in 
the S-Phase of mitosis 143, hence morphological confirmation of the mode of cell death is 
also required 141. 
The term apoptosis comes from the Greek "a7t07t'tcocJtcr", meaning the falling of 
petals from a flower, and was coined by Kerr, Wyllie & Currie in 1972 to describe an 
active physiological cell death process with a morphological pattern (Figure I.I) that 
contrasted with that found in necrosis 144. Subsequently the term has been widely applied 
145 and has wrongly become synonymous with programmed cell death 146, which is in fact 
the embryological process whereby numbers of cells are pruned during development 147. 
Apoptosis has also been widely applied to neuronal death throughout the nervous system, 
although subsequent critical appraisal has not confirmed this assumption to be true for 
many forms of neuronal death that actually exhibit mixed features of necrosis and 
apoptosis 146. 
Some axotomised primary sensory neurons display apoptotic morphological 
features at both the light 98 and electron microscopic level 148, and are positively labelled 
by TUNEL or ISEL 92,98,99,102. However the number of apoptotic neurons is small 
compared to the massive cell death which occurs 98, and neurons are also present that 
display other morphological features 56,57,96 now known to be potentially compatible with 
neuronal death 146. Finally, although neuronal death is reduced by inhibition of protein 
synthesis 92, a feature of apoptosis, this may merely be due to shunting of amino acids into 
glutathione synthesis 149, and so it may be that cell death actually occurs by an active 
process which is not strictly apoptotic. 
After peripheral nerve transection glial cells in the DRG also die 92,98, and although 
the significance of this is uncertain in the spinal cord 150 it has been suggested to compound 
the effects of the initial injury 138. In neonates glial death occurs with a slower time course 
to that of neuronal death 100, but the timecourse in adults has not been described. 
1.5 Mechanism ofDRG Neuronal Death 
Very few studies have directly investigated the mechanism of primary sensory 
neuronal death after peripheral axotomy, and so one must infer from other models. The 
normal developmental apoptosis in sympathetic ganglia and DRG's that occurs at 
b · E15 18' h 151 h b . l' . d 17151-155 h em ryomc stages - In t e rat as een extensIve y Investigate' ,as as 
cell death initiated in neuronal cell lines by neurotrophin withdrawal 120,154,156-160, axotomy 
153,158, and other in vitro stimuli 161. The caenorhabditis elegans nematode 162,163, aplysia 
californica mollusc 17, and various transgenic mouse models have proved informative 
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154,164,165, and since active cell death (e.g. apoptosis) is by definition an ordered process, it 
is reasonable to assume that a similar final pathway exists irrespective of the initiating 
cause 166. 
Within the injured neurons pathways for cell death and for regeneration are 
triggered in response to antidromic electrical activity and neurotoxic cytokines from the 
site ofaxotomy 103,104, although the principal determinant of the proportion of neurons that 
subsequently die appears to be the loss of target derived neurotrophic support 17,103 that 
arises secondary to interruption of retrograde axonal transport. Evidence of this comes 
from the protective effects of exogenous neurotrophic factor administration after 
experimental nerve injuries in adults 47. For example primary sensory neuronal loss was 
prevented by NGF delivered either intrathecally 109, or locally in a silicon tube 105,167, and 
when delivered by a fibronectin mat used for gap repair loss of 40-50llm diameter CGRP 
positive neurons was reduced in the monkey 168. LIF is also protective after peripheral 
axotomy 87,106, but the effects ofGDNF 169, NT-3 109,148, CNTF 83,148,158, and BDNF seem 
to depend upon the route of administration 83,109 and the subpopulation ofDRG neurons 
under consideration 164,169. 
Signalling is effected principally through the mitogen activated protein kinase 
(MAPK), c-Jun kinase (JNK), and PI3 kinase pathways 82,103,170, which lead to 
transcription of both cell death (via JNK,PI3K) 65 and regenerative (via MAPK) 170 genes. 
These pathways increase c-Jun cell protein activity. A member of the AP-1 superfamily, c-
Jun is a gene transcription regulator whose levels/activity increase after trophin withdrawal 
65,171,172, axotomy 64,66,173,174 or oxidative stress 65, and which is appears to be essential for 
apoptosis 65,172,175. However, c-Jun level is not specific for apoptosis 64,172 since it is also 
increased in actively regenerating neurons 174,176 and those protected from apoptosis 177, so 
it may merely have a role in initiating homeostatic and regenerative responses 178. In 
contrast, another immediate early gene, c-fos, does appear to be specific for apoptosis 172 
since its induction coincides with the appearance of apoptotic morphology and the 
irreversible stages of the cell death cyele 65. 
Cell death proteins have been well characterised in lower order species, and much 
of our knowledge of the mammalian system comes from the identification of homologous 
proteins, or cDNA sequences. In the nematode caenorhabditis elegans the protein ced-3 is 
pro-apoptotic 162 and has structural homology with the cysteine protease interleukin-1~­
converting enzyme (ICE) in mammals 162, whilst ced-9 is known to be anti-apoptotic 179 
and to have structural homology with proteins of the mammalian Bel family 179,180. 
Although Bel-xs can be pro-apoptotic 179-181, Bel-2, and Bel-xl are said to be anti-apoptotic, 
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indeed "the prototypic regulator of mammalian cell death is the proto-oncogene bcl-2" 154, 
Although their mechanism of action remains uncertain, they act downstream of c-Jun 65,177 
and may have antioxidant activity 179 or reverse the effects oftrophin withdrawal 182,183, 
Bcl-2 is known to arrest the cell cycle 161 at GOII 184, and to inhibit caspase activation 170 
primarily by an effect to limit mitochondrial calcium flux and the release of pro-apoptotic 
molecules 161,179,185, 
Bax is an AP-l cell death protein that reverses the arrest of the cell cycling caused 
by Bc1 184, and has been proposed as part of the trophin withdrawal apoptotic pathway 
152,163,171, Although Bax-mRNA levels do not alter significantly after axotomy when the 
DRG is considered as a whole 186, Bax levels do increase in small DRG neurons 64, The 
Bax:Bcl ratio is predictive of entry into the irreversible stages of apoptosis 64,147,187, 
although the exact mechanism for this remains uncertain since unlike intracellular calcium, 
isolated Bcl, or Bax levels are not predictive of apoptosis 157,188, Bax associated events 
occur downstream of c-Jun activity, but upstream of the ICE/caspase dependent steps, and 
may include c-fos induction 177, One way in which the Bcl:Bax ratio may determine the 
cell's fate is by an effect upon the abortive entry into the cell cycle that has been 
implicated in the mechanism ofpost-axotomy neuronal death 184,189,190, although it is more 
likely that the protective role ofBcl is due to mitochondrial protection 185, 
In a range of conditions mitochondria playa central role in neuronal death 
53 185 191 192 hr h h ~ 'I f 'd' b I' h 'f' , , , t oug t e lal ure 0 OXI atlve meta 0 Ism, t e generatIOn 0 reactive oxygen 
species, and the release of pro-a pop to tic molecules that trigger the caspase cascade 185, 
Furthermore, axotomy induced retrograde degeneration occurs in association with 
perikaryal accumulation of mitochondria and oxidative stress 53,193, an effect which may be 
mediated by increased nitric oxide synthase NOS activity 194,195 and mitochondrial NO 
levels 196-198, In normal neurons transient increases in NO reversibly inhibit complex IV 
activity in the mitochondrial electron transport chain as part of the physiological 
respiratory regulation of ATP production 199, However sustained pathological increases 
after axotomy may cause permanent inhibition of cytochrome C (complex I), thereby 
disrupting the electron transport chain 199 and causing the generation of reactive oxygen 
species (ROS) 197, It is postulated that as the bioenergetic dysfunction worsens 
dysregulation of mitochondrial membrane potential (MMP) 185,196,200 and calcium levels 
may occur 191, further increasing the production ofROS 191, Mitochondrial protophores 
may then open, directly triggering neuronal death by the release of cytochrome-C (which 
activates caspase-9), and other apoptosis inducing factors (AlF's) that act downstream of 
the caspases 185,197,201, Mitochondrial bioenergetic dysfunction is also implicated as the 
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cause ofNRTI associated DSP in HIV disease, this time secondary to iatrogenic inhibition 
of DNA polymerase-y 202. It is postulated that the resulting inhibition of mitochondrial 
replication leads to an overall reduction in neuronal oxidative metabolic capacity, leaving 
the cells unable to meet the metabolic demands of maintaining (and regenerating) long 
peripheral axons 203. Hence a chronic glove and stocking pattern of neuropathy develops 
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Considerable evidence exists for the role of reactive oxygen species (ROS) such as 
peroxynitrite (ONOO-), lipid peroxidation, and oxidative stress as mediators of neuronal 
death 147,166,193,197,198, although direct evidence from primary sensory neurons in vivo 
remains rare. Mn-superoxide dismutase activity increases 30% in the DRG after axotomy, 
suggesting an attempted homeostatic response to the generation ofROS 205 that may be 
cytoprotective since ROS are generated early in the cell death pathway, rather than being 
the final effector mechanism 120. Although some antioxidant agents, such as SOD, Bcl, 
and N-acety1cysteine, are protective against ROS 120,160,179,206, others are not 160, and it is 
not generally concluded that the successful agents act purely by a direct antioxidant 
mechanism 160,179,206. 
Another interesting feature of active neuronal death is that many of its stimuli may 
involve attempted entry into the cell cycle 190. For example NT-3 withdrawal and Bax both 
promote entry into the cell cycle 184,207, and IL-ll3 and induces apoptosis in neurons 
arrested at the growth phase G liS 189. The anti-apoptotic agent Bcl arrests cell cycling 161 
at GOIl 18\ and other anti-apoptotic agents such as acety1cysteine and protein synthesis 
inhibitors also inhibit entry into the cell cycle 159,160. Thus axotomy may cause abortive 
entry into the cell cycle, at a time at which this cannot be sustained 207, with the result that 
neurons apoptose. 
The ced-3 homologue ICE, which converts prointerleukin-ll3 into interleukin-ll3 
(IL-ll3) in mammals 189, also plays a role in neuronal death since trophin withdrawal' 
apoptosis ofDRG neurons is almost eliminated by expression of the ICE-inhibitory viral 
gene crmA 145,162. In keeping with the cell-cycle theory of neuronal death, IL-ll3 induces 
apoptosis in neurons arrested at the growth phase G liS, and antibodies against it, or its 
type 1 receptor, limit apoptosis 189. Eleven other ICE-like proteases, or "caspases" have 
now been identified 208,209, and they may be activated by a range of mechanisms such as 
trophin withdrawal, axotomy, Fas ligand or p75 activation 82, and mitochondrial disruption 
185. The caspases, particularly caspases-3 & 9 156,210-212, are intrinsic to active neuronal 
death 156,177,209,213, appearing in the pathway downstream ofBax activation and c-fos 
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induction 177, and leading to DNA fragmentation by activated a-spectrin proteases such as 
DNAse-1 147,185. 
Thus the mechanism by which peripheral axotomy brings about the death of some 
DRG neurons may proceed as portrayed in Figure 1.2. 
1.6 Potential Interventions to Reduce Primary Sensory Neuronal Death 
The poor sensory outcome found after peripheral nerve injury, particularly chronic 
injuries, would therefore seem to be due to a variety of causes. Schwann cell atrophy and 
loss of GGF responsiveness 27,43 combine with endoneurial fibrosis and other changes in 
the distal stump to impair peripheral nerve regeneration 17. The impaired regenerative 
capacity of individual neurons 17 combines with poor topographical and sensorimotor 
specificity during regeneration 18 to further reduce the appropriate reinnervation of target 
sensory organs, which may themselves be severely atrophic. However the single most 
important determinant of poor sensory outcome is likely to be the death of up to 50% of 
the entire sensory neuronal pool, since "the first prerequisite for axonal regeneration is the 
survival of the neuron following injury" 17,17. Primary sensory neuronal death after 
peripheral nerve injury is therefore the principal concern of this thesis. 
Peripheral nerve repair may reduce neuronal death by reapproximating the axons to 
the distal nerve stump at a time when synthesis of neurotrophic factors is upregulated, and 
it may be that by repairing the nerve as early as possible after injury the extent of neuronal 
death could be limited. However the magnitude of any potential protective benefit is not 
known, patients frequently do not reach surgical services for many hours after sustaining 
peripheral nerve injuries, and primary nerve repair is not always clinically feasible (cf 1.2). 
A clear need therefore exists for alternative, adjuvant therapies to reduce neuronal death. 
Administration of exogenous neurotrophic (NTF), and other growth factors has 
been shown to reduce neuronal death after peripheral axotomy 47,105,106,167,214,215 (cf 1.5), 
and to reverse many of the other deleterious changes 81,164,216-223. Yet despite over 30 years 
of research since the discovery of nerve growth factor 224NTF's have failed to find a 
mainstream clinical application, and "growth factors have had no real effect on the clinical 
management of nerve injuries ... " 7 for variety of reasons. Firstly, NTF's act on specific 
subpopulations of neurons 7,47, and so a complex cocktail would be necessary to prevent 
the death of all subtypes, despite evidence that exogenous NTF's may interact to negate 
their own efficacy 225. Furthermore, efficacy may vary unpredictably depending upon the 
exact timing of administration 226,227, there are concerns over potential carcinogenic actions 
and toxicity in other cell types 228, and side effects 229-231 and complications at injection 
Figure 1.2: Schematic Pathway for Primary Sensory Neuronal Death After 
Peripheral Axotomy 
Peripheral nerve injury causing axotomy 
~ 
Cellular disruption & antidromic electrical activity 
Neurotoxic cytokine release 
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Generation of reactive oxygen species & altered cellular & mitochondrial redox level 
~ 
Phosphorylation of c-Jun 
~ 
Induction of c-Jun target genes (c-Jun, Bel, cell death genes, cell regeneration genes) 
Decreased transduction of protective genes 
~ 
Possible attempted entry into the cell cycle 
Ratio of Bc1:Bax determines whether cell enters irreversible stage of cell death process 
~ 




Cal pain activation 
DNA fragmentation by alpha-spectrin proteases 
Morphological changes of apoptosis develop 
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sites 229 have limited the use of systemic administration. As a result, most experimental 
studies have used local delivery by continuous intra-thecal administration 214, even though 
this may not be clinically applicable 232. There is therefore a pressing need for an 
alternative approach using an easily administered, clinically safe therapy, which will 
prevent neuronal death in a range of subpopulations, and in response to a variety of insults. 
In contrast to the specificity of neurotrophic factors 47, there appears to be relative 
homogeneity between neuronal subpopulations in the way that the initiation of neuronal 
death is signalled and then effected 103,166. The preservation of these mechanisms within 
different neuronal subpopulations means that a therapeutic agent acting at the signalling, or 
effector level of the cell death process ought to be protective for a wide range of neuronal 
subtypes after injury. Mitochondrial bioenergetic dysfunction, which may be mediated by 
increased NO synthesis 196-198, and the ensuing generation of reactive oxygen species and 
release of pro-apotoptic molecules 185 are particularly attractive targets given their potential 
role in neuronal death in a range of neurodegenerative and traumatic pathologies 
166,185,198,206,233-238 
Various other agents have been used experimentally to reduce neuronal death, but 
their clinical applicability is uncertain. For example the cytokine regulator linomide was 
associated with a 60-80% reduction in DRG neuronal death 10\ and the protein synthesis 
inhibitor cycloheximide has also been shown to reduce neuronal death 92,239, however both 
would have significant side effects if used clinically. Two potentially neuroprotective 
therapies are however available that are safely used for other applications in current 
clinical practise. N-acetyl cysteine (NAC) is an established glutathione substrate 240,241 
which has been shown to be neuroprotective in vitro against a range of stimuli 197,242,243, 
and may potentially inhibit the effects of reactive oxygen species. The second agent, L-
acetyl-carnitine (LAC), is a physiological protein which has neurotrophic effects 244,245, 
and which plays an essential role in mitochondrial oxidative metabolism, both as an acetyl-
group donor 246, and by facilitating the transport of long-chain free fatty acids across the 
inner mitochondrial membrane 247. LAC is neuroprotective in vitro 245,248, and is currently 
showing clinical promise in patients with neuropathy 249. Both these agents therefore have 
the potential to address the intermediate events in neuronal death, particularly 
mitochondrial bioenergetic dysfunction. 
1.7 Aims 
The overall aim of this project was therefore to identify a clinically applicable 
therapeutic strategy that might improve the sensory outcome of peripheral nerve injuries by 
reducing the death of primary sensory neurons, and facilitating their subsequent 
regeneration into the target tissues. 
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The first step in achieving this aim was to describe the timecourse of primary 
sensory neuronal death after a defined peripheral nerve injury in order to identify 
experimentally relevant timepoints for the study of potentially neuroprotective strategies, 
and in order to identify a potential therapeutic window for future clinical interventions. 
Therapeutic strategies with immediate clinical potential (early nerve repair, NAC & LAC 
treatment) were then tested for their ability to reduce neuronal death. Finally, the most 
promising agent was then tested for its ability to enhance the regenerative capacity of 
surviving neurons in both an animal model of chronic nerve injury, and in the clinical 
setting of a chronic neuropathy with a predominantly bioenergetic aetiology, namely 
nucleoside analogue antiretroviral therapy (NR TI) associated distal symmetrical 
polyneuropathy (DSP) in HIV disease. 
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Chapter 2. Methods 
Systems of statements, in order to be ranked as scientific, must be capable of conflicting with possible, or 
conceivable, observations. 
Karl Popper 
A very clever brain can catch a heffalump, if only he knows the right way to go about it. 
A.A. Milne 
2.1 Pre-Operative Preparation of Materials 
Blind ending silicone tubes for the encapsulation of transected sciatic nerve stumps 
were prepared from high-grade silicone rubber tubing (Philip Harris Scientific Supplies, 
Product Number T88-S420) of internal diameter Imm. The tubing was washed and soaked 
for 24 hours in distilled water, before air drying, cutting the tubes to length (Smm) and 
sterilising them with gamma-irradiation (3MRad. for SO hours). At the time of surgery the 
tubes were soaked in sterile saline, and then doubly ligated with 3/0 Prolene® using a 
minimum of S throws on a surgeon's knot. This created a blind ending tube some 4mm 
long, with an internal diameter of Imm, into which the nerve stumps were sutured in order 
to prevent spontaneous regeneration (Figure 2.1j). 
L-acetyl-carnitine (LAC, Sigma Tau, Italy) was supplied as an anhydrous powder 
which was reconstituted in sterile normal saline to give a stock solution of 19/ml. This 
solution was stored at 4°C, and was further diluted with sterile normal saline prior to 
injection in order to give an injection volume of Imllanimal. 
N-acetyl-cysteine (NAC, Evans Medical Ltd., U.K.) was supplied as a sterile 
200mg/ml solution ("Parvolex®"), which was stored at 4°C prior to use. Prior to injection 
this solution was diluted with sterile S% glucose solution to give an injection volume of 
O.3mllanimal for intravenous injections, and Imllanimal for intraperitoneal injections. 
2.2 Operative Procedures: 
All work was performed in accordance with the terms of the Animals (Scientific 
Procedures) Act 1986 (A.S.P.A.), Project License Number PPL 70/42lO, and Personal 
Licence Number PIL70/1S040. An in-house strain of Sprague-Dawley rats was used for all 
animal work (Royal Free & University College Medical School Comparative Biology Unit, 
London, U.K.). 
2.2.1 Anaesthesia 
Inhalational anaesthesia was employed for all operative procedures involving 
subsequent recovery, and intraperitoneal sodium pentobarbitone for all terminal procedures 
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Figure 2.1: Unilateral Sciatic Nerve Division, Ligation & Capping 
With the animal suitably anaesthetised, a skin 
incision is made rostral to the femur [A], and the 
rectus femoris muscle split along the line of its 
fibre [B] to expose the underlying sciatic nerve 
[C]. The nerve is then divided at the upper 
border of quadratus femoris (arrowhead) [D], 
and both the proximal (hollow arrow) and distal 
(solid arrow) nerve stumps ligated [E] and 
sutured into silicon caps [F]. The proximal nerve 
stump is then buried deep to quadratus femoris 
[G]. Scale bar 5mm. 
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involving trans cardiac perfusion fixation. For all other tissue harvest procedures CO2 
narcosis was used. 
2.2.1 a Inhalational Anaesthesia 
Anaesthesia was induced by placing the animal into a perspex induction box 
containing room air. Halothane® (4% in oxygen) was then instilled into the box at 6l1min 
until anaesthesia was achieved, as determined by loss of the usual righting reflex. The 
animal was then removed from the induction box, and its hindlimb shaved and prepped 
with Hydrex® (Adams Healthcare, U.K.), before being transferred to the operating table, 
where anaesthesia was maintained with halothane (1.5-2.5% in oxygen) delivered by a 
nose mask (Figure 2.1 a) at a flow rate of 0.5-1.5l1min. A suction scavenging device was 
employed to minimise contamination of room air with halothane, and a similar scavenging 
device used to clean the air of the induction box prior to anaesthetising the next animal. 
An adequate depth of surgical anaesthesia was ensured before commencing any 
operative procedures by demonstrating the abscence of any flexor withdrawal response to 
paw pinching in both hindlimbs, this was also tested at frequent intervals during the 
procedure. At the end of each procedure analgesia was administered subcutaneously (10% 
solution of Temgesic®, 0.1mll100g body weight), and anaesthesia was then reversed with 
100% inhaled oxygen, before placing the animal into a warmed chamber (30°C) for 
recovery. Animals were inspected frequently, and housed overnight in a warmed recovery 
room prior to returning to their normal environment within 48 hours. 
2.2.1 b Terminal Anaesthesia 
Terminal anaesthesia was induced by intra-peritoneal injection of a lethal dose 
(0.5mllkg body weight) of Sagattal™ (Rhone Merieux, sodium pentobarbitone 60mg/ml), 
and death confirmed by exsanguination in keeping with Schedule 1 ofthe A.S.P.A. 1986. 
2.2.1 c C02 Narcosis 
Animals were individually placed into an induction chamber filled with room air, 
and carbon dioxide (C02) narcosis induced by inflow of CO2 at 4-6l1min, until respiration 
ceased. Death was confirmed by cervical dislocation in keeping with Schedule 1 of the 
A.S.P.A 1986. 
2.2.2 Sciatic Nerve Division & Cappim! 
Each experimental group consisted of 6 animals, and these were terminated for 
tissue harvest at 1,4 days, 1, 2 weeks, and 1, 2, 4, 6 months after nerve transection (cf. 
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2.3.2). Each animal was anaesthetised and prepped (cf. 2.2.1 a) before making a 2cm skin 
incision parallel to the femur, which began 1cm caudal to the hip (Figure 2.1a). The 
biceps femoris muscle was split along the line of its fibres (Figure 2.1 b), thereby exposing 
the underlying sciatic nerve, and the wound was held open by appropriately placed 
retractors (Figure 2.1c). Care was taken at all times to avoid trauma to the nerve. 
Under binocular magnification (8x objective lens), and using microsurgical 
techniques, the sciatic nerve trunk was gently mobilised from below the origin of the 
muscular branch to the hamstring muscles, to just above its division into the tibial and 
common peroneal nerves at the lower border of adductor magnus in the peroneal fossa 250. 
Using No.5 micro-forceps the nerve was held by the epineurium, divided at the upper 
border of quadratus femoris with micro-nerve scissors (Figure 2.1 d), and a 3mm segment 
was resected from the distal stump. 
Both the proximal and distal nerve stumps were ligated with 6/0 Prolene® (Figure 
2.1e), and then sutured into the silicone caps (cf. 2.1) with single 9/0 Ethilon® epineurial 
sutures (Figure 2.1j). The capped proximal nerve stump was then buried in a pocket 
dissected deep to quadratus femoris, and then closed by approximating quadratus femoris 
to the obturator extemus using a 4/0 Vicryl® suture (Figure 2.1g). To further reduce any 
chance of spontaneous regeneration the distal nerve stump was also reflected posteriorly 
into the cleft between the semimembranosus muscle and the overlying accessory head of 
the rectus femoris. 
The retractors were removed, the rectus femoris edges approximated, and the skin 
closed with interrupted 4/0 Polydioxanone (PDS®) sutures. 
2.2.3 L-Acetyl-Carnitine (LAC) Treatment after Sciatic Nerve Division & Capping 
There were 3 treatment groups, each consisting of 6 animals, in which every animal 
was anaesthetised (cf. 2.2.1a), and the sciatic nerve divided, ligated and capped as 
described above (cf. 2.2.2). Immediately after closing the skin incision, each animal was 
given a 1ml intraperitoneal (i.p.) injection ofL-acetyl-camitine (LAC) ("low-dose" group: 
Smglkg; "high-dose" groups: 2Smglkg) in sterile normal saline (cf. 2.1). Subsequently the 
animals were given LAC by i.p. injection ("low-dose" group: Smglkg; "high-dose" groups: 
2Smglkg) 12 hourly for 14 days until the animals in the low-dose group, and in one of the 
two high-dose groups were terminated for tissue harvest (cf. 2.3.2). Animals in the 
remaining high-dose treatment group continued to receive SOmglkg of LAC by once daily 
i.p. injection (volume of injection=lml), until being terminated for tissue harvest 2 months 
after the nerve transection. 
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There were three control groups. One sham treatment group received injections of 
sterile saline in an identical pattern to the animals being treated with LAC, and was 
terminated 2 weeks after nerve transection. Two further groups of animals underwent the 
same nerve transection procedure, but did not receive any injections ("no treatment"). One 
of these groups was terminated 2 weeks after nerve transection, and the other group after 2 
months. Treatment regimes are summarised in Table 2.1. 
2.2.4 N-Acetylcysteine (NAC) Treatment After Sciatic Nerve Division & Capping 
There were 3 treatment groups, each consisting of 6 animals. Each animal was 
anaesthetised (cf. 2.2.1a), and the procedure for division, ligation and capping of the sciatic 
nerve was performed as described above (cf. 2.2.2). Immediately after closing the skin 
incision, each animal was given a O.3ml intravenous (i.v.) injection ofN-acetyl-cysteine 
(NAC) (low-dose group: 15mglkg; high-dose groups: 75mglkg) in sterile 5% dextrose. 
Subsequently the animals were given 12 hourly intravenous injections ofNAC (low-dose 
group: 15mglkg; high-dose groups: 75mglkg), under halothane general anaesthesia for a 
total of 5 doses, before switching to i.p. injection. Two weeks after nerve transection the 
animals in the low-dose group, and in one of the two high-dose groups were terminated for 
tissue harvest (cf. 2.3.2). Animals in the remaining high-dose treatment group then 
continued to receive 150mg/kg NAC by once daily i.p. injection (volume of 
injection=1ml), until being terminated for tissue harvest 2 months after the nerve 
transection. 
There were three control groups. One sham treatment group received injections of 
5% dextrose in an identical pattern to the animals being treated with NAC, and was 
terminated 2 weeks after nerve transection. The two "no treatment" groups described 
above (cf. 2.2.3) were also used as 2 week, and 2 month controls in this study. 
Treatment regimes are summarised in Table 2.1. 
2.2.5 Sciatic Nerve Division & Primary Repair 
This experimental group comprised 6 animals. Each was anaesthetised (cf. 2.2.1a), 
and the sciatic nerve was exposed and divided at the upper border of quadratus femoris in 
the same manner described for sciatic nerve transection experiments (cf. 2.2.2). The nerve 
was then immediately repaired using four 9/0 Ethilon® interrupted epineurial sutures, 
placed at 6, 12,9, and 3 o'clock, the rectus femoris edges approximated, and the skin 
closed with interrupted 4/0 PDS® sutures. Animals were terminated for tissue harvesting 
two weeks later (cf. 2.3.2). 
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Table 2.1: L-acetyl-carnitine (LAC) & N-acetyl-cysteine iliAC) Treatment Regimes 
Drug: Intra-Operative Dose First 2 Weeks Post-Op 
Dose: 75mglkg b.d. (every 12 hours) 
Dose: 75mglkg i.v. 
First 5 doses given as i.v. injection, total 
High-Dose Total injection volume O.3mlldose injection volume O.3mlldose 
NAC Made up in sterile 5% Dextrose 6th dose onward given as i.p. injections, total 
injection volume 1mlldose 
Give dose after closing the skin 
Injection made up with sterile 5% Dextrose 
Dose: 25mglkg i.p. Dose: 25mglkg b.d. (every 12 hours) 
High-Dose Total injection volume 1mlldose Given as i.p. injections, total injection volume 
LAC Made up in sterile normal saline 1mlldose 
Give dose after closing the skin Injection made up with sterile normal saline 
Doses: NAC 15mglkg Doses: NAC 15mglkg 
Low-Dose LAC5mglkg LAC dose 5mglkg 
Regimes Injection schedule & volumes Injection schedule & volumes identical to high-
identical to high-dose regime dose regime 
- ----- ----------
From 2 Weeks Post-Op Until Harvest 
Dose: 150mglkg o.d. (once daily) 
Give as i.p. injection, total injection 
volume 1mlldose 




Dose: 50mglkg o.d. (once a daily) 
Give as i.p. injection, total injection 
volume 1mlldose 
Injection made up with sterile normal 
saline 
2.2.6 Sciatic Nerve Division & Earlv Secondary Repair 
The animal was anaesthetised (cf. 2.2.1a), the sciatic nerve was exposed in the 
same manner described for sciatic nerve transection experiments (cf. 2.2.2), and then 
divided at the upper border of quadratus femoris using micro-instruments. 
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A pocket was then dissected deep to the quadratus femoris muscle, into which the 
proximal nerve stump was inserted, and held out to its physiological length with a single 
epineurial 9/0 Ethilon® suture into the muscle. The quadratus femoris was then 
approximated to the obturator extemus with a 4/0 Vicryl® suture, closing the intermusclar 
pocket. 
The distal stump was reflected posteriorly into the cleft between the 
semimembranosus and the overlying accessory head of the rectus femoris, and held out to 
length with a single epineurial 9/0 Ethilon® suture into the semimembranosus muscle. 
The retractors were removed, the rectus femoris edges approximated, and the skin closed 
with interrupted 4/0 PDS® sutures. 
One week later the animals were re-anaesthetised (cf. 2.2.1a), the original skin 
wound reopened, and the rectus femoris split as before. The nerve stumps were mobilised 
after removing the epineurial sutures, and then co-apted using four 9/0 Ethilon® 
interrupted epineurial sutures placed at 6, 12,9, and 3 o'clock. The retractors were then 
removed, the rectus edges reapproximated, and the skin closed with interrupted 4/0 PDS® 
sutures. Animals were then terminated for tissue harvesting (cf. 2.3.2) one week later (ie. 
two weeks after nerve transection). 
2.2.7 Sciatic Nerve Division & Late Secondary Nerve Graft Repair 
Experimental groups consisted of 5 animals. Each animal was anaesthetised (cf. 
2.2.1a), and the sciatic nerve exposed (cf. 2.2.2) and divided with micro-instruments at the 
upper border of quadratus femoris; no segment of distal stump was resected. 
In order to prevent spontaneous regeneration, both nerve stumps were ligated with 
6/0 Prolene® using a double surgical knot, before being sutured into silicone rubber caps 
using single 9/0 Ethilon® epineurial sutures (cf. 2.2.2). The proximal stump was sutured 
out to its physiological length within the intermuscular cleft deep to the quadratus femoris, 
using a single 9/0 Ethilon® suture. The pocket over the proximal stump was then closed 
by approximating the quadratus femoris to the obturator extemus with a 4/0 Vicryl® 
suture. 
The distal stump was reflected posteriorly into the cleft between the 
semimembranosus and the overlying accessory head of the rectus femoris, and held out to 
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its physiological length with a single 9/0 Ethilon® suture into the muscle. The retractors 
were removed, the rectus femoris edges approximated, and the skin closed with interrupted 
4/0 PDS® sutures. 
Two months later the animals were re-anaesthetised (cf. 2.2.1 a), the original skin 
wound reopened, and the rectus femoris split as before. Using micro-instruments under 8X 
binocular magnification, the nerve stumps were mobilised, the silicone caps removed, and 
any remaining adventitial tissue trimmed away. The nerve stumps were then trimmed back 
to "healthy" nerve (>2mm from the 6/0 Prolene® ligature), leaving a gap of ~ 1 cm between 
the stumps. 
The gap was then repaired using a reversed 1 cm long sciatic nerve isograft, freshly 
harvested from inbred siblings under terminal anaesthesia (cf. 2. 2.1 b). The graft was 
reversed, and anastomosed to both nerve stumps using 1 % Ethilon® interrupted 
epineurial sutures placed at 6, 12, 9, and 3 o'clock (Figure 2.2a), further sutures were 
occasionally added if required. The length of the nerve graft was measured under 
physiological tension, so that there was a lcm gap between the proximal and distal nerve 
stumps in the resulting repair (Figure 2.2b). The retractors were removed, the rectus 
femoris edges reapproximated with 4/0 Vicryl® interrupted sutures, and the skin closed 
with interrupted 4/0 PDS® sutures. 
One group of animals was treated with L-acetyl-carnitine (SOmglkglday) by 
intraperitoneal injection, with the first dose given immediately the nerve repair was 
performed and thereafter using the same daily regime as described for the 2 month "high-
dose" group in section 2.2.3. All animals were terminated for tissue harvesting (cf. 2.3.2) 6 
weeks after nerve repair. 
2.3 Tissue Harvesting Procedures 
2.3.1 Schedule 1 Termination 
Animals were terminated in accordances with Schedule 1 of the A.S.P.A 1986, by 
either terminal anaesthesia (cf. 2. 2.1 b), or CO2 narcosis (cf. 2. 2.1 c). 
2.3.2 Dorsal Root Ganglia 
All perfusion work was carried out in an appropriate fume-cupboard using a 
Watson-Marlow SOSSIRL peristaltic pump set at 2S-3Srpm, and Smm internal diameter 
tubing. An intravenous 18 gauge cannula (Abbocath-T Venisystems TM) was attached to the 
tubing, and the whole system primed with Phosphate Buffered Saline (PBS) chilled to 4°C. 
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Figure 2.2: Late Secondary Nerve Repair Using Reversed Sciatic Nerve Graft 
Late secondary nerve graft repair [A). Two months after transection of the sciatic nerve a lcm 
segment of sciatic nerve isograft was harvested from a sibling, reversed and used to perform a lcm 
gap repair [A). After limited trimming of both nerve stumps the graft was inserted, using four 10/0 
Ethilon® epineurial sutures [B) placed in order at 6, 12,3,9 o'clock for each anastomosis. Scale bar 
equals Smm. 
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With the animal deeply anaesthetised (cf. 2.2.1b), as shown by absence of both the 
paw pinch-withdrawal reflex and the corneal reflex, the heart was exposed by a clam-shell 
incision through the chest wall and the left ventricle cannulated under direct vision with the 
18 gauge PTFE cannula. The cannula was advanced into the ascending aorta and secured 
with a microvascular clamp, and the right atrium incised under direct vision to ensure 
exsanguination, and to provide an outflow for the perfusing fluids. Perfusion was 
commenced with 300ml of PBS at a pump rate of3Sr.p.m., to flush the vascular system 
free of blood. The perfusate was then switched to chilled 4% paraformaldehyde (PF A), 
and the animal perfused with 400ml at a pump rate of20-30r.p.m. 
Immediately after fIxation a dorsal skin incision was made along the spine, and the 
skin and paravertebral musculature reflected laterally. Using 3.SX magnifIcation and 
micro-rongeurs, the spinal canal was de-roofed, beginning in the sacral region and 
proceeding rostrally. Taking care to avoid damaging neural structures, the spinal processes, 
laminae, and pedicles, were removed to expose the spinal cord and lumbar dorsal root 
ganglia (DRG) up to the level ofT8, above the lumbar enlargement. The lumbar DRG's 
were identifIed, with the LS DRG's lying immediately rostral to the L6 vertebra 
approximately at the level ofthe iliac crests 250. The correct vertebral level was confIrmed 
by counting the lumbar vertebrae rostrally from Ll, below the last rib, and the L4 and LS 
DRG's were carefully dissected out from their intervertebral foramina, taking care to avoid 
holding the ganglia directly, but rather using the spinal roots or nerves instead. The 
ganglia were then immediately placed into 4% PFA for 6 hours post-fIxation at room 
temperature, before being removed and placed into a cryoprotectant solution containing 
IS% sucrose & 0.1 % sodium azide in PBS. Three further rinses were then performed over 
36 hours, and the samples stored at 4°C prior to the preparation of frozen blocks (cf. 
2.4.1a). 
DRG's for electron microscopy were harvested using the same protocol, except that 
only SOml of PBS was used, and pre-fIxation was achieved with SOOml ofa solution of3% 
glutaraldehyde & 1 % paraformaldehyde in PBS. Ganglia were stored in the same fIxative 
solution at 4°C prior to processing for electron microscopy (cf. 2.4.1 b). 
2.3.3 Late Secondary Nerve Graft Repairs 
Animals were terminated by CO2 narcosis (cf. 2.2.1c) in accordance with the terms 
of the Animals (ScientifIc Procedures) Act 1986. 
The original skin incision was reopened, and extended down to the calcaneum. The 
rectus femoris was split along the line of its fIbres, to expose the underlying conduit repair. 
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The integrity of the repair was checked, and the sciatic nerve mobilised proximally, and 
distally down to the gastrocnemius muscle. The sciatic nerve was then pinched proximal 
to the repair, using Number 5 microforceps, and the gastrocnemius inspected for any 
visible fibre contraction. 
The sciatic nerve was divided 5mm proximal, and 10mm distal to the nerve repair, 
and the nerve graft removed in continuity, and pinned onto a flat plastic splint using 25 
gauge needles through the ends of the sciatic nerve stumps. The specimen was then 
immediately placed into Zamboni's fluid for post-fixation. 
After 12-16 hours post-fixation at 4°C, the nerve repairs were removed from 
Zamboni's solution and placed into a cryoprotectant solution of 15%Sucrose & 
0.1 %Sodium Azide in PBS. Three further rinses were then performed over 36 hours, and 
the samples were stored at 4°C prior to the preparation of frozen blocks (cf. 2.4.1a). 
2.3.4 Human Skin Biopsies 
This study was performed in agreement with the terms of the Helsinki Declaration, 
after appropriate review by the local research ethics committee. Cutaneous excision 
biopsies were taken from consenting patients with established HIV -associated peripheral 
neuropathy (DSP) before and then after treatment with LAC, and also from asymptomatic 
HIV negative controls (cf. 8.2). 
Skin biopsies were excised from a site 1/3 of the way from the lateral malleolus to 
the head of the fibula, in whichever leg the patient felt to be more symptomatic. Having 
obtained the patient's consent, 2-5ml oflocal anaesthetic (1 % lignocaine+adrenaline) was 
instilled subcutaneously into the area of the biopsy. The skin was prepped using aqueous 
Betadine, and the operative field defined with sterile drapes. Taking care to avoid inducing 
crush artefacts a 0.5cm x lcm ellipse of skin was then excised with a scalpel and #15 
blade, such that the long axis of the ellipse lay parallel to the tension lines in the skin. The 
biopsy was pinned onto a flat plastic sheet at its physiological length using 25 gauge 
needles, and then placed into Zamboni's solution for post-fixation. 
The biopsy wound was closed with interrupted 4/0 SurgiproTM sutures and 
steristrips, and non-adherent gauze was applied (Melolin™) with an adhesive TegadermTM 
dressing. Sutures were removed after 14 days, and steristrips were reapplied for a further 7 
days. 
After 12-16 hours post-fixation at 4°C temperature, the samples were removed from 
Zamboni's solution and placed into a cryoprotectant solution containing 15% sucrose & 
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0.1 % sodium azide in PBS. Three further rinses were then performed over 36 hours, and 
the samples were stored at 4°C prior to the preparation of frozen blocks (cf. 2.4.1a). 
2.4 Tissue Sectioning & Staining 
2.4.1 a Preparation orFrozen Blocks 
Small aluminium foil boats were prepared on a Perspex form (lOxl2mm for DRG's 
& skin biopsies, 1Ox27mm for nerve repairs). The base of the boat was filled with OCTTM, 
and the tissue samples were then removed from PBS-Sucrose solution and inserted into the 
foil boats thus (one sample per block): 
a) DRG's: these were placed upon their long axis to allow longitudinal sectioning. The 
exact orientation along this axis was randomised, in keeping with 
stereo logical rules for vertical sectioning. 
b) Nerve Repairs: these were trimmed to leave 3mm of both the proximal and the 
distal nerve stump in continuity with the repair, and were then 
placed along their longitudinal axis, with a single piece of rat liver 
placed at the level of the proximal anastomosis, and a double piece 
at the level of the distal anastomosis (Figure 2.3a). 
c) Skin Biopsies: these were placed with the epidermal surface flat on the base of the 
foil boat, and the longitudinal axis of the biopsy randomly oriented 
relative to the walls. 
The tissue samples were then fully covered in OCTTM blocking medium, and 
immersed into liquid Nitrogen until frozen. Blocks were stored at -40°C prior to 
sectioning. 
2.4.1 b Preparation orBlocks for Electron Microscopy 
DRG's were post-fixed in 1 % osmium tetroxide in O.1M phosphate buffer at 37°C, 
dehydrated in acetone and embedded in Vestopal. 
2.4.2a Sectioning orDorsal Root Ganglia for TUNEL & Optical Disection 
Each entire DRG was cut into serial 30llm cryosections on a Bright® OTP 
Cryostat, and every section was collected onto a pair ofVectabond® (Vector, U.K.) coated 
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Figure 2.3: Tissue Blocking & Sectioning: 
A. Blocking Nerve Repairs: 
'\ (Suture 
r-------fr~ ..... . .. -.-. --;---;-;--;~ ..... ~ 
• 10mm • • 
Distal - -, 
Nerve repairs were blocked into OC'fTM with small blocks of liver ( • )to indicate the position of 
the end of the nerve stumps, and to differentiate proximal (single piece of liver) from distal (two pieces 
of liver). 
B. Serial Sectioning of Dorsal Root Ganglia: 
#1 2 3 
5 6 7 
9 10 11 
13 14 15 
17 18 19 
20 21 22 












28 29 30 31 
32 33 34 
Ref: ...... 
Ganglion B 
Every serial 30/lm cryosection from each dorsal root ganglion was collected in order onto a pair 
ofvectabond® coated glass slides to facilitate subsequent systematic random sampling. 
C. Systematic Random Collection of Skin Biopsy Cryosections 
# 1 4 7 10 13 16 
19 22 25 28 31 34 
37 40 43 46 49 52 
PGP 9.5 CGRP VIP PGP 9.5 CGRP VIP 
After discarding a random number of 15 /lm cryosections, every 3rd section was collected onto 
slides labelled for the primary antiserum to be used. In this way a systematic random sample of 





glass slides, in rows of 4 sections (Figure 2.3b). This facilitated systematic random 
sampling (for optical disection), counting of the total number of sections from each 
ganglion (for Cavalieri estimation of ganglion volume), and allowed one to note which 
sections, if any, detached during subsequent staining. 
All sections were air-dried overnight on a warming plate, before being placed into 
slide racks, sealed in aluminium foil, and stored at -40°C for a maximum of 2 weeks. 
Sections were thawed at 37°C for 6 hours prior to staining. 
2.4.2b Sectioning o(Nerve Repairs for Quantitative Immunohistochemistry 
The nerve repairs were cut into longitudinal 15 ~m cryosections. Sections were 
discarded until the nerve stumps were reached, and seen to be present in the sections, 
thereafter every second serial section was collected onto 6 Vectabond® coated glass slides. 
This gave a random sample of sections from the region of the repair containing the 
majority of regenerating fibres, and ensured that no two sections to be stained with anyone 
antiserum were consecutive. 
All sections were air-dried overnight on a warming plate, before being placed into 
slide racks, sealed in aluminium foil, and stored at -40°C for a maximum of 2 weeks. 
Sections were thawed at 37°C for 6 hours prior to staining. 
2.4.2c Sectioning o(Human Skin Biopsies for Quantitative Immunohistochemistry 
Human skin biopsies were cut into a systematic random sample of 15~m vertical 
cryosections. A random number from 1-10 was picked, and this number of sections were 
discarded before beginning the collection of every third serial section onto a set of 6 
Vectabond® coated glass slides (Figure 2.3c). 
All sections were air-dried overnight on a warming plate, before being placed into 
slide racks, sealed in aluminium foil, and stored at -40°C for a maximum of 2 weeks. 
Sections were thawed at 37°C for 6 hours prior to staining. 
2.4.3 Triple Staining (DRG's for TUNEL Microscopy & Optical Disection) 
Sections were permeabilised by microwave irradiation (478Watts for 1.5 minutes 
with a 1.51 water load) and rapid cooling in iced PBS. TdT Uptake Nick-End Labelling 
(TUNEL) (Promega Apoptosis Detection System Fluorescein) was then performed in 
accordance with the recommended protocol 251, which was adapted ("Triple Staining 
Protocol", Appendix 5), to allow simultaneous staining with Hoechst 33342 (H33342) and 
Propidium Iodide (PI). Hoechst 33342 is a non-specific nuclear stain which allows 
excellent determination of nuclear morphology 137,137,138,138,252. Although PI exclusion by 
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an intact plasmalemma is used in vitro to demonstrate cell viability, in permeabilised fixed 
frozen sections the neuronal cytoplasm is exposed, giving PI at higher concentrations 
access to demonstrate the cytoplasmic morphology by staining of intracellular organelles. 
Each stain can be visualised separately using fluorescence microscopy and band specific 
filters. 
The protocol was tested upon cryosections of various tissues that are known to 
reliably contain apoptotic cells, and in each case TUNEL positive cells were successfully 
demonstrated (Figure 2.4). To ensure that no artefactual errors arose between operated 
and control sides as a result of possible differences in staining conditions, the DRG's from 
both the control and axotomised sides of each experimental animal were always sectioned 
and stained together. A positive biological control (rat testis), and a negative experimental 
control (normal DRG sections with omission ofTdT enzyme during staining) were also 
included in each staining run. 
Slides were mounted with glass covers lips using glycerine in PBS (c£ Appendix 
8.5). The edges ofthe coverslips were sealed with DPX, and the slides were stored at 4°C 
prior to fluorescence microscopic examination for TUNEL within 48 hours. 
2.4.4 Immunohistochemistry (Nerve Repairs) 
Sections were stained by indirect fluoresence immunohistochemistry according to 
the protocol given in Appendix 7, using primary antisera against "pan-axonal marker of 
neuroftlaments" (PAMNF, Affmiti U.K.) as a general neuronal marker, and S-lOO (DAKO, 
Denmark) as a Schwann cell marker. Dual staining was performed on all sections. 
PAMNF was visualised using a Cy-3 conjugated secondary antibody (Cy-3 horse 
anti-mouse, Amersham Pharmacia U.K.), whilst S-l 00 staining was visualised by an FITC-
conjugated secondary antibody (FITC goat anti-rabbit, Vector U.K.). Non-specific tissue 
binding of the secondary antibodies was prevented by pre-incubation of tissue sections 
with normal goat (Sigma-Aldrich U.K.) or normal horse (Sigma-Aldrich U.K.) sera, and 
non-specific hydrophobic attachment was reduced by co-incubation with normal rat serum 
(DAKO, Denmark). 
After staining glass covers lips were mounted using glycerine in PBS (cf. Appendix 
8.5), and stored at 4°C. Sections were then examined within 24 hours of staining (cf. 
2.5.4), and all images for quantification of staining captured (cf. 2.5.5). 
2.4.5 Immunohistochemistry (Skin Biopsies) 
Both the pre- and post-treatment biopsies from a patient were processed 
together in order to eliminate minor variabilities between staining runs. Sections were 
41 
Figure 2.4 Verification of TUNEL Protocol in Positive Cells in Positive Biological 
Control Tissues 
The TUNEL staining protocol was tested in several tissues known to contain apoptotic cells. TUNEL 
positive cells (arrows) were found in sections of rat testis [A), serum deprived Schwann cells [B), and at 







stained by indirect fluoresence immunohistochemistry according to the protocol given in 
Appendix 6, using primary antisera against protein gene product 9.5 (polyclonal rabbit 
antiserum to PGP9.5, Affiniti U.K.), calcitonin gene related peptide (polyclonal rabbit 
antiserum to CGRP, Affmiti U.K.), and vasoactive intestinal polypeptide (polyclonal rabbit 
antiserum to VIP, Affmiti U.K.). Antibodies to PGP9.5 bind to all fibre-types, since 
PGP9.5 is a constitutive cytoplasmic component of all nerve fibres, whereas the peptide 
neurotransmitter CGRP is specifically found in small, C and Ao sensory fibres, and the 
neurotransmitter VIP is present in cholinergic, sympathetic postganglionic efferent fibres. 
Single antibody staining was used for all sections, and was visualised using a fluorescein 
conjugated secondary antibody (FITC-conjugated goat anti-rabbit serum, Vector u.K.). 
Non-specific tissue binding of the secondary antibody was prevented by co-incubation of 
tissue sections with normal goat serum (NGS, Sigma-Aldrich, U.K.). 
After staining, glass covers lips were mounted using glycerine in PBS (cf. Appendix 
8.5), and stored at 4°C. Sections were then examined within 24 hours of staining, and all 
images for quantification of staining captured (cf. 2.5.3). 
2.4.6 Staining tor Electron Microscopy 
Blocks were trimmed on a Pyramitome (LKB, Sweden) and sectioned with a 2128 
Ultratome (LKB). Serial 1 Jlm sections were cut from the ganglia and examined by light 
microscopy. Having identified a representative neuron, ultrathin (60-70nm) sections were 
collected on formvar-coated one-hole copper grids for electron microscopic examination, 
and stained with uranyl acetate and lead citrate. 
2.5 Analysis & Quantification 
In each study all analysis was performed by one individual using coded slides in 
order to reduce observer error. 
2.5.1 TUNEL Staining 
Changing between fluorescent filters easily permitted differentiation of neurons 
from satellite cells on the basis of their size, relative distribution, and their larger, paler 
nuclei (Figure 2.5b). The reliability of these features was previously confirmed in separate 
experiments where staining with PI and H33342 was combined with immunostaining using 
antisera to pan-neurofilaments (Affmiti U.K.), and the satellite cell marker S-100 (DAKO, 
U.K.). 
Figure 2.5: Neuron Counting by Optical Disection: The C.A.S.T. Grid System & 




The C.A.S.T. Grid™ stereological system [A) comprised an Olympus BX50 fluorescence 
microscope, with a continuous interactive video display (red arrow). The stage has a microcator to 
record manual movement in the Z-axis (pink arrow), and its movement in the X-V plane is controlled 
by the C.A.S.T. Grid™ software via a MuIticontrol2000™ unit (yellow arrow) during sampling and 
optical disection. 
Neurons (hollow arrow) were easily differentiated from satellite cells (solid arrows) during 
optical disection, and TUNEL analysis, on the basis of their larger, nuclei paler which stained less 
intensely with Hoechst 33342 [B). Scale bar equals lOllm. 
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All sections were examined for the presence of TUNEL positive cells using 
fluorescence microscopy and a 20x objective lens (Olympus BX60 microscope). Cells 
were confirmed to be neurons, or satellite cells by further examination under a 40x 
objective, and the morphology of each TUNEL positive neuron was examined by 
switching fIlters to visualise the nuclear and cytoplasmic staining. In every case the serial 
sections immediately before and after the section containing the TUNEL positive neuron 
were inspected to ensure that each positive neuron was only counted once. Absolute 
numbers of TUNEL positive neurons were therefore obtained for each ganglion. 
At each timepoint the number of TUNEL positive cells was expressed either for 
individual ganglia (L4 or L5), or as a combined (L4+L5) count. For neurons the total 
number per experimental group was used, whilst for satellite cells a mean figure per animal 
(within that experimental group) was calculated. 
2.5.2 Stereology 
Neuron counts were performed using an Olympus BX50 microscope with 
parfocalised 60x oil immersion and 4x objectives. Stereo logy was facilitated by a 
continuous video output, and a stage which was motorised in the X-Yplane under the 
control ofC.A.S.T. Grid™ software (Figure 2.5a). The number of surviving L4 & L5 
DRG neurons was estimated by the stereological technique of optical disection 124,135,136, 
124,135using an Olympus WU filter to permit simultaneous visualisation of both PI and 
H33342 staining. Neurons were easily distinguished from satellite cells on the basis of 
their size, and their larger, paler staining nuclei (Figure 2.5b). 
With this technique one initially estimates the ganglion's volume by using the 
Cavalieri Principle 130, which states that the volume of a structure approximates very 
closely to its mean cross-sectional surface area multiplied by its height. Mean surface area 
( a ) is calculated from measurements of the surface area (a) often or more serial sections 
in a systematic random sample from the ganglion. The "height" of the ganglion equals the 
total number of tissue sections cut from the ganglion (s) multiplied by the mean thickness 
of those sections ( t ). The volume ofthe ganglion (Vref) is therefore calculated thus: 
Vref = a. t. s 
(Vref= Volume of DR G) ( a = mean area of section ) 
( t = mean section thickness) ( s = total number of sections) 
In stereo logy every cell has an equal chance of being counted, obviating any bias due to 
variations in cell size, or distribution within the ganglion. Central to this tenet are the 
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counting rules associated with the optical disector bricks, and the process of systematic 
random sampling at all levels of the process after tissue sectioning. Sampling is achieved 
by starting from a randomly chosen start point, and then systematically moving through the 
ganglion, or tissue section, in a series of predetermined steps. 
In practise, a systematic random sample of the serial sections from each ganglion 
was obtained for volume estimation as follows. The start section (1 st_3rd of the serial 
sections) was selected using a random number table, and was examined along with every 
3rd subsequent section from the ganglion (Figure 2.6a). Where this randomisation 
procedure resulted in fewer than the required minimum often sections being available, the 
procedure was altered to select every second section (start section 1 st or 2nd). 
The neuron containing area (a) of each section was measured using C.A.S.T.-
Grid™ (Version 1) software by tracing its margins under a 4x objective (Figure 2.6b). The 
thickness (t) of every section examined was also directly measured, using a stage-mounted 
microcator and a 60x oil immersion objective, by focusing down from the surface of the 
section, to the focal plane at its underside. Results were then used for calculation of mean 
- -
section thickness ( t ), mean surface area ( a ), and hence of ganglion volume (V ref). 
The density, or ''Numerical Volume" (Nv), of neurons within the ganglion was then 
determined by using a series of optical disector bricks. These are cuboid, computer 
generated geometrical constructs of a known volume which are placed within the same 
tissue sections selected for volume estimation (Figure 2.6d). Systematic randomisation is 
performed in the X and Y-axes by movements (X -steps & Y -steps) from a random start 
point (Figure 2.6c). Using an objective lens with a narrow focal plane «1 Jim) the 
disector bricks are generated by focusing down through a predetermined distance within 
the thickness (Z-axis) of the tissue section. 
In practice, optical disection and systematic random placement of optical bricks 
within each section was performed by the C.A.S.T.-Grid™ system, which controlled a 
microscope stage motorised in the X-Yplane (Figure 2.6c). Manual movement in the Z-
axis (focusing down through the section) was tracked by the stage-mounted microcator .. 
The disector volume (V dis) was 81702 Jim3, X-steps and Y -steps were 300 Jim. 
The leading edge of the nucleus was used as the unique point ofthe neuron for cap 
counting; standard stereo logical counting frames 130 and optical disector counting rules 
were employed 136. These rules determine that only particles lying entirely within the 
volume of the bricks, or crossing any of three mutually perpendicular faces are counted. A 
"cap" is a particle, or neuron in this case, which meets the counting rules employed 
(Figure 2.6d). Neurons which cross any of the opposite three faces are not counted 
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Figure 2.6: Estimation of Volume & Neuron Count Within Dorsal Root Ganglia 
x 
Collect every 30~m serial section (total number of 
sections = s ) 
Randomly assign start section #1-3 
Examine every 3rd section 
(total number examined = Nsect ) 
Trace outline ofDRG section using 4x objective lens. 
Area (a) quantified by C.A.S.T. Grid system. 
Section thickness (t) measured with microcator. 
Calculate mean surface area ( a ) & thickness ( t ) of 
DRG sections: 
a = l: a / N sect t = l: t / Nsect 
Estimate Volume ofDRG (Vref) by Cavalieri Principle: 
Vref = a . t. s 
Set x & y steps between disector bricks. 
Within each area traced for volume estimation the c.A.S.T. 
Grid randomly assigns a start point and then systematically 
moves around the section in predetermined X & Y steps, 
placing a disector at each point. 
Each optical disector brick is therefore a tissue volume 
(x. y . b) created by focusing down through the tissue 
section. 
There are reference volumes above & below the 
disector, giving 3 inclusion & 3 exclusion faces. 
Neurons crossing an inclusion face ("caps") are 
included in the count (Npar), those crossing an exclusion 
face are not counted ("profiles"). 
The density of neurons (Nv) within the total number of 
disectors used (Ndis) is then calculated, and used to 
estimate the total number of neurons present within the 
ganglion: 
V dis = (x. y . h) . N dis Nv = Npar / Vdis 
Neuron Count Nv • Vref 
Due to the systematic random placement (sampling) of the disector bricks, and the 
equal number of inclusion and exclusion faces, every neuron within a ganglion has 
an equal chance of being counted, irrespective of its size or relative distribution. 
Neuron counts are therefore statistically unbiased. 
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("profiles"). The mean cap count was 148 (SD27.S) per ganglion, in keeping with the 
requirement to count between 100 and 200. 
The "cap" count thereby obtained is divided by the total volume within which 
counting was performed (i.e. individual disector brick volume multiplied by the total 




Vdis . Ndis 
(Nv= Numerical volume of neurons) (V dis = Volume of each optical dis ector brick) 
(Ndis = Number of optical disector bricks used) 
Finally, the numerical volume (Nv) of neurons is multiplied by the volume of the 
ganglion (Vref) to give the estimated number of neurons within the ganglion: 
Neuron Count N v • V ref 
(Neuron Count = estimated number of neurons per ganglion) 
The same sampling schedule, stereo logical counting frame, and optical disector 
counting rules were used for every count, and the number of neurons was expressed for 
individual ganglia (L4 or LS) and as a combined (L4 plus LS) count for each side 
(axotomised, or contralateral control). The combined L4+S count was used for the studies 
detailed in Chapters 3-5, since this comprises 98.4% ofthe entire sciatic nerve pool 253, 
and because individual counts are less sensitive as indicators of the effect ofaxotomy (cf. 
3.4.2). Neuronal loss was calculated by subtracting the number of neurons in axotomised 
ganglia from that in their contralateral controls. Loss was then expressed as a percentage of 
the neuron count in the control ganglia. 
2.5.3 Area o[Immunostaining (Skin Biopsies) 
All quantification was performed upon coded sections by one individual in order to 
eliminate inter-observer error. After staining, each section was examined by fluorescence 
microscopy on an Olympus BX60 microscope using a 20x objective lens. For each 
primary antibody a systematic random sample of 6 visual fields including both epidermis 
and dermis (PGP9.S & CGRP), or subcutaneous sweat glands alone (PGP9.5 & VIP) was 
captured for analysis using a high resolution fluid cooled digital spot camera (Diagnostic 
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Instruments U.S.A., Model 1.3.0). Similar exposure settings were used for every image 
captured. 
The area of immunostaining in each captured image was subsequently quantified 
by image analysis using Image-Pro-Plus™ (Version 4.0) software. First the colour 
immunofluorescent image (Figure 2.7a) was converted into greyscale (Figure 2. 7b), and 
then the area of interest (epidermis, dermis, or sweat gland) outlined by tracing its margins 
(Figure 2.7 c). An intensity threshold was then applied in order to differentiate the bright 
immunostaining from any low-level background autofluorescence, and the area of staining 
was calculated by the software package after manually deselecting any residual areas of 
background staining (Figure 2. 7d). Similar intensity thresholds were applied to every 
image quantified. 
The area of immunostaining was expressed either as a total area of immunostaining 
(f.lm2) or as a fraction of the total area of interest, whether that was epidermis, dermis, or 
sweat gland ("fractional area of immunostaining"). The area of immunostaining 
approximates closely to the actual area of each type of nerve fibre present, and therefore 
permits quantification of cutaneous innervation by each fibre type. 
The innervation present before commencing oral LAC (cf. 8.2) was compared to 
that found after 6 months of treatment (Le. change in fractional area of irnmunostaining, 
expressed as a percentage ofthe pre-treatment value), and both results were compared to 
the level of innervation found in non-neuropathic mv negative controls. For Patient 1 the 
innervation present 6 months after discontinuing LAC treatment was also quantified, and 
expressed relative to that present before discontinuing treatment. 
2.5.4 Regeneration Distance (Late Secondary Nerve Repairs) 
Regeneration distance was measured as the distance from the end of the proximal 
stump, to the tip of the most distal nerve fibre in each nerve graft, or distal stump where 
fibres had crossed the fulllcm gap (Figure 2.8a). After examining all the stained sections 
from a given repair in order to fmd the most distal fibres, the regeneration distance was 
measured under fluorescence microscopy using a graticulated lOX eyepiece, and lOX 
objective lens, such that each graticule measured a O.lmm distance. The mean 
regeneration distance for each type of repair was then calculated, and expressed in 
millimetres. 
2.5.5 Area o[Immunostaining (Late Secondary Nerve Repairs) 
All the stained sections from a given repair were examined by fluorescence 
microscopy using a lOX objective lens, in order to identify the two sections exhibiting 
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Figure 2.7: Quantification of Cutaneous Innervation by Image Analysis and Indirect 
Immunohistochemistry 
Quantification of cutaneous innervation by image analysis (Image-Pro-Plus®) and indirect 
immunohistochemistry with a FITC-conjugated secondary antibody. Positive staining shows as 
green fluorescence against the red background of the non-specific stain Pontamine Sky Blue [A). 
First the colour image is converted to a monochrome green image, which in turn is converted to 
greyscale [B]. The area of interest (epidermis, dermis, or sweat gland) is then outlined manually 
[C), and an intensity threshold applied to select only the areas of staining, which are brighter than 
the background [D]. The software then quantifies the selected area, which is expressed either as a 
total area (~m2), or as a percentage of the area of interest. Scale bar equals 40Jlm. 
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Figure 2.8: Measurement of Regeneration Distance and Area of Immunostaining as 





Nerve repairs were cut into 151lm cryosections and stained by indirect immunohistochemistry with 
antisera against the pan-neuronal marker PAMNF (red fluorescence) and the Schwann-cell marker 
S-100 (green fluorescence). Where the two stains overlap yellow fluorescence is seen. Regeneration 
distance [A] was measured from the end of the proximal stump to the tip of the most distal 
regenerating nerve fibre (blue arrow) using a graticulated eyepiece and a lOx objective lens. Surface 
area of immunostaining [B] was quantified by image analysis (Image-Pro-PlusTl\1) in a band of images 
captured at 20x magnification across the full width of the repair, and situated 1mm distal to the end 
of the proximal nerve stump (red rectangle). Area of immunostaining was expressed either as a total 





the best nerve regeneration. Due to the pattern in which serial sections were collected onto 
the slides, the two selected sections were always non-consecutive. 
In both the sections selected for measurement, a contiguous band of images lying 
1mm distal to the end of the proximal stump was captured across the full width of the graft 
using a high resolution fluid cooled digital camera (Diagnostic Instruments, U.S.A.), and a 
20X objective lens (Figure 2.8b). In each band of images the area ofimmunostaining for 
either S-100, or PAMNF was then measured using Image-Pro-Plus™ image analysis 
software. 
This process involved converting the monochrome colour image (red for PAMNF, 
green for S-100) into a greyscale image, and then applying an intensity threshold to select 
only the bright areas ofimmunostaining. Occasional areas of bright background staining 
were then deselected manually, and the total area of staining within that field recorded, 
along with the total area of the field. This process was repeated for all the images from 
each section, and the total area of immunostaining summated, along with the total area of 
the nerve graft present in the fields. The area of immunostaining was also calculated as a 
percentage of the area of the nerve graft, in order to facilitate comparison between nerve 
grafts of different diameters. 
A total often measurements was therefore recorded for each type of repair, and the 
mean value used for statistical comparison. Total area ofimmunostaining was expressed 
in Ilm2, and percentage area was quoted directly. 
2.5.6 Electron Microscopy Analysis 
Ultrathin sections were examined in a JEOL 100CX electron microscope at either 
3000X or 5000X magnification, and representative micrographs were taken. 
2.5.7 Statistical Analysis 
Statistics are like women, mirrors of purest virtue and truth, or like whores, to use as one pleases. 
Theodor Billroth 
Statistical comparisons were performed using SigmaStat™ (Version 2.0) software. 
Groupwise comparisons were performed by ANOV A, and pairwise comparisons by 
Students t-test, or the Mann-Whitney Rank-Sum Test where data distribution was non-
parametric, or not normal (assessed by the Kolmogorov-Smirnov Test). Comparison 
between pre- and post-treatment results within each individual was performed using the 
Paired t-test, or the Mann-Whitney Rank-Sum Test where data distribution was not normal. 
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Chapter 3. Timecourse & Morphological Features of Primary 
Sensory Neuronal Death After Peripheral Axotomy 
3.1 Introduction 
The extensive primary sensory neuronal death found after experimentally induced 
peripheral nerve lesions 47,55,97,107,1O8,1ll,113,1l4 (cf. 1.4) is likely to be a major factor in the 
poor clinical outcome of peripheral nerve trauma (cf. 1.1), and although a variety of stimuli 
may initiate neuronal death, loss of target derived neurotrophic support appears to be the 
most important determining the magnitude of neuronal death which ensues (cf. 1.5). The 
precise timecourse of this neuronal death remains undefined (cf. 1.4), as does that of 
satellite cell death within the adult DRG (cf. 1.4), and yet it should define the most relevant 
timepoints at which to study the effects of any putative neuroprotective strategies. The 
timecourse of neuronal death is also of fundamental clinical importance in defining a 
potential therapeutic window for any future neuroprotective interventions. 
The morphological features of post-axotomy primary sensory neuronal death are 
also of interest since there is debate over the mechanism by which neurons die, and this has 
clinical implications due to the difference in the therapeutic approaches to apoptosis and 
necrosis. Neuronal death has classically been deemed to occur by apoptosis 17 in a variety 
of settings, and there is recent evidence in support of this for axotomised primary sensory 
neurons 98, however other authors have postulated an active form of cell death that 
involves mixed morphological features of apoptosis and necrosis 146,254,255. 
This study therefore aimed to determine the timecourse of primary sensory neuron, 
and satellite cell death after a defined peripheral nerve transection. TUNEL was used as a 
marker of individual cell death in order to identify the onset of neuronal death, and to 
detect low rates of cell death (cf. 1.4). The magnitude of neuronal loss was then quantified 
from neuron counts obtained by the optical disector technique (cf. 1.4), and the 
morphological features of neuronal death were established using light and electron 
microscopy. 
3.2 Methods 
Under halothane anaesthesia young adult male Sprague-Dawley rats underwent 
either left or right-sided unilateral sciatic nerve division, and measures were taken to 
prevent spontaneous regeneration (cf 2.2.2). After survival periods of 1,4 days, 1,2 
weeks, 1,2,4 & 6 months (n=6 per timepoint) ipsilateral axotomised, and contralateral 
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control L4&L5 ganglia were harvested (cf. 2.3.1) for the preparation of frozen blocks (cf. 
2.3.2). Animals were also harvested (n=3) for electron microscopy of ganglia after a 
survival period of2 weeks (cf. 2.3.2). 
For TUNEL and stereological studies, each entire ganglion was cut into serial 
30llm cryosections (cf. 2.4.1a & 2.4.2a), and a microwave permeabilisation technique 
employed to optimise the sensitivity of a triple staining protocol (cf. 2.4.3) which 
incorporated TdT Uptake Nick-End Labelling (TUNEL), nuclear counterstaining with 
Hoechst 33342 (H33342) and cytoplasmic counterstaining with Propidium Iodide (PI). 
Each stain was visualised separately using fluorescence microscopy and band specific 
filters, allowing neurons to be easily distinguished from satellite cells on the basis of their 
size, relative distribution, and their larger, paler nuclei (Figure 2.5b). 
All sections were examined for the presence of TUNEL positive cells (cf. 2.5.1), 
and absolute numbers of TUNEL positive neurons were obtained for each ganglion. At 
each timepoint the number of TUNEL positive cells was expressed either for individual 
ganglia (L4 or L5), or as a combined (L4+L5) count. For neurons the total number per 
group was used, whilst for satellite cells a mean figure per animal was calculated. 
Stereological techniques were employed to obtain statistically unbiased estimates 
ofDRG volume, by the Cavalieri Principle 130, and the number of surviving L4 & L5 DRG 
neurons by the optical disector technique 124,135,136 (cf. 2.5.2). During optical disection an 
Olympus WU filter was used to allow simultaneous visualisation of both PI and H33342 
staining. Standard stereological counting frames, and optical disector counting rules were 
employed, and all stereology was performed using the c.A.S.T. Grid software system. 
Neuron counts were expressed both for individual ganglia (L4 or L5) and as a 
combined (L4 plus L5) count for each side (axotomised, or contralateral control). The 
number of neurons dying as a result of peripheral axotomy ("neuronal loss") was 
calculated by subtracting the number of neurons in axotomised ganglia from that in their 
contralateral controls, and was expressed as a percentage of the neuron count in the control 
ganglia. 
Separate DRG's were prepared for electron microscopy (cf. 2.4.1 b), and 
representative ultrathin sections cut for the preparation of electron micrographs (cf. 2. 4. 6). 
Statistical analysis of results was performed using the techniques described 
previously (cf. 2.5.7). 
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3.3 Results 
3.3.1a Morphology (Light Microscopy) 
TUNEL positive neurons displayed a range of morphologies (Figure 3.1A-C, E), 
although all had abnormal nuclei (H33342 staining) exhibiting pyknosis, chromatin 
condensation, or even nuclear fragmentation. Whilst many had cytoplasmic features 
typical of apoptosis (nuclear eccentricity, pyknosis, granulation, vacuolation) (Figure 3. lA, 
B), some exhibited an apparently normal cytoplasmic morphology (Figure 3.1 C). Satellite 
cells with abnormal, intensely stained, irregular, condensed or ring-shaped nuclei were 
frequently seen. Whilst many were TUNEL positive, a substantial minority were negative. 
Apart from the classical pattern of chromatolysis and nuclear eccentricity, other 
morphologically abnormal, but TUNEL negative neurons were seen. "Ghost cells", which 
are thought to represent the site of fully involuted apoptotic neurons, were occasionally 
found (Figure 3.1F), as were morphologically apoptotic neurons. Grossly dilated and 
vacuolated cells (Figure 3.1D) were found at every timepoint, with a peak incidence 1-2 
months after axotomy. These cells were found almost exclusively in axotomised ganglia, 
and had eccentric, elliptical nuclei, with a degree of chromatin condensation. Two such 
cells were TUNEL positive (Figure 3.1E). 
3.3.1 b Morphology (Electron Microscopy') 
Two weeks after axotomy, many primary sensory neurons showed essentially 
normal morphology (Figure 3.2A). Others exhibited morphological features ofaxotomy, 
with nuclear eccentricity and intact, normally distributed intracellular organelles (Figure 
3.2B). Many neurons in varying degrees of degeneration were also present (Figure 3.2C-
E), as were apoptotic bodies and occasional dilated, vacuolated cells. 
Mitochondrial swelling occurred in the absence of nuclear, or endoplasmic reticular 
disruption (Figure 3.2C), whilst structural disruption ofthe mitochondrial cristae was 
accompanied by the prominent nuclear irregularity and a degree of endoplasmic reticular 
dissolution (Figure 3.2D). Complete loss of normal mitochondrial morphology, with the 
appearance of vacuolation and mitochondrial disruption, occurred in conjunction with 
nucleolar fragmentation and other morphological features of cell death (Figure 3.2E). At 
higher magnification the extent of the disruption to the normal mitochondrial architecture 
that precedes nuclear dissolution is apparent, particularly when contrasted to neighbouring 
cells (Figure 3.2F). 
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Figure 3.1 Light Microscopic Morphological Features of Primary Sensory Neurons 
After Peripheral Axotomy 
Morphology of primary sensory neurons after peripheral axotomy. Positive TUNEL staining shows as 
green fluorescence, cytoplasmic staining by Propidium Iodide shows as red, and nuclear staining by 
Hoechst 33342 shows as blue. TUNEL positive neurons (solid arrows) showed a range of cytoplasmic 
morphologies (A-C, E). Typical features included pyknosis (A), granulation (A), vacuolation (B), and 
membrane blebbing (B). However some cells were essentially normal in appearance (C). Numerous 
enlarged and grossly vacuolated neurons were found at all timepoints studied (D, E, F). Generally 
such cells were TUNEL negative (outline arrow, D & F), however two TUNEL positive cells were 
found (E). Ghost cells (asterisks) were found in axotomised ganglia at early timepoints. Scale bar 
equals 20llm. 
Figure 3.2A&B: Electron Microscopy of Primary Sensory Neurons in 
a~ (...." 
B. 
Scanning electron micrographs of primary sensory neurons in axotomised ganglia, progressive 
deterioration of neuronal morphology can be seen. 
A. Cells initially show little morphological abnormality. 
B. Chromatin condensation and nuclear irregularity and peripheralisation then occurs, 
although mitochondria remain generally intact (arrows). Scale bar equals 2/J.m. 
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Figure 3.2C&D: Electron Microscopy of Primary Sensory Neurons in 
Axotomised Ganglia 
Scanning electron micrographs of primary sensory neurons in axotomised ganglia. 
C. Mitochondrial sweUing, and disruption of the cristae is evident (arrowheads), although the 
structure of the endoplasmic reticulum is maintained, and there is little nuclear abnormality. 
D. Vacuolation and loss of mitochondrial structure (arrows) is accompanied by nuclear irregularity, 
and disruption of the endoplasmic reticulum (asterisk). Scale bar equals 2/-lm. 
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Figure 3.2E&F: Electron Microscopy of Primary Sensory Neurons in 58 
Scanning electron micrographs of primary sensory neurons in axotomised dorsal root ganglia. 
E. In a dying neuron prominent nuclear irregularity, and nulcleolar fragmentation occurs in association 
with mitochondrial disruption, vacuolation (arrowheads), and rupture (arrows). Scale bar equals 211m. 
F. Higher power field illustrating the mitochondrial swelling (arrow), disruption of the cristae (arrowhead), 
and vacuolation (vertical arrowheads) that accompany nuclear eccentricity and irregularity. Normal 
mitochondria (inverted arrows) are seen in a neighbouring neuron that did not exhibit the morphological 
changes ofaxotomy. Scale bar equals Illm. 
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3.3.2 Terminal Deoxyribonucleotidyl Transferase Uptake Nick End Labelling 
(TUNEL Staining) 
TUNEL positive cells were found at all depths within tissue sections. The number 
found at each timepoint after axotomy is given in Table 3.1. 
TUNEL positive neurons were only found in axotomised ganglia, and were present 
at all timepoints (Figure 3.3). The cumulative (L4 plus L5) number ofTUNEL positive 
neurons at 1 day after axotomy was 2 cells/group, and first became significantly different 
from control ganglia after 1 week (15 cells/group, p<0.05). Numbers peaked at 25 
cells/group after 2 weeks (p<0.001), falling thereafter to 2 cells/group at 6 months. 
TUNEL positive satellite cells were present at all timepoints, and were more numerous in 
axotomised ganglia than in control ganglia. Subtracting the mean cumulative (L4+L5) 
count on the control side from that of the axotomised side gave a reflection of the number 
of satellite cells which were TUNEL positive due the direct effect ofaxotomy . This count 
was 6.8 cells per animal at 4 days, peaked at 20.2 cells at 2 months, and was 10.7 cells at 6 
months after axotomy (Table 3.1). 
3.3.3 Stereolo&a/ 
The number of neurons surviving after axotomy is given in Table 3.2, along with 
the calculated percentage neuronal losses. The mean neuron count in control L4 ganglia 
was 13983 (SD 568) and 16285 (SD 1313) for L5. No statistically significant differences 
were found between control ganglia at different timepoints (Figures 3.4-3.6), or between 
sides for L4 (right 13648, SD 1633; left 14187,SD 1633) or L5 (right 16574, SD 2853; left 
16112, SD 1864) ganglia. 
In axotomised ganglia the magnitude of neuronal loss was greater in L5 (peak loss 
7878 neurons, 43.6%) than L4 (peak loss 5024 neurons, 34.6%), however the timecourse 
of neuronal loss was comparable (Figures 3.4 & 3.5). No neuronal loss had occurred at 4 
days post-axotomy, indeed counts were marginally higher in the axotomised ganglia than 
in the contralateral controls (hence the calculation of "negative" loss in Table 3.2). 
Neuronal loss (L4+L5) in axotomised ganglia was first evident at 1 week post-axotomy 
(14.8% compared to control ganglia, p=0.045), reaching 35% at 2 months (p<0.001). 
Despite the fact that loss peaked 4 months after axotomy (39.2%; Table 3.3), the 
percentage loss found at 4 and 6 months was not statistically different from that found 2 
months after axotomy (Figure 3.6). 
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The change in the volume (Vref) ofthe neuron containing region of ganglia which occurred 
both as a result of the increasing age of animals over the study period, and due to the effect 
of peripheral axotomy is shown in Table 3.3. Axotomy caused a significant reduction in 
Vref (L4 plus L5) at 1 week post-axotomy (87.9% of control, p=0.04), which then fell to 
80.8% of control by 6 months (p<0.001). An age related increase of 68.4% in L4 and 
68.3% in L5 occurred in the neuron containing volume of control ganglia, whilst 
axotomised L4 and L5 ganglia both increased by only 28.0%. 
Table 3.1: Timecourse of Positive TUNEL Staining in Neurons & Satellite 
Cells After Peripheral Axotomy 
DRGNeurons Satellite Cells 
(total count per group) (mean count per ganglion) 
Control Axotomised Control Axotomised 
Timepoint Ganglia Ganglia Ganglia Ganglia 
L4+ L4 L5 L4+ L4 L5 L4+ L4 L5 L4+ LS L5 L5 LS 
1 day 0 1 1 2 5.5 4 10.3 5.5 4.8 10 
4days 0 5 3 8 2.2 4.3 6.5 7 6.3 13 
1 week 0 2 13 15 0.8 7.2 8 4.7 12 17 
* * * * 
2weeks 0 13 12 25 3.5 7.8 11 12 11 22 
* * ** * * 
1 month 0 4 2 6 3 2.7 5.7 4 10 14 
* 
2months 0 2 3 5 20 11 31 17 34 51 
4months 0 1 0 1 7.5 5.2 13 13 9.7 22 
* 
6months 0 2 0 2 5 2.3 7.3 8.2 9.8 18 
Figures are based upon experimeutal groups of 6 animals at each timepoint. 
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Total number of TUNEL positive neurons per group of 6 animals at each timepoint from 1 day up to 
6 months after sciatic nerve transection. Counts from L4 ganglia are in blue, from L5 in brown, and 
the combined L4+5 count is in green. TUNEL positive neurons are present 24 hours after axotomy, 
numbers peak 2 weeks after axotomy, and positive neurons are still present 6 months later 
(* p<O.05 compared to control). 
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Table 3.2: Change in Primary Sensory Neuron Counts After Peripheral 
Axotomy 
Control Ganglia Axotomised Ganglia Percentage Neuronal 
Mean (SD) Mean (SD) Loss 
Timepoint 
L4 L5 L4+L5 L4 L5 L4+L5 L4 L5 L4+L5 
4days 14233 15972 30205 15138 16413 31551 -6.0% -3.0% -4.5% (2810) (669) (1122) (4829) (1377) (3322) 
1 week 13517 14966 28483 11005 13256 24261 18.6% 14.3% 14.8% (2064) (2193) (1447) (452) (939) (2352) * * 
2weeks 13949 15692 29641 11239 12077 23317 19.0% 23.0% 21.3% (1193) (2198) (926) (1305) (1500) (876) * * ** 
1 month 14658 14647 29305 11349 11520 22869 22.6% 25.6% 22.0% (1953) (948) (474) (2497) (1727) (1295) ** ** ** 
2months 13948 17597 31545 9751 10709 20460 30.1% 39.1% 35.1% (1007) (2524) (999) (1230) (1082) (873) ** ** ** 
4months 14536 18055 32591 9511 10315 19826 34.6% 43.6% 39.2% (801) (2279) (791) (655) (621) (237) ** ** ** 




Figures are based upon experimental groups of 6 animals at each timepoint. 
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Timepoint After Peripheral Axotomy 
The timecourse of neuronal loss within the L4 dorsal root ganglia is shown. No loss had 
occurred 4 days after peripheral axotomy, however by 1 week an 18.6% loss had occurred 
(p<0.05). Loss then continued to increase until reaching 35% at 4 months after injury 
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The timecourse of neuronal loss within the L5 dorsal root ganglia is shown. No loss had occurred 
4 days after peripheral axotomy, however by 1 week a 14.3% loss had occurred (p>0.05). Loss 
then continued to increase until reaching 23% (p<0.05) at 2 weeks, and 39.1 % at 2 months after 
injury (p<O.OOI). The neuron loss at 4, and 6 months was not significantly greater (p>0.05) than 
at 2 months. 
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Figure 3.6 Effect of Peripheral Axotomy Upon Cumulattive L4 + L5 DRG 
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weeks month months months months 
Timepoint After Peripheral Axotomy 
The timecourse of sensory neuronal loss after peripheral nerve injury is shown. The number of 
neurons present in control ganglia (black) remained constant throughout the study period at 
~30,000 neurons per ganglion pair. The number of neurons in axotomised ganglia is shown in blue, 
and the calculated neuron loss (control- axotomised counts) is shown in brown. Four days after 
axotomy no neuron loss had occurred, however by 1 week after injury a 14.8% loss had occurred 
(p<O.05 compared to control). Loss then gradually increased, reaching a plateau by 2 months after 
injury (35% loss, p<O.OOI), and the neuron loss found at 4 & 6 months (39.2% & 34.5% 
respectively) was not significantly greater (p>O.05) than that found at 2 months. 
Table 3.3: Effect of Age & Peripheral Axotomy Upon Neuron Containing 
Volume of Dorsal Root Ganglia 
Age Related Increase Neuron Containing Volume of 
(from 4 days post-axotomy) Axotomised Ganglia 
Timepoint 
In Neuron Containing Volume of Ganglia (% of Control) 
Control Axotomised Control Axotomised L4 L5 L4+LS L4 L4 LS LS 
4 days 111% 105% 108% 
1 week 19.3% 3.0% 3S.9% 3.7% 9S% 80% 87.9% 
* * * * 
2weeks 30.1% -3.2% 22.7% -2.7% 82% 82% 82.6% 
* * * * 
1 month IS.0% -11.2% -2.3% -26.7% 85% 79% 82.2% 
* * * * 
2months 32.2% -4.6% 0.0% -3.1% 80% 69% 73.4% 
* * * * ** 
4months 63.4% 17.3% 69.3% 16.4% 80% 72% 7S.S% 
** ** * * * ** 
6months 68.4% 28.0% 68.3% 28.0% 82% 80% 80.8% 
* * ** * * * ** 
Figures are based upon experimental groups of 6 animals at each timepoint. 
*p Value <O.OS, **p Value <0.001 (left hand columns compared to to volume at 4 days post-axotomy, 




The experimental model was standardised as far as possible, since factors such as 
age and the proximity of the nerve transection to the ganglia affect the DRG neuronal 
response to injury 256,257, and the magnitude ofDRG neuronal loss 118. All animals 
68 
therefore underwent sciatic nerve division at the same age, and the level of transection was 
standardised against an anatomical landmark in the mid-thigh. Spontaneous regeneration of 
the transected sciatic nerves (which would restore distal trophic support) was prevented by 
ligating and capping both nerve stumps, and burying the proximal stump in an 
intermuscular pocket. This procedure also created significant physical barriers to the 
uptake by the proximal stump of distal stump derived neurotrophic factors, thereby 
clarifying the role of withdrawal of target organ and distal stump derived neurotrophins in 
determining the magnitude of neuronal death in vivo. 
TUNEL was initially proposed as a specific marker for apoptosis 140, however 
positive staining has subsequently been found in necrosis 141,142, and in the S-Phase of 
mitosis 143. Despite this, TUNEL remains a valid technique for detecting DNA 
fragmentation, which is the earliest irrefutable point of neuronal death. The results 
presented herein should therefore be interpreted as referring simply to cell death, and not 
specifically to apoptosis. 
Methodological concerns have previously been expressed over the sensitivity of 
TUNEL and ISEL staining due to inadequate tissue permeabilisation by traditional 
enzymatic methods, such as digestion with Proteinase-K 98,139. Microwave irradiation of 
tissue sections increases the efficacy of permeabilisation sufficiently to give a sensitivity of 
>90% with no reduction in specificity 139, and we therefore optimised a microwave 
permeabilisation protocol to maximise the sensitivity ofTUNEL staining. Despite using 
thick (30flm) tissue sections, penetration of the TUNEL reagents was not impaired, since 
TUNEL positive cells were found at all depths within tissue sections and not just in the 
surface layer. The specificity ofTUNEL staining was confirmed by the fact that all 
TUNEL positive cells exhibited abnormal nuclear morphology. 
Since optical disection avoids both the statistical bias of assumption based 
techniques 258 and the potential underestimates inherent to the physical disector technique, 
due to lost caps 124,131,259, it has been proposed as the ideal technique for estimation of 
neuron numbers. Although the technique has been validated both theoretically, and 
empirically against serial reconstruction counts ofDRG neurons 125,134, accuracy is 
dependent upon adherence to certain rules 129. Volume estimation by the Cavalieri 
Principle 130 requires the use of at least ten sections, whose thickness must be known 
accurately. Accordingly, section thickness was measured directly from the sections after 
staining, rather than assumed to be equal to that at which the sections were cut (tissue 
shrinkage during staining may invalidate such an assumption 135. Adequate numbers of 
caps were counted (cf. 2.5.2) to meet the requirement of 100-200 per ganglion 129, and at 
28% and 19% respectively the X & Y dimensions of the disector frame employed were 
>4% of the X & Y step distances 135. 
3.4.2 Neuron Counts 
The mean neuron counts in control ganglia (L4 13983, SD 568; L5 16285, SD 
1313; L4+L5 30268, SD 2548) were in agreement with other results in the literature 
obtained by optical 132,260,261 and physical 98 disector methods. There was no difference 
between the counts obtained from the left or right sides, negating concerns over other 
experimental models involving lesions on one side only 98. 
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Combined L4+5 counts have been calculated since this comprises 98.4% of the 
entire sciatic nerve pool 253. Furthermore, the variance in counts from individual control 
ganglia is greater than that found for combined counts (coefficient of variation L4 12%, L5 
14%, L4+5 8%). This suggests that biological constancy is maintained in the total number 
of neurons in the sciatic nerve root pool, rather than in the number of neurons present in 
anyone ganglion. As indicators of the effect ofaxotomy , changes in the combined counts 
are therefore more sensitive than changes in counts from individual ganglia. 
3.4.3 Neuronal Loss 
At 39.2%, the peak neuronal loss was broadly in keeping with results in the 
literature 55,113,114, although smaller losses have been reported 98,107,108. Variations may be 
due to different animal models, counting techniques, or levels ofaxotomy. Also, the 
procedure used to prevent spontaneous regeneration in this study may have excluded 
trophic support from the distal stump more completely than in other studies, resulting in 
greater neuronal death. One may estimate that 56-75% of the neurons that were actually 
axotomised died, since only 54-70% of neurons in L4 & L5 DRG's contribute axons to the 
sciatic nerve at the mid-thigh 108,253,262. That neuronal loss was greater in L5 than L4 
ganglia reflects the greater contribution of L5 neurons to the sciatic nerve at the mid-thigh 
262 
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3.4.4 Timecourse of Neuronal Death 
Primary sensory neuronal death was found to commence within 24 hours of sciatic 
nerve transection, as shown by the presence of TUNEL positive neurons at 1 day post-
axotomy. Whilst previous studies have given the exact onset of neuronal loss as being at 4 
55 to 10 108 days, we demonstrate that statistically significant neuronal loss in fact begins at 
7 days after sciatic nerve transection in the mid-thigh. The delay between the start of 
neuronal death, and that of neuronal loss reflects both the time taken for individual neurons 
to progress from DNA fragmentation to complete involution, and for the rate of death to 
increase sufficiently to overcome the masking effect of the normal biological variation in 
neuron numbers. 
Neurons take a few hours to progress from DNA fragmentation, and therefore 
positive TUNEL staining, to eventual involution in vitro 239,263 whilst a delay of days was 
found to be the case in axotomised neonatal facial motoneurones in vivo 123. In this study, 
at most 6 days passed between positive TUNEL staining and the occurrence of significant 
neuronal loss. Although cell death in the first few days may have occurred at too slow a 
rate to translate into significant neuronal loss, the full course of sensory neuronal death in 
vivo, from beginning (DNA fragmentation) to end (neuronal loss), appears to last some 
days. 
TUNEL staining also exhibits an earlier peak (at 2 weeks post-axotomy) than 
neuronal loss (at 4 months post-axotomy). ISEL staining (a marker specific for single, 
rather than double-strand DNA breaks) was similarly found to peak at 3 weeks post-
axotomy 98, although the count was only a single neuron less at 2 weeks. The peak 
incidence of DNA fragmentation, and so of neuronal death, therefore occurs some 2-3 
weeks after peripheral nerve transection. 
Neuronal loss was found to occur predominantly during the first 2 months after 
injury, since the losses found at 4 and 6 months were not significantly different to that 
found 2 months after axotomy. This is broadly in keeping with the literature although no 
previous study has involved sufficiently long survival times 55, and been as detailed 55,98,108. 
The discrepancy between the timecourse of TUNEL staining, and that of neuronal 
loss reflects a difference in what each technique detects. As a marker of DNA 
fragmentation TUNEL staining detects the beginning of a cell's death, rather than the 
subsequent elimination reflected by neuronal loss. TUNEL positivity therefore precedes 
loss, with the number of positive neurons at any timepoint reflecting the rate of cell death, 
whilst neuronal loss quantifies the total number of cells which have died up until then. 
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It was unclear for exactly how long neuronal death continues after a peripheral 
nerve injury. As discussed previously, neuronal loss is a relatively crude measure ofthis, 
and various studies have not found any statistically significant increase in neuronal loss 
beyond 1-2 months after axotomy 55,98,108; current results). Indeed there is a trend (not 
statistically significant) for neuronal loss to be less at 6 months post-axotomy than at 2 
months (Groves et aI., 1997 98; current study). However it is clear from the presence of 
morphologically apoptotic 98, and TUNEL positive neurons, that neuronal death does 
continue for at least 6 months after axotomy. Death is likely to be due to axotomy rather 
than old age, since control ganglia showed no evidence of neuronal death, and since L4 
neuron counts at 3 months and 3 years of age in male Sprague-Dawley rats are not 
statistically different 260. In the cat however, neuronal loss may continue up to 18 months 
post-axotomy 264, although this result was obtained using assumption-based counting 
techniques and may not be entirely accurate as a result. 
It is the large discrepancy between the number of TUNEL positive neurons found, 
and the magnitude of neuronal loss that remains to be adequately explained. The number 
of TUNEL positive neurons found in this study was low (although greater than in other 
studies), yet this was unlikely to be due to inadequate permeabilisation since microwave 
irradiation was used, as discussed previously. It is not clear from the literature for how 
long a dying cell will stain positively with TUNEL in vivo, although estimates range from 
as little as 2-5 minutes 139. In Gavrieli's original description cells are described as being 
TUNEL positive before they are morphologically apoptotic 139, and it is likely that cells are 
potentially TUNEL positive for only a few hours before condensation into nucleosomes 
masks the DNA fragments 122. This condensation precedes the more advanced 
morphological features of apoptosis, and indeed whilst positive ISEL staining of neurons 
peaks at 3 weeks post-axotomy, numbers of morphologically apoptotic neurons are still 
increasing at 4 weeks 98. This brief time window for staining is therefore the most likely 
explanation for the discrepancy between the small number of TUNEL positive neurons, 
and the large number lost. Additionally, some neuronal death may occur without any 
potentially stainable DNA strand breakage, as has been demonstrated in other cell types 
146 
3.4.5 Mechanism of Neuronal Death 
Electron microscopy (EM) revealed a similar pattern of morphological findings to 
those previously described for axotomised or dying neurons 56,98,146,265, with a mixture of 
apoptotic and other features (cf. 3.3.1 b). Although a more extensive study would be 
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required in order to attempt an accurate morphological consideration of the mode of death 
265, the relationship between neuronal death and mitochondrial accumulation, swelling and 
disruption was highlighted. This has previously been shown in retrogradely degenerating 
neurons of the dorsal lateral geniculate nucleus 53, but has not been specifically 
demonstrated in axotomised primary sensory neurons. 
TUNEL positive neurons exhibiting no abnormalities of cytoplasmic morphology 
were found at the light microscopic level, and may represent apoptotic cells caught just 
prior to the development of visible morphological features 143,155. Many neurons did 
display cytoplasmic granulation, vacuolation, pyknosis and membrane irregularities in 
keeping with apoptosis, however the morphological findings were not all classically 
apoptotic, and these limited fmdings may therefore add to the current debate over the 
precise morphological pattern of neuronal death. 
The grossly dilated and vacuolated cells which were predominantly found in 
axotomised ganglia have been previously described 57, and demonstrated to be large, GAP-
43 positive, myelinated neurons containing proteinaceous material 56. Since none of the 
neurons were ISEL positive 56 the features were ascribed to regeneration rather than cell 
death. However our fmding of two TUNEL positive neurons may mean that such dilation 
is in fact a morphological feature of post-axotomy adult primary sensory neuronal death. 
The previous failure to demonstrate DNA fragmentation could merely be a result of the 
small number of such neurons, and the small percentage of dying neurons detected by 
DNA fragment labelling. Furthermore, the number of such cells present closely matches 
the timecourse of neuronal loss, and is reduced by NT3 administration 56, which might be 
expected to increase regeneration 47. Recent electron microscopical studies reviewed by 
Clarke 146 have cast doubt upon the classical apoptotic description of adult neuronal death, 
and his Type 3B ("cytoplasmic") cell death has morphological features similar to those 
found here. Apoptosis has been discounted as the mechanism in other forms of adult 
neuronal death 266, and it may be the case therefore that the dilated vacuolated morphology 
is another pattern of death in myelinated primary sensory neurons. 
3.4.6 Effect ofAxotomy Upon Ganglion Volume 
The 27% rise in control L4 dorsal root ganglion volume between 2 and 6 months of 
age matches the previously described 28% increase in volume from 3 to 30 months of age 
260, since ganglion volume reached its maximum by 4 months of age in this study (Table 
3.3). A 68% increase in volume was found in both L4 and L5 control ganglia over the first 
6 months of life, however in axotomised ganglia volume increased by only half as much 
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(28%), presumably reflecting their reduced cellularity. Axotomy caused a volume 
reduction in both L4 and L5 ganglia when compared to controls that commenced 1 week 
after axotomy and plateaued after 2 months. Axotomised ganglia were not only smaller 
than controls, they also shrank from their baseline volume (before neuronal loss 
commenced 4 days after axotomy), and did not begin to exhibit the normal age related 
increase in ganglion volume until after the main period of neuronal death had finished (i.e. 
after 2 months post-axotomy). Loss of volume may therefore reflect the actual loss of cells, 
but since it was of a lesser magnitude than neuronal loss it must also reflect the reduction 
in volume of surviving neurons 55. This implies that as neurons die the spatial relationship 
of surviving cells is altered, which may have implications for local neuron-glia 
interactions, and for local concentrations of trophic factors. 
3.4.7 Axotomy Induced Satellite Cell Death 
ISEL positive satellite cells have previously been noted 98 in control and 
axotomised ganglia, however the timecourse of cell death was not reported. TUNEL 
positive satellite cells were consistently found within axotomised ganglia, and showed a 
definite temporal relationship to sciatic nerve division with a peak 2 months after axotomy. 
In this adult study the TUNEL positive neuronal peak preceded the satellite cell peak by 6 
weeks, as opposed to 3 days in neonates 100, implying a difference in the precise 
relationship. Delayed oligodendrocyte death after optic nerve 121, and spinal cord injury 138 
has been noted in adults, where it was thought to be due to axonal degeneration, and was 
implicated in demyelination of surviving axons, and expansion of the cord lesion. The 
presence of TUNEL positive satellite cells in control ganglia may represent constant 
physiological turnover in this potentially labile cell population, although the marked 
increase in the number of positive cells 2 months after axotomy suggests a direct effect of 
contralateral axotomy, perhaps mediated by degeneration ofneurites in crossed tracts. 
These facts imply that adult primary sensory neuronal death induces delayed secondary 
death of satellite cells, perhaps mediated by trophic interdependence mechanisms or 
neurotoxic cytokines. The significance of satellite cell death is unclear, however it merits 
further investigation given the key role which satellite cells play in maintaining the 
neuronal capacity to resist oxidative stress and cell death. 
3.4.8 Conclusions 
These results therefore offer a logical time-structure for in vivo experiments on 
primary sensory neuronal death, and for testing any potential therapies to prevent neuronal 
death. The secondary satellite cell death described remains to be fully characterised, as do 
the precise mechanisms of neuronal death, and the features that differentiate the neurons 
which survive from those that die. 
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Chapter 4. The Effect of Peripheral Nerve Repair Upon 
Axotomy Induced Sensory Neuronal Death 
4.1 Introduction 
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As previously discussed (cf. Chapter 2), it is likely that the single most important 
determinant of the poor sensory outcome after peripheral nerve injury is the death of a 
substantial proportion of the primary sensory neurons in the injured nerve's sensory 
neuronal pool (cf. 3.4.3). Reducing this neuronal death ought therefore to improve 
outcome. Surgical repair is the standard treatment for peripheral nerve injuries, yet despite 
the known protective effects of exogenous neurotrophic factors 47,105,109,217, the effect of 
nerve repair (which restores trophic support from the distal stump 17) upon sensory 
neuronal death is not clear. Nor is it known whether the timing of the nerve repair after 
injury affects the extent of neuronal death. 
Sensory neuronal death after crush injuries (axonometsis) is markedly less than that 
found after nerve transections (neurometsis) 107,116, yet in both cases neurons are 
peripherally axotomised. The principal difference is that with a crush injury the connective 
tissue structure of the nerve remains intact, and so the axon stumps therefore remain in 
contact with the distal segment of the nerve which produces the neurotrophic factors that 
are so essential for neuronal survival 17. By reapproximating the proximal and distal nerve 
stumps, surgical repair of a transected nerve may result in a situation more akin to a crush 
injury and so have a protective effect against sensory neuronal death 116,1l7. If this were the 
case, then one would expect that the earlier the nerve is repaired the greater the protective 
benefit would be. 
The importance of the timing of peripheral nerve repair upon neuronal death is also 
of great clinical importance, since it would affect not only the planning of elective nerve 
repairs (as in brachial plexus injuries), but potentially influence the way in which trauma 
surgery services are structured. Currently, peripheral nerve repairs are not generally 
considered to require immediate repair, and cases are frequently postponed for some days 
due to lack of theatre availability. If the timing of nerve repair were to determine the 
magnitude of sensory neuronal death, and so the potential for the return of normal 
sensation, then the current situation would be unacceptable and a restructuring to allow 
patients more rapid access to surgical nerve repair would become necessary. 
This study therefore aimed to establish, in principle, whether or not the timing of 
nerve repair does affect the magnitude of sensory neuronal death occurring after a 
peripheral nerve transection, as determined by TUNEL, and stereo logical neuron counts. 
4.2 Methods 
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In two groups of young adult male Sprague-Dawley rats (n=6 per group) a 
unilateral sciatic nerve transection was performed, and the nerve was then repaired by 
epineurial suture coaptation either immediately (cf. 2.2.5), or following a 1 week delay (cf. 
2.2.6). The animals were terminated (cf. 2.3.1) and the L4 & 5 dorsal root ganglia (DRG) 
harvested (cf. 2.3.2), 2 weeks after the initial nerve transection. The ganglia were 
processed (cf. 2.4.1a, 2.4.2a & 2.4.3) for quantification of neuronal death by TUNEL (cf. 
2.5.1), and by stereological determination of the number of sensory neurons using the 
optical disector technique (cf. 2.5.2). 
A control group, whose nerves were not repaired, was provided by a group of 
animals whose ganglia were harvested 2 weeks after sciatic nerve transection, as described 
in the previous chapter (cf. Chapter 3). 
4.3 Results 
The timing of peripheral nerve repair affected the number of TUNEL positive 
neurons present in axotomised DRG's, as is displayed in Table 4.1, and Figure 4.1. 
Contralateral control ganglia did not contain any TUNEL positive neurons, and the number 
present in axotomised L4+5 ganglia 2 weeks after axotomy was 25cells/group (p<0.001 
compared to contralateral control ganglia) when the sciatic nerve was not repaired. This 
count was almost halved when the nerve was repaired after a 1 week delay (14cells/group, 
p=0.016 vs. contralateral control ganglia), and immediate nerve repair resulted in an even 
greater reduction in the number ofTUNEL positive neurons, to 11 cells/group (p=0.002 vs. 
control ganglia), which reached statistical significance (p<0.05 vs. no repair). The 
difference between the counts obtained after immediate and delayed repair was not 
statistically significant however. 
A similar pattern was found when the number of dying neurons (neuronal loss) was 
quantified. In the group whose sciatic nerves were not repaired 21.3% of all L4+5 DRG 
neurons had died (6324 neurons, p<O.OOI compared to contralateral control ganglia) within 
2 weeks of nerve transection (Table 4.1, Figure 4.1). Neuronal1oss was reduced after 
nerve repair, being 12.4% (2450 neurons, p>0.05 vs. control ganglia) in the group whose 
nerves were repaired after a 1 week delay, and 4.80% (1236 neurons, p>0.05 vs. control 
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Table 4.1: Effect of the Timing of Nerve Repair Upon Sensory Neuronal Death 
No Nerve Delayed Nerve Immediate Nerve 
Repair Repair Repair 
Mean Neuronal Loss 
6324 2450 1236 L4+L5Combined .. 
TUNEL Positive Neuron 
Count (per Group) 25 14 11 
L4+5 Combined ** * * 
Figures are based upon experimental groups of 6 animals at each timepoint. 
*p Value <0.05, **p Value <0.001 (compared to contralateral control). 
Figure 4.1: Effect of the Timing of Nerve Repair Upon Sensory Neuronal 
Death 
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TUNEL Neuron Loss 
Both the number ofTUNEL positive neurons (plain bars), and the neuron loss (hatched bars) 
found 2 weeks after sciatic nerve transection are reduced by peripheral nerve repair. Immediate 
repair (green) is more protective than repair after a 1 week delay (pink), when to compared to 
nerves which were not repaired (blue). 
(* p<0.05 compared to no nerve repair; ** p<O.OOl compared to contralateral control ganglia). 





In order to limit confounding factors such as the proximity of the nerve transection 
to the ganglia, the experimental model was standardised as far as possible (cf. 3.4.1), and 
the nerve repairs were performed using standard clinical techniques in order to maximise 
the clinical applicability of the results. The merits ofTUNEL as a marker of neuronal 
death, particularly when combined with microwave tissue permeabilisation have been 
discussed previously, as have the benefits of optical disection in producing statistically 
unbiased neuron counts for the calculation of neuronalloss (cf. 3.4.1). 
DRG's were harvested 2 weeks after transection of the sciatic nerve, since this was 
when neuronal death peaked in animals whose nerves were not repaired (cf. 3.4.4), and 
was the earliest timepoint at which neuronal loss was highly statistically significant 
(p<O.OOl). Cumulative results for L4 & L5 ganglia were also used to maximise the 
sensitivity of the experiment in detecting any effect upon the death of sensory neurons in 
the sciatic nerve pool (cf. 3.4.1). This is also the reason that a mid-thigh lesion was 
employed, rather than a more distal lesion comparable to the more common clinical 
injuries to the median or ulnar nerves at the wrist, or to digital nerve injuries. By using a 
lesion that induces a greater magnitude of neuronal death 17, the chance of detecting a 
protective effect against neuronal loss is enhanced. Results still ought to be directly 
applicable to distal nerve injuries, since the lesser magnitude of neuronal loss found with 
these injuries 118 probably reflects the smaller number of neurons which are actually 
axotomised, and the response of neurons which are actually injured may remain constant 
267 (cf. 1.4). 
4.4.2 Nerve Repair Reduces Primary Sensory Neuronal Death 
Nerve repair, and its timing, was found to reduce sensory neuronal death. The 
number of TUNEL positive neurons present 2 weeks after axotomy was almost halved by 
repair after a one week delay, and was further reduced after immediate nerve repair, an 
effect which reached statistical significance (p<O.05). The same pattern was found for 
neuronal loss; 21.3% of all L4 & L5 DRG neurons had died two weeks after transection of 
the sciatic nerve, yet when the nerve was repaired after a one week delay this loss was 
halved, to 12.4%. Neuronal loss was further halved after immediate repair, to 4.8%, 
thereby demonstrating the protective effect of early nerve repair. During the first week 
after sciatic nerve transection 14.8% of neurons die (Table 3.2), so the fact that the loss 
found in the delayed repair group one week later (2 weeks after nerve injury) was no 
greater would further suggest that surgical nerve repair is indeed highly neuroprotective. 
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The fact that the differences in neuronal loss between groups with or without nerve 
repair were not statistically different is most probably due to the fact that 2 weeks is not 
long enough to develop a difference of the magnitude required for statistical 
differentiation. Additionally, the fact that the difference between the neuron counts 
obtained from axotomised, and control ganglia was highly statistically significant 
(p<O.OOI) when the sciatic nerve was not repaired, but did not reach statistical significance 
in either of the nerve repair groups suggests that the effect of nerve repair upon neuronal 
loss was real. 
Peripheral crush injuries do not involve physical disruption of the nerve trunk and 
cause less neuronal death than transections 107,116, whilst immediate nerve repair reduces 
sensory neuronal death to the same level as that found after a crush injury at the same site 
107. It would therefore seem likely that although the mechanism by which nerve repair 
reduced neuronal death remains to be clarified, restoration of physical continuity between 
the proximal and distal nerve stumps is likely to be involved. 
The reduction in neuronal death is unlikely to be due to a reduction in the local 
production of neurotoxic inflammatory cytokines or antidromic electrical activity by the 
distal stump, since delayed repair was protective despite potentially involving additional 
trauma to the nerve during the second procedure. The most likely explanation for the 
reduction in sensory neuronal death is therefore that by repairing the nerve the axons in the 
proximal stump are brought into close proximity with the distal stump, whose Schwann 
cells are the principal source of neurotrophic factors after nerve injury 17,90. Further 
confirmation of this has come from subsequent experiments in our laboratory in which a 
primary lcm gap repair was performed using either an acellular bioresorbable conduit, or 
one containing cultured autologous Schwann cells. Whilst sensory neuronal death was not 
affected by repair with an acellular conduit, a substantial reduction in neuronal death 
occurred after repair with a conduit containing Schwann cells. 
4.4.3 Conclusions 
These results therefore give further support to the hypothesis that loss of distal 
stump neurotrophic support is the major factor determining the magnitude of neuronal 
death after peripheral axotomy, however the clinical implications of this study are more 
profound. It would appear that surgical nerve repair does reduce sensory neuronal death 
after peripheral nerve injury, and that the earlier the repair is performed, the greater the 
protective effect. This has obvious clinical importance for both elective and emergency 
nerve surgery, since it would seem that sensory outcome might be improved by repairing 
the nerve as soon after injury as is clinically feasible. 
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Further work is required to establish whether nerve repair is equally protective in 
more distal nerve injuries, and to defme the maximum acceptable delay between injury and 
performing nerve repair. However from the results of the timecourse study (cf. Chapter 3) 
it is clear that neurons begin to die within 1 day of peripheral nerve injury, so that it would 
seem inadvisable to delay repair even by 24 hours where there is no contraindication to 
primary repair. Equally it would seem advisable to perform early secondary nerve repairs 
within two weeks of injury, as that is when neuronal death reaches a peak, and to perform 
late secondary nerve repairs within two months of injury since neuronal loss is virtually 
complete by this timepoint (cf. 3.4.4). 
Chapter 5. Therapeutic Potential of N-acetyl-cysteine in 
Peripheral Nerve Trauma 
5.1 Introduction 
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Sensory neuronal death is probably the single most important factor determining 
the poor sensory outcome of peripheral nerve injuries (cf. 1.1), and yet no therapies are 
currently clinically available that reduce it. Despite the reduction in neuronal death 
achieved by immediate nerve repair (cf. 4.4.2) there is still a need for an adjuvant therapy, 
since immediate nerve repair did not eliminate neuronal death, nor is it likely to be 
clinically feasible for the majority of patients (cf. 1.6). Although the administration of 
exogenous neurotrophic factors (NTF's) is neuroprotective after experimental peripheral 
and central nervous system lesions 17,105,106,214,215, their immediate clinical applicability 
remains doubtful (cf. 1.6). 
In contrast to the specificity of neurotrophic factors 47, there appears to be relative 
homogeneity in the way that the initiation of neuronal death is signalled and then effected 
in different subpopulations 103,166 (cf. 1.5). A therapeutic agent acting at this level ofthe 
cell death process therefore ought to be protective for a wide range of neuron subtypes 
against a wide range of stimuli. As described previously (cf. 1.6), the apparent role of 
reactive oxygen species generation in neuronal death (cf. 1.5) makes N -acety I-cysteine, 
and other antioxidants potentially attractive as clinically applicable neuroprotective agents 
268 after ischaemia reperfusion or trauma 269. The additional roles of abortive entry into the 
cell cycle, and glutathione dependent nitric oxide mediated mitochondrial bioenergetic 
dysfunction (cf. 1.5) makes N-acetyl-cysteine particularly attractive (cf. 1.6) since it not 
only has direct antioxidant properties, but may also affect regulation of the cell cycle, and 
is a glutathione substrate. 
NAC is currently in clinical use as a mucolytic agent in respiratory disease and as a 
treatment for paracetamol (acetominophen) poisoning 241, where it acts to maintain 
glutathione levels in hepatocytes. Glutathione acts a free radical scavenger in neurons 270, it 
helps maintain mitochondrial oxidative metabolism by protecting the cytochrome oxidase 
complex I from NO mediated damage 199, and improves neuronal survival in response to a 
range of insults in vitro 197,242,243. By acting as a cysteine donorNAC maintains 
intracellular glutathione levels 191, and is neuroprotective for a range of neuronal cell types 
against a variety of stimuli in vitro 160,206,271-273. NAC may therefore reduce neuronal death 
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by blocking attempted entry into the cell cycle, and by improving the capacity to maintain 
redox balance, and normal mitochondrial function. 
Similarities exist between the mechanisms underlying post-axotomy neuronal death 
throughout the entire nervous system, both peripheral and central 166, and as a result, any 
intervention that reduces primary sensory neuronal death may also have therapeutic 
implications for the management of brain, and spinal cord trauma. This study therefore 
investigated the effect of systemic NAC treatment upon primary sensory neuronal death 
after peripheral nerve injury with the aim of determining its potential for therapeutic use in 
clinical practice. A combination of TUNEL staining, and neuron counting by the optical 
disector technique was used to assess the effect of treatment upon neuronal survival (cf. 
1.4). 
5.2 Methods 
Groups of young adult male Sprague-Dawley rats (n=6) underwent unilateral 
sciatic nerve division (cf. 2.2.2), and immediately after nerve transection parenteral 
treatment with N-acetyl-cysteine (NAC) was commenced at either 150mg/kglday ("high-
dose"), or 30mg/kglday ("low-dose") as detailed in section 2.2.4. Another experimental 
group ("sham treatment") received an identical volume of 5% dextrose solution (cf. 2.2.4), 
and all animals were dosed until termination (cf. 1.2.1b). Two further control groups were 
provided by the animals whose DRG's were harvested 2 and 4 months after sciatic nerve 
transection in the timecourse study (cf. Chapter 4). 
The L4 & L5 DRG's were harvested from both the axotomised, and contralateral 
control sides (cf. 2.3.2) at either 2 weeks (all treatment groups), or 2 months (one "high-
dose treatment", and one "no treatment" group) after sciatic nerve transection (cf. 2.2.4). 
The ganglia were then processed (cf. 2.4.1 a, 2.4. 2a & 2.4.3) for quantification of neuronal 
death by TUNEL (cf. 2.5.1), and by stereo logical determination of the number of surviving 
neurons using the optical disector technique (cf. 2.5.2). The mean cap count was 152 
(SD25.6) per ganglion, in keeping with the requirement to count between 100 and 200, and 




No adverse effects upon animal behaviour were found, and weight gain during the 
study period was not significantly affected at either 2 weeks (p=O.87) or 2 months (p=O.30) 
by NAC treatment. 
5.3.1 Morphology 
When compared to normal ganglia (Figure 5.1A), prominent morphological 
changes were present in the axotomised ganglia of untreated animals, with the majority of 
neurons exhibiting nuclear eccentricity, and chromatolysis (Figure 5.1B). Neurons 
displaying features of apoptosis (cytoplasmic granulation, vacuolation, membrane 
irregularities) were seen, as were numerous enlarged, and grossly vacuolated neurons. 
Although the morphological findings were unchanged by sham treatment with 5% dextrose 
solution (Figure 5.1 C), NAC caused a qualitative improvement in neuronal morphology, 
which was more pronounced after high-dose NAC treatment (Figure 5.1 E) than after low-
dose treatment (Figure 5.1 D). 
5.3.2 TUNEL Staining 
The effect ofNAC treatment upon the number of TUNEL positive neurons, and the 
neuronal loss found 2 weeks after axotomy is summarised in Table 5.1, whilst Table 5.2 
gives the equivalent fmdings 2 months after axotomy. 
TUNEL positive neurons were only found in axotomised ganglia, and all exhibited 
nuclear morphological features of cell death (chromatin condensation, and nuclear 
irregularity, or fragmentation). These neurons displayed a similar range of cytoplasmic 
morphologies to those described in chapter 3.3.la (Figure 3.1). Two weeks after sciatic 
nerve transection the total number of TUNEL positive neurons present in the axotomised 
L4&5 ganglia of untreated animals was 25 neurons per group of 6 animals, and sham 
treatment had no significant effect (19 neurons/group, p=0.405). Treatment with NAC at 
both the low (7 neurons/group), and high (2 neurons/group) doses used did however cause 
a reduction in the number of TUNEL positive neurons, when compared to either sham 
treatment (low-dose p=O.065; high-dose p=O.003), or no treatment (low-dose p=O.015; 
high-dose p=O.002). The number ofTUNEL positive neurons found in axotomised ganglia 
2 months after axotomy was also reduced by high-dose NAC treatment (Table 5.2). 
Figure 5.1: Effect ofN-acetyl-cysteine (NAC) Treatment Upon Primary Sensory 
Neuronal Morphology After Sciatic Nerve Transection 
Dorsal root ganglia 2 weeks after sciatic nerve 
transection stained with the nuclear dye 
Hoechst 33342 (blue fluorescence) and the 
cytoplasmic dye propidium iodide (red 
fluorescence). Control ganglia [A] contain 
neurons with normal cytoplasmic 
morphology, surrounded by numerous 
smaller satellite cells, in which nuclear 
staining predominates. 
Two weeks after sciatic nerve transection [B] gross morphological changes are evident, with most 
neurons displaying nuclear eccentricity, membrane irregularities, and cytoplasmic granulation or 
vacuolation (hollow arrow). Apoptotic neurons are also evident (solid arrow). Morphology was not 
affected by injections of sterile 5% glucose (sham treatment) [C], and was only slightly improved after 
low-dose NAC treatment [D]. After high-dose NAC treatment neuronal morphology is significantly 
more normal [E]. Scale bar equals 40~m. 
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Table 5.1: Effect ofN-acetyl-cysteine mAC) Treatment Upon Sensory Neuronal 
Death 2 Weeks After Axotomy 
Control Ganglia Axotomised Ganglia Percentage (L4+5) (L4+5) Neuronal Loss Treatment Group Mean (SD) Mean (SD) (L4+5) 
TUNEL Neuron TUNEL Neuron 
Count Count Count Count 
No Treatment 0 29641 25 23317 21% (2268) (2146) 
Sham Treatment 0 29845 19 23625 21% (1553) (1899) 
Low Dose NAC 0 30844 7 30441* 1%* (30mg/kg/day) (1567) (2321) 
High Dose NAC 0 31761 2* 30699* 3%* (150mg/kg/day) (2804) (4942) 
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The total number of positive neurons present in the axotomised, or contralateral control ganglia of 
each experimental group (n=6) is shown. Neuron counts are the mean (standard deviation) number of 
neurons present in either the axotomised, or contralateral control L4 & L5 dorsal root ganglia of each 
experimental group. Neuronal loss was calculated by subtracting the mean neuron count in the 
axotomised ganglia from that in the contralateral control ganglia, and is expressed as a percentage of 
the control value. * P value <0.05 compared to sham treatment. 
Table 5.2: Effect of N-acteyl-cysteine mAC) Treatment Upon Sensory 
Neuronal Death 2 Months After Axotomy 
Control Ganglia Axotomised Ganglia 
(L4+5) (L4+5) Percentage 
Treatment Group Mean (SD) Mean (SD) Neuronal Loss 
TUNEL Neuron TUNEL Neuron (L4+5) 
Count Count Count Count 
No Treatment 0 31545 5 20460 35% (2446) (2138) 
High Dose NAC 0 30034 3 29243* 3%** (150mg/kg/day) (4539) (4100) 
~. .. - ---_._-
The total number of positive neurons present in the axotomised, or contralateral control ganglia of 
each experimental group (n=6) is shown. Neuron counts are the mean (standard deviation) number of 
neurons present in either the axotomised, or contralateral control L4 & L5 dorsal root ganglia of each 
experimental group. Neuronal loss was calculated by subtracting the mean neuron count in the 
axotomised ganglia from that in the contralateral control ganglia, and is expressed as a percentage of 
the control value. * P value <0.05, ** P Value <0.005 compared to no treatment. 
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5.3.3 Neuronal Loss 
The effect ofNAC treatment upon the number of neurons present in both 
axotomised, and contralateral control DRG's 2 weeks after nerve injury is shown in Table 
5.1, and 2 months after injury in Table 5.2. Two weeks after axotomy the mean number of 
neurons present in the non-axotomised, contralateral control ganglia (L4+5) of untreated 
animals was 29641 (SD2268), and this was not significantly affected by sham treatment 
with 5% dextrose solution (29845 neurons, SD1553; p=0.86), or by treatment with NAC 
(low-dose 30844 neurons, SD3839, p=0.58; high dose 31761 neurons, SD2804, p=0.18). 
Two months after axotomy there was still no difference between the counts obtained from 
untreated animals (31545 neurons, SD2446), and those from animals which received high 
dose NAC treatment (30034 neurons, SD4539; p=0.52). 
Two weeks after axotomy 21 % (p=0.002 vs. control ganglia) of all neurons in the 
axotomised L4&5 ganglia had died in the groups receiving sham treatment (Table 5.1), and 
this was the same as occurred in animals which received no treatment (21 % loss, p=0.96). 
This loss of neurons was almost completely eliminated by treatment with NAC (low-dose 
NAC 1% loss, p=0.019; high-dose NAC 3% loss, p=0.031) (Figure 5.2), and the same 
protective effect was still present 2 months after axotomy (no treatment 35% loss; high-
dose NAC 3% loss, p=0.002) (Table 5.2). Although the number of neurons in axotomised 
L4 & L5 DRG's was significantly less than in the contralateral control ganglia ofthe 
"sham treatment" (p=0.002), and "no treatment" groups (p=0.002 at 2 weeks post-
axotomy, p<O.OOI at 2 months), there was no significant difference in the groups receiving 
NAC treatment at either 2 weeks (low-dose p=0.83; high-dose p=0.64) or 2 months (high-
dose p=0.41) after axotomy. 
Statistical analysis of results was performed using the techniques described 
previously (cf. 2.5.7). 
Figure 5.2 Effect of N-acetyl-cysteine (NAC) Treatment Upon Primary 
Sensory Neuronal Death After Peripheral Nerve Injury 
35 35 
30 




= 25 1 
-

































The total number of TUNEL positive neurons per experimental group of 6 animals (stippled 
bars), and the percentage neuron loss (plain bars) at both 2 weeks, and 2 months after sciatic 
nerve transection is shown. There was no significant difference between groups receiving sham 
treatment (5% glucose injections; maroon bars) and no treatment (blue bars). Both low-dose 
(30mg/kglday; black bars) and high-dose (150mg/kglday; green bars) NAC treatment was 
associated with a reduction in both the number of TUNEL positive neurons, and in the percentage 
















After sciatic nerve transection, numbers of TUNEL positive neurons reach a peak 2 
weeks after peripheral axotomy, in contrast neuronal loss begins one week after axotomy 
and is virtually complete 2 months later (cf. 3.4.4). A 2 week timepoint was therefore 
initially used in this study to reveal the effect ofNAC treatment at a time when neuronal 
death, as demonstrated by TUNEL staining, reaches a peak in the absence of any 
intervention. Having demonstrated an overall protective effect 2 weeks after axotomy, the 
experiment was repeated with a 2 month timepoint in order to determine whether the 
neuroprotective effect was lasting, and to establish its magnitude, since by 2 months after 
injury neuronal loss is essentially complete. 
The mean neuron counts obtained from control ganglia (30618, SD 2969) were in 
agreement with other results in the literature obtained by stereo logical methods 
98,102,132,260,261, verifying the accuracy of the counting technique used and the neuronal 
losses that were calculated. 
NAC treatment was given parenterally in order to bypass variabilities in 
gastrointestinal absorption, and the considerable effects offtrst pass metabolism 241. 
Treatment was initially given intravenously in order to achieve peak tissue levels as 
quickly as possible after peripheral nerve injury, and animals were not pre-treated since 
this would not be clinically possible in the majority of nerve injuries. Maintenance 
treatment was then administered intraperitoneally, since this route is associated with a 
more sustained increase in serum levels, and has considerable animal welfare beneftts 
compared to intramuscular injection. After an initial 2 weeks of twice daily dosing, the 
same total dose ofNAC was administered once daily for welfare reasons, and because the 
principal period of neuronal death then been passed (cf. 3.4.4). 
5.4.2 NAC Treatment Reduces Neuronal Loss and DNA Fragmentation After 
Peripheral Nerve Transection 
Systemic treatment with NAC (l50mglkg/day) brought about a signiftcant 
reduction in both the number of TUNEL positive neurons and the neuron loss found 2 
weeks after peripheral axotomy. Neuronal death was prevented, rather than just delayed, 
since this protective effect was found to be preserved 2 months after axotomy, by which 
time neuronal loss has effectively fmished in the absence of treatment. Even at a reduced 
dose, NAC (lOmglkg/day) was still signiftcantly effective in preventing neuronal death, 
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and evidence of a dose response was apparent in the increased number of TUNEL positive 
neurons, and in the worsened morphological fmdings. The neuronal loss at 2 weeks was 
slightly higher in the high-dose group than in the low-dose group, but the difference lies 
comfortably within the variability of the counting technique, and probably does not reflect 
a less protective effect since the TUNEL count was lower than with low-dose NAC. As 
previously discussed, TUNEL is a more sensitive marker of cell death at 2 weeks post-
axotomy than neuronal loss and it is likely that if both treatment doses were given for 2 
months, then the neuronal loss would be less in the high-dose group. 
Neuronal death cannot have been completely eliminated, since TUNEL positive 
neurons were present in NAC treated ganglia, however it was reduced to the extent that the 
overall neuronal loss in both treatment groups was only 2% at 2 weeks after axotomy 
(control count 3l323, SD 3238; operated count 30581; SD 3793). The neuroprotective 
effect was still present 2 months after axotomy, when loss was only 3%. This represents 
the salvage of around 5,500 neurons per animal at 2 weeks, and of more than 10,000 
neurons, at 2 months after axotomy, amounting to over a third of the total sensory neuronal 
pool. The massive reduction in neuronal loss was not merely an artefact of the way in 
which it is calculated, since NAC treatment did not affect upon the number of neurons in 
control ganglia. Equally it is evident that neuroprotective effect is due to NAC, and not 
merely to the act of intraperitoneal injection, since treatment with the vehicle solution 
(sterile 5% dextrose) had no effect upon either the number of TUNEL positive neurons, or 
upon neuronal loss. 
5.4.3 Mechanism of Action 
There are a variety of mechanisms by which N-Acetylcysteine (NAC) may 
potentially exert its neuroprotective effect, however since studies using primary sensory 
neurons are scarce, it is necessary to draw upon other experimental models of neuronal 
death. 
Axotomy causes a loss of distal neurotrophic support, which initiates neuronal 
death possibly via an effect upon cellular redox balance, and oxidative stress. NGF, the 
prototypic neurotrophin, stimulates L-cysteine uptake for glutathione synthesis 274-276, and 
BDNF & bFGF also induce glutathione peroxidase activity within neurons 277. BDNF 
deprivation induces nitric oxide synthase (NOS) activity in cultured motorneurons (MN), 
which precedes the onset of cell death, and is prevented by antioxidants 278. The 
antioxidant effect ofNAC may therefore mimic some of the effects of neurotrophic 
support, and NAC also has complex effects upon neurotrophic factor signalling pathways 
within neurons, for example by uncoupling NGF activation of mitogen activated protein 
kinases (MAPK's) from that ofRas 279. NAC also blocks the activation of c-Jun Kinase 
(JNK), and so prevents apoptosis in trophic factor deprived PC12 cells 175. 
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Axotomy induced retrograde degeneration occurs in association with perikaryal 
accumulation of mitochondria, and oxidative stress that may be worsened by 
mitochondrial dysruption 53 (cf. 3.4.5). Root avulsion induces 30% MN death, and 
involves oxidative stress 193, and NOS activity 194,195. Nerve injury therefore increases 
mitochondrial nitric oxide (NO) production, due to an increase in the activity of both 
inducible nitric oxide synthase (iNOS) in neuroglia, and constitutive NOS (nNOS) within 
neurons. This is one of the mechanisms by which the mitochondrial electron transport 
chain may be disrupted, since transient increases in NO cause reversible inhibition of 
complex IV, and sustained increases may cause permanent inhibition of cytochrome C 
(complex I) 197. This effect is enhanced by mitochondrial glutathione depletion 197, and 
blocked by augmenting glutathione levels in vitro 280. Disruption of the electron transport 
chain disturbs the cell's redox balance, and favours the generation of reactive oxygen 
species (ROS) which can disturb mitochondrial membrane potential (MMP) 200, disrupt 
calcium homeostasis, and lead to cell death 197,201. NAC protects mtDNA from damage due 
to increased NO, or oxidative stress, similarly to the anti-apoptotic Bcl-2 281, which also 
has antioxidant, mitochondrial protective effects 282. 
Glutathione depletion, particularly depletion of mitochondrial glutathione 270,283, 
increases the susceptibility of neurons to a variety of toxic stimuli, such as glutamate 
toxicity, ischaemia reperfusion, oxidative stress 197,242,284, and serum or trophic factor 
withdrawal 175. Neurons have a less resistance to oxidative stress than astroglia 240,285,286, 
due to limited capacity for glutathione synthesis, and increasing glutathione levels may 
therefore be protective 197,242,270, since glutathione is one of the principal defenses against 
ROS and oxidative stress within neurons 197. However glutathione does not cross the 
blood-brain barrier, and neurons cannot synthesise thiols, being dependent upon astrocytes 
for the supply of precursor peptides in order to maintain glutathione levels in response to 
oxidative stresses 287,288. Cysteine is the rate limiting precursor in glutathione synthesis 287, 
and can be readily taken up as NAC 240. In vitro NAC causes an increase in neuronal 
glutathione levels 240,272,279,289,290, an effect enhanced by co-culture with astroglia 291, and 
NAC protects glia in culture 286, working synergistically with CNTF to protect 
oligodendrocytes 206. Given the key role that glia play in neuronal glutathione synthesis, 
and survival, this protective effect may be of importance in vivo, and NAC, which crosses 
the blood-brain barrier, does reduces retinal ganglion cell death after axotomy in vivo 292. 
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At high doses NAC has direct reductant 272,279 and antioxidant effects, and can 
block lipid peroxidation by peroxyntitrate (ONOO-) 290. However the antioxidant role of 
NAC, and of the glutathione which it produces, is not sufficient to fully explain its 
neuroprotective effect, since the D-stereoisomer (D-NAC) is also protective for PC12 
neuronal cells after trophin withdrawal, unlike other antioxidants studied, but cannot be 
used for glutathione synthesis 160. Mice deficient in NT-3 (a neurotrophic factor) exhibit 
primary sensory neuronal death due to disco-ordinated cell cycling 207, and this may 
explain the protective action ofL- and D-NAC, since both regulate cell cycling, and DNA 
synthesis 160. This effect requires protein synthesis, gene transcription, and activation of 
the Ras-extracellular signal-related kinase pathway (ERK), but is independent of the PI3 
kinase pathway, unlike the protective effect ofNGF 293. However, since NAC blocks 
DNA synthesis, but not cell death, independently ofERK activation, cell cycle control is 
not the sole mechanism 293. 
The neuroprotective effect ofNAC may therefore be due to a combination of its 
antioxidant, and reductant properties, the promotion of glutathione synthesis, and to 
preventing abortive entry into the cell cycle by injured neurons. 
5.4.4 Conclusions & Clinical Relevance 
This study has demonstrated that NAC, which may also have analgesic properties 
289, is highly neuroprotective in an in vivo model of peripheral nerve injury. This further 
confirms the postulated roles of NO induced mitochondrial dysfunction, reactive oxygen 
species, glutathione depletion, and abortive cell cycling in the death of adult primary 
sensory neurons. Further research is required to define the precise mechanism of action, 
and so to increase the understanding of the events culminating in neuronal death. NAC is 
currently under investigation in a model of brachial plexus injury, and research is required 
to establish whether NAC and similar compounds may have therapeutic roles in other 
forms of trauma to the nervous system, such as brain and spinal cord injury. A further 
question is whether or not NAC will improve peripheral nerve regeneration, as well as 
neuronal survival. 
A pressing clinical need exists for a treatment that reduces sensory neuronal death 
after peripheral nerve trauma, and the results of this study strongly suggest that NAC may 
be a suitable agent. Unlike other antioxidant agents under investigation for their 
neuroprotective effects, such as BN80933269, NAC already has a proven safety profile in 
the clinical environment, and clinical trials in peripheral nerve trauma could therefore 
begin in the near future, once the effect ofNAC upon peripheral nerve regeneration has 
been determined. 
92 
Chapter 6. Clinical Potential of L-acetyl-carnitine in the 
Treatment of Peripheral Nerve Injuries 
6.1 Introduction 
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The neuroprotective potential ofNAC was described in the previous chapter, where 
it was argued that NAC' s principal mechanism of action was likely to be via maintaining 
neuronal glutathione levels and so countering the effects of reactive oxygen species, or 
possibly by inhibiting NO mediated mitochondrial bioenergetic dysfunction and abortive 
cell-cycling. It would be theoretically preferable to intervene earlier in the cascade of 
events, although not sufficiently far upstream that the protective effect would cease to be 
applicable in a range of neuronal subpopulations against a variety of insults would be lost. 
The apparent ubiquity of mitochondrial bioenergetic dysfunction as a prelude to the 
generation of reactive oxygen species and neuronal death 53,185,191,192 makes it an intriguing 
target for therapeutic intervention, and one agent which may act at this level is L-acetyl-
carnitine (LAC). 
LAC is the acetyl ester ofL-camitine, and is the predominant acylcarnitine in 
human tissues. Both peptides have a physiological role in the transport of long-chain free 
fatty acids (FF A) across mitochondrial membranes 247,294, although there are differences in 
their other actions. LAC is also an acetyl-group donor in oxidative metabolism 246,247, has 
antioxidant activity 295,296, and increases the expression and affinity ofneurotrophin 
receptors for nerve growth factor (NGF) 244,245,297. In-vitro LAC is neuroprotective 244,245,248 
and prevents mitochondrial uncoupling 248, whilst in-vivo it increases peripheral nerve 
regeneration after peripheral nerve lesions 298,299. LAC is currently showing promising 
results in clinical trials for diabetic neuropathy 249,300 and mv -associated peripheral 
neuropathy 301, where regeneration of neurites into target tissues has been demonstrated 
(cf.8.4). 
This study therefore investigated the effect of systemic LAC treatment upon 
primary sensory neuronal death after peripheral nerve injury, using TUNEL to identifY 
individual dying neurons, and neuron counting by the optical disector technique to quantifY 
the overall neuronal loss which occurred (cf. 1.4). 
6.2 Methods 
Groups of young adult male Sprague-Dawley rats (n=6) underwent unilateral 
sciatic nerve division (cf. 2.2.2), and immediately after nerve transection parenteral 
treatment with L-acetyl-camitine (LAC) was commenced at either 50mglkglday ("high-
dose"), or 10mg/kg/day ("low-dose") as detailed in section 2.2.3. Another experimental 
group ("sham treatment") received injections of an identical volume of sterile saline (cf. 
2.2.3), and all animals were treated until termination (cf. 2.2.1 b). Two further control 
groups were provided by the animals whose DRG's were harvested 2 and 4 months after 
sciatic nerve transection in the timecourse study (cf. Chapter 4). 
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The L4 & L5 DRG's were harvested from both the axotomised, and contralateral 
control sides (cf. 2.3.2) at either 2 weeks (all treatment groups), or 2 months (one "high-
dose treatment", and one "no treatment" group) after sciatic nerve transection (cf. 2.3.2). 
The ganglia were then processed (cf. 2.4.1 a, 2.4.2a & 2.4.3) for quantification of neuronal 
death by TUNEL (cf. 2.5.1), and by stereological determination of the number of surviving 
neurons using the optical disector technique (cf. 2.5.2). The mean cap count was 158 
(SD2S.8) per ganglion, in keeping with the requirement to count between 100 and 200, and 
all other sampling parameters were the same as discussed previously (cf. 3.2, 2.5.1. & 
2.5.2). 
TUNEL counts were expressed as the total number of positive neurons in the L4 
and LS DRG's of each experimental group of 6 animals, and neuron counts were expressed 
as a mean combined (L4 plus LS) count for each side (axotomised, or contralateral 
control). Neuronal loss was then calculated by subtracting the neuron count in a pair of 
axotomised ganglia from that of their contralateral controls, and the mean loss was then 
expressed as a percentage of the mean neuron count in the control ganglia. 
Statistical analysis of results was performed using the techniques described 
previously (cf. 2.5.7). 
6.3 Results 
No adverse effects upon animal behaviour were found, and weight gain during the 
study period was similar in all groups at both 2 weeks (p=0.198) and 2 months (p=0.343). 
6.3.1 Morpholof!Y 
Prominent morphological changes were evident in the axotomised ganglia of 
untreated animals (Figure 6.1 B), with the majority of neurons exhibiting nuclear 
eccentricity, and chromatolysis. Neurons displaying features of apoptosis (cytoplasmic 
granulation, vacuolation, membrane irregularities) were seen, as were numerous enlarged, 
and grossly vacuolated neurons. Morphological findings were unchanged by sham 
treatment with normal saline, however low-dose LAC caused a qualitative improvement in 
Figure 6.1: Effect ofL-acetyl-carnitine (LAC) Treatment Upon Primary Sensory 
Neuronal Morphology After Sciatic Nerve Transection 
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Dorsal root ganglia 2 weeks after sciatic nerve transection stained with the nuclear dye Hoechst 33342 
(blue fluorescence) and the cytoplasmic dye propidium iodide (red fluorescence). Control ganglia [A] 
contain neurons with normal cytoplasmic morphology, surrounded by numerous smaller satellite cells, 
in which nuclear staining predominates. Two weeks after sciatic nerve transection [B] gross 
morphological changes are evident, with most neurons displaying nuclear eccentricity, membrane 
irregularities, and cytoplasmic granulation or vacuolation (hollow arrow). Apoptotic neurons are also 
evident (solid arrow). Morphology is somewhat improved after low-dose LAC treatment, although 
nuclear eccentricity and membrane irregularity remains frequent [C]. After high-dose LAC treatment 
neuronal morphology is significantly more normal [D). Scale bar equals 40llm. 
! 
neuronal morphology (Figure 6.1 C), which was even more pronounced after high-dose 
LAC treatment (Figure 6.1D). 
6.3.2 TUNEL Staining 
The effect of LAC treatment upon the number of TUNEL positive neurons, and 
upon the neuronal loss found 2 weeks after axotomy is summarised in Table 6.1, while 
Table 6.2 gives the equivalent findings 2 months after axotomy. 
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TUNEL positive neurons were only found in axotomised ganglia. There was no 
difference between the treatment groups in the morphology of the TUNEL positive 
neurons, which exhibited a range of cytoplasmic morphologies identical to those described 
previously (cf. 3.3.1a & 5.3.1). Two weeks after sciatic nerve transection the total number 
of TUNEL positive neurons present in the axotomised L4&5 ganglia of untreated animals 
was 25 neurons per group of 6 animals. Whilst sham treatment had no significant effect 
upon the number ofTUNEL positive neurons (33 neurons/group, p=0.937), a significant 
reduction in the number of TUNEL positive neurons did occur with LAC treatment at both 
the low (6 neurons/group, p=0.009), and high (3 neurons/group, p=0.004) doses used 
(Figure 6.2). A reduction in TUNEL positive neurons was also found with high-dose 
LAC 2 months after axotomy (Table 6.2, Figure 6.2). 
6.3.3 Neuronal Loss 
Two weeks after axotomy the mean number of neurons present in the unoperated 
contralateral control ganglia (L4+5) of untreated animals was 29641 (SD 2268). This was 
similar to the equivalent count in sham treated (30257, SD 3261; p=0.61), or low-dose 
LAC treated (30167, SD 1877; p=0.67) animals, but lower than that in the high-dose LAC 
treated group (33646, SD 875; p<0.05). However, by 2 months after axotomy the 
contralateral control ganglia of untreated animals (31545, SD 2446) once again contained a 
similar number of neurons to those in the high-dose LAC treated group (30560, SD 4294; 
p=0.36). 
In the animals receiving no treatment a loss of 21 % of all L4&5 neurons 
(axotomised mean 23317, SD 2146; unoperated control mean 29641, SD 2267) occurred 
during the first two weeks after axotomy, and this rose to 35% after 2 months (axotomised 
mean 20460, SD 2138; control mean 31545, SD 2446) (Figure 6.2). Two weeks after 
axotomy neuronal loss was not affected by sham treatment (21 % loss, p=0.99), but was 
almost completely eliminated by LAC treatment (low-dose LAC 0% loss, p=O.OOl; high-
dose LAC 2% loss, p=0.006), and this protective effect was preserved 2 months after 
axotomy (high-dose LAC -4% loss, p<O.OOl) (Figure 6.2). 
Table 6.1: Effect ofL-acetyl-carnitine (LAC) Treatment Upon Neuronal Death 2 
Weeks After Axotomy 
Control Ganglia Axotomised Ganglia 
(L4+5) (L4+5) Percentage 
Treatment Group Mean (SD) Mean (SD) Neuronal Loss 
TUNEL Neuron TUNEL Neuron (L4+5) 
Count Count Count Count 
No Treatment 0 29641 25 23317 21% (2268) (2146) 
Sham Treatment 0 30257 33 23958 21% (3261) (2510) 
Low Dose LAC 0 30167 6* 30270** 0%** (lOmg/kg/day) (1877) (2100) 
High Dose LAC 0 33646* 3* 33077** 2%* (50mg/kg/day) (875) (2410) 
TUNEL positive neuron counts are expressed as the total number of positive neurons present in 
the axotomised, or contralateral control ganglia of each experimental group. Axotomised, and 
contralateral control ganglia neuron counts are stated as the mean (standard deviation) count per 
experimental group. Neuronal loss is calculated as the mean neuron count in the axotomised 
ganglia subtracted from that in the control ganglia, expressed as a percentage of the control value. 
* P value <0.05, ** P value <0.001 compared to no treatment. 
Table 6.2: Effect of L-acetyl-carnitine (LAC) Treatment Upon Neuronal 
Death 2 Months After Axotomy 
Control Ganglia Axotomised Ganglia 
(L4+5) (L4+5) Percentage 
Treatment Group Mean (SD) Mean (SD) Neuronal Loss TUNEL Neuron TUNEL Neuron (L4+5) Count Count Count Count 
No Treatment 0 31545 5 20460 35% (2446) (2138) 
High Dose LAC 0 30560 1 31642* -4%** (50mg/kg/day) (4294) (3775) 
TUNEL positive neuron counts are expressed as the total number of positive neurons present in 
the axotomised, or contralateral control ganglia of each experimental group. Axotomised, and 
contralateral control ganglia neuron counts are stated as the mean (standard deviation) count per 
experimental group. Neuronal loss is calculated as the mean neuron count in the axotomised 
ganglia subtracted from that in the control ganglia, expressed as a percentage of the control value. 
* P value <0.05, ** P value <0.001 compared to no treatment. 
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Figure 6.2 Effect of L-acetyl-carnitine (LAC) Treatment Upon Primary 




















































The total number of TUNEL positive neurons per experimental group of 6 animals (stippled 
bars), and the percentage neuron loss (plain bars) at both 2 weeks, and 2 months after sciatic 
nerve transection is shown. There was no significant difference between groups receiving sham 
treatment (sterile normal saline; maroon bars) and no treatment (blue bars). Both low-dose 
(5mglkg/day; black bars) and high-dose (50mglkglday; green bars) L-acetyl-carnitine (LAC) 
treatment was associated with a reduction in the number of TUNEL positive neurons, and a 
reduction in percentage neuron loss to zero in some groups 

















As a marker of DNA fragmentation TUNEL staining detects the beginning of an 
individual neuron's death and therefore precedes the cell's subsequent elimination, which 
will be reflected by neuronal loss (cf. 1.4, Figure 1.1). TUNEL staining is therefore a 
more sensitive marker of cell death, as very small neuronal losses may be entirely masked 
by the normal biological variability in neuron numbers (cf. 3.4.4). 
The timepoints of 2 weeks, and 2 months after sciatic nerve transection were used 
as they reflect both the peak of neuronal death, and of neuronal loss, as has been discussed 
previously (cf. 3.4.4), along with the use of combined L4 & L5 counts (cf. 3.4.2). 
Adequate numbers of caps (158, SD 25.8) were counted to meet the requirement of 100-
200 per ganglion 129, and the mean neuron count obtained from control ganglia was 30969 
(SD 2858) per ganglion pair. This is in agreement with other results in the literature 
98,102,132,260,261, and with the results obtained in the previous two studies (cf. 3.4.2 & 5.4.1), 
verifying the accuracy of the counting in this study. 
LAC levels were not measured in this study since both parenteral and enteral 
administration of LAC have previously been demonstrated to increase plasma and CNS 
levels 302,303. The dose of50mg/kg/day is comparable to the dose of LAC used clinically 
for the treatment of peripheral neuropathies (cf. 8.2), and in diabetic rats was sufficient to 
normalise sciatic nerve LAC content 304, when given by intraperitoneal injection. 
Parenteral administration was used in order to eliminate variability due to gastrointestinal 
absorption, and treatment was initially given 12 hourly in order to maintain peak serum 
levels of LAC. Once the principal period of neuronal death was over at 2 weeks after 
injury, the same total daily dose was administered once daily for reasons of animal welfare. 
6.4.2 LAC Treatment Reduces Neuronal Death and Eliminates Neuronal Loss After 
Peripheral Nerve Transection 
At both timepoints studied, systemic treatment with LAC (50mg/kg/day) led to a 
significant reduction in all the markers of neuronal death. The reduction in the number of 
TUNEL positive neurons found 2 weeks after peripheral axotomy was matched by an even 
greater reduction in neuronal loss, and neuronal death was prevented, rather than just 
delayed, since this protective effect was found to be preserved 2 months after axotomy. 
Even at the reduced dose of 10mg/kg/day LAC therapy was still significantly effective in 
preventing neuronal death, with a dose response effect being evident in the worsened 
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morphological changes and in the number of TUNEL positive neurons, when compared to 
high-dose LAC treatment. Hence the low-dose regime was not used in the 2 month groups. 
The lack of any apparent dose response in neuronal loss after 2 weeks of LAC treatment 
most likely reflects both the small difference in the number of dying neurons (TUNEL 
results) between dose levels, and the fact that 2 weeks is a relatively early timepoint for 
minor differences in rates of neuronal death to translate into differences in neuronal loss. 
When all three treatment groups are considered together, LAC treatment was found 
to have completely eliminated the neuronal loss normally found after sciatic nerve 
transection (control ganglia count 31457, SD 3041; operated ganglia count 31663; SD 
2931). Since occasional TUNEL positive neurons were present in LAC treated ganglia 
neuronal death cannot have been completely eliminated, but the protective effect was 
dramatic nonetheless. Around 6,000 neurons per animal at 2 weeks, and over 10,000 
neurons at 2 months after axotomy, were salvaged by LAC treatment, and this amounts to 
protection of almost the entire sensory neuronal pool. 
The reduction in calculated neuronal loss was not merely an artefact of changes in 
the number of neurons in control ganglia, since LAC treatment did not appear to have any 
effect upon the number of neurons in the control ganglia. A minor, but statistically 
significant increase was found 2 weeks after axotomy in the group treated with high-dose 
LAC (33646, SD 875), but this was likely to be an artefact of the unusually low standard 
deviation in this group, rather than a real effect of treatment, since the mean count lay well 
within the normal distribution of counts for untreated and sham treated animals (mean 
29949, SD 2697). Two months after axotomy there was no difference between the 
untreated, and high-dose LAC groups. 
Finally, it is evident that the reduction in neuronal death was due to LAC rather 
than the act of drug administration, since 2 weeks after axotomy sham injections of sterile 
normal saline had had no effect upon either neuronal loss, or upon the number of TUNEL 
positive neurons. 
6.4.3 Mechanism o[Action 
The precise mechanism by which LAC prevents primary sensory neuronal death 
after peripheral axotomy remains to be determined, although it is likely that its activity is 
due to attenuation of both the initiator, and effector mechanisms of cell death. 
Firstly, LAC may attenuate the loss of distal neurotrophic support by enhancing 
neurotrophin responsiveness, since it is known to increase NGF binding capacity 297, and to 
potentiate the effects ofNGF 244,245. Secondly, LAC facilitates the transport of cytosolic 
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long-chain free fatty acids across mitochondrial membranes and provides acetyl groups for 
maintenance of aerobic glycolytic pathways 246,247, in preference to the normal shift into 
the less efficient pentose phosphate shunt 305,306. LAC may therefore prevent failure of 
mitochondrial oxidative metabolism, which is integral to the cell death pathway 185,191, at a 
time when energy requirements are increased in support of the regenerating neurites 305, 
and this effect has been demonstrated in-vitro 248. Finally, the antioxidant role of LAC 295 
may be of benefit in preventing cell damage by the free oxygen species 296 whose 
generation is thought to be of major importance in the effector mechanism of cell death 
197,198 
6.4.4 Conclusions & Clinical Relevence 
Experimentally, LAC enhances sensory neuronal survival in vitro 244,245 and has 
been demonstrated to increase motor nerve regeneration after peripheral axotomy 298, 
which in neonates may be due to recruitment of ectopic motorneurones, or to increased 
motorneuronal survival 307. Clinically, LAC has an excellent safety profile, and is under 
investigation as a treatment for diabetic neuropathy, and HIV-associated peripheral 
neuropathy where it is known to reduce analgesic requirements 301,308, and to cause 
cutaneous nerve fibres to regenerate to normal control levels in the dermis and sweat 
glands 308. 
Further work needs to be undertaken to clarify the required duration of treatment 
with LAC, its precise mechanism of action, and studies are now underway to determine its 
effects in other models of trauma to the nervous system. However the evidence would 
suggest that LAC is a clinically safe drug when administered either orally or parenterally, 
and that it promotes sensory neuronal survival after peripheral nerve trauma, as well as 
enhancing the capacity for peripheral nerve regeneration. The results presented herein 
therefore suggest that LAC may indeed be the first effective, clinically applicable agent for 
adjuvant pharmacotherapy in the management of major peripheral nerve trauma such as 
brachial plexus injuries, and clinical trials are now being scheduled. 
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Chapter 7. L-acetyl-carnitine Improves Nerve Regeneration 
Indepently of Neuronal Survival 
7.1 Introduction 
L-acetyl-camitine (LAC) is known to improve nerve regeneration after acute nerve 
injuries 298, and this has been ascribed to improvements in neuronal metabolic capacity, 
and nerve growth factor (NGF) responsiveness 244,245,297. However in light of the 
demonstration that LAC virtually abolishes sensory neuronal death after sciatic nerve 
transection (cf. Chapter 6), it is now unclear whether the reported improvement in 
regeneration is due to an increase in the regenerative potential of individual neurons, or to 
an increase in the number of regenerating neurons, secondary to a reduction in cell death. 
This question is of clinical importance in two scenarios; firstly in the setting of 
peripheral nerve surgery, and secondly in the setting of chronic neuropathy. If LAC proves 
to be clinically effective in reducing sensory neuronal death after peripheral nerve injury it 
will then become important to determine the appropriate duration of treatment after nerve 
repair. If LAC improves regeneration only via its neuroprotective role, then treatment 
need only be given for the first 2 months, until the period of sensory neuronal death is over 
(cf.3.4.4). However if LAC also improves the regenerative potential of individual neurons 
then treatment should be continued until target reinnervation is completed, which may take 
many months in the case of proximal injuries 5,11. 
Secondly, in the case of the chronic neuropathies that occur in conditions such as 
diabetes 309 and HIV disease 26,204, the problem is not merely sensory neuronal death 310,311, 
but also the inability of neurons to maintain long peripheral axons and to regenerate into 
the target tissues as a result of chronic metabolic insufficiency 26. If LAC can be 
demonstrated to improve nerve regeneration after injury independently of its effect upon 
neuronal death, then it may have greater therapeutic potential in these chronic disease 
states. 
The effect of LAC treatment upon nerve regeneration following late secondary 
sciatic nerve repair 2 months after nerve transection was therefore determined by 
quantitative immunohistochemistry. The sensory neuronal death induced by nerve 
transection will have been virtually complete by this time after injury, and any effect upon 
nerve regeneration ought therefore to primarily reflect an improvement in the regenerative 
capacity of individual neurons. 
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7.2 Methods 
Two groups of young adult male Sprague Dawley rats (n=5) underwent an initial 
unilateral sciatic nerve division, followed by repair with a 1cm reversed sciatic nerve graft 
two months later (cf. 2.2.7). In one group the animals were treated with L-acetyl-camitine 
(50mg/kglday) by intraperitoneal injection, as detailed in section 2.2.7, from the time of 
nerve repair until termination (cf. 2. 2.1 b) six weeks after repair. The sciatic nerves were 
harvested (cf. 2.3.3), and processed for (cf. 2.4.1a, 2.4.2b & 2.4.4) for 
immunohistochemical quantification of regeneration distance (cf. 2.5.4, Figure 2.8), and 
percentage area ofimmunostaining against S-100 as a Schwann cell marker, and PAMNF 
as a pan-neuronal marker (cf. 2.5.5). Area ofimmunostaining was measured in a band of 
images captured with a 20X objective lens, and situated 1mm distal to the end ofthe 
proximal nerve stump (cf. 2.5.5, Figure 2.8). 
All quantification was performed by the same observer, and care was taken to 
ensure that similar settings were employed for both experimental groups during the image 
capturing and thresholding process. Statistical analysis of results was performed using the 
techniques described previously (cf. 2.5.7). 
7.3 Results 
7.3.1 Regeneration Distance 
In both experimental groups axons had crossed the full width of the repair, and 
reached the cut end of the distal nerve stump in all cases, and as a result no effect of LAC 
treatment upon mean regeneration distance could be demonstrated (LAC treatment 
12.9mm, SD 0.90; control 13.3mm, SD 1.53). There was no visible gastrocnemius 
contraction in response to pinching the nerve proximal to the repair in any animal. 
7.3.2 Area oflmmunostaining 
The effect of LAC treatment upon the area of immunostaining is summarised in 
Table 7.1 and Figure 7.1. The total area ofimmunostaining in LAC treated nerve repairs 
was significantly greater than control both for PAMNF (LAC 2122451lm2, SD 41861; 
control 58259 Ilm2, SD 25405; p<O.OOl), and for S-100 (LAC 2366411lm2, SD 41841; 
control 112295 Ilm2, SD 29902; p<O.OOl). 
The mean percentage area of immunostaining was also significantly greater in the 
LAC treated group than control, both for PAMNF (LAC 24%, SD 9.5; control 7.3%, SD 
2.3; p=0.008), and S-100 (LAC 26%, SD 10; control 14%, SD 2.1; p=0.012). The total area 
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Table 7.1: Effect of L-acetvl-carnitine (LAC) Treatment Upon Nerve Regeneration 
Total Area of Immunostaining Percentage Area of Immunostaining (f.1m2) 
Treatment Group Mean (SD) Mean (SD) 
PAMNF S100 PAMNF S100 
No Treatment 58259 112295 7.3% 14% (25405) (29902) (2.3) (2.1) 
High Dose LAC 212245** 236641 ** 24%* 26%* 
(50mg/kg/day) (41861) (41841) (9.5) (10) 
The mean area ofimmunostaining for nerve fibres (PAMNF), or Schwann cells (S-100) within 
reversed sciatic nerve grafts harvested 6 weeks after a late secondary repair of a 1 em gap in the 
rat sciatic nerve (2 month interval between transection & repair). Percentage area of 
immunostaining equals the total area expressed as percentage of the total area of graft within 
which staining was measured. * P value <0.05, ** P value <0.001 compared to no treatment. 
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Figure 7.1 Effect of L-acetyl-carnitine (LAC) Upon Nerve regeneration After 
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The effect of LAC treatment (50mg/kg/day; maroon bars) upon the total, and percentage areas 
of immunostaining for PAMNF (plain bars) and S-100 (stippled bars) 6 weeks after late 
secondary nerve repair is shown compared to untreated controls (blue bars). LAC treatment 
resulted in significant increases in both total, and percentage areas of immunostaining for nerve 
























of nerve graft present in the quantified sections was slightly higher in the LAC treated 
group (967046 11m2, SD 279641) than in the controls (774571 11m2, SD 146813), but the 
difference was not statistically significant (p=0.21). 
7.4 Discussion 
7.4.1 Methodology 
Repairs were performed 2 months after nerve transection as sensory neuronal loss 
has reached a plateau value by this timepoint (cf. 3.4.4). This delay made end-to-end 
epineurial repair unfeasable due to retraction of the nerve stumps, and nerve grafts were 
therefore used to bridge the resulting gap since this is the standard clinical technique. 
P AMNF is a constitutive component of all mammalian nerve fibres, and so the area 
of immunostaining with antisera against it gives a reliable determination of the area of 
nerve fibres present in a tissue section. Similarly S-100 is a marker of all Schwann cells, 
and so it provides a means to quantify the Schwann cell response to regenerating neurites. 
Grafts were harvested 6 weeks after nerve repair, and the area of immunostaining was 
measured 1 mm distal to the end of the proximal nerve stump, as this site had proved the 
most informative in previous unpublished research into nerve regeneration through 
bioartificial nerve conduits. 
Artefactual variations in the total area ofimmunostaining may arise if there are 
differences in the area of nerve graft in which staining is measured. Such differences may 
arise either because of actual differences in the diameters of the nerve grafts used, or 
because of variability in the exact position within the graft at which the section was cut. 
Since the nerve is cylindrical, longitudinal sections cut at slightly different positions in the 
graft will inevitably have different diameters. Hence the area of immunostaining was also 
expressed as a percentage of the area of the graft to compensate for this effect. 
The dose of LAC, dosage schedule, and route of administration was chosen for the 
reasons explained in the previous chapter (cf. 6.4.1), and no sham injection group was 
included since there was no effect found in the previous study (cf. 6.3.2 & 6.3.3). 
7.4.2 L-acetyl-carnitine (LAC) Improves Nerve Regeneration Independently of 
Neuronal Survival 
Two months after sciatic nerve transection sensory neuronal loss within the L4 & 
L5 DRG's has reached a peak plateau value (cf. 3.4.4), and so nerve repair at this timepoint 
relies upon a relatively stable pool of surviving neurons. Any effect of LAC treatment 
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upon nerve regeneration therefore ought to be primarily the result of an effect upon the 
regenerative capacity of individual neurons, rather than upon neuronal survival. Although 
the nerve repair involves limited trimming of the proximal nerve stump, this is unlikely to 
cause such substantial neuronal death as the original transection, since the neurons which 
were most susceptible to axotomy induced death will have died already. Furthermore the 
nerve is then immediately repaired, and this will limit any death that might have occurred 
otherwise (cf. 4.4.2). 
Although there was no demonstrable difference in regeneration distance as a result 
of LAC treatment, this may simply be due to the manner in which regeneration distance 
was calculated. The distal nerve stumps were trimmed ~3mm distal to the nerve repair, 
and so any difference in the distance which fibres travelled beyond that point would not be 
detected. Such a difference could be detected by studies using earlier timepoints, or by 
seeking evidence of target organ reinnervation at later timepoints. 
The total area of immunostaining with antisera against P AMNF, hence the total 
area of regenerating nerve fibres, was significantly greater in the LAC treated group than 
in the untreated controls (Figure 7.1), and this was matched by a comparable increase in 
the total area of immunostaining for Schwann cells (S-100). The increase was not an 
artefact of the slightly greater area of nerve graft present in the LAC treated tissue sections, 
since the percentage area of immunostaining for both nerve fibres (227% increase), and 
Schwann cells (87% increase) was also significantly greater in the LAC treated group. 
Neurite ingrowth causes Schwann cell proliferation 47,90, and this may explain why LAC 
treatment also caused an increase in the percentage area of immunostaining for Schwann 
cells. 
7.4.3 Mechanism orAction 
The precise mechanism by which LAC improved nerve regeneration after late 
secondary repair is not yet certain. Neuronal energy requirements are increased during 
regeneration 305, and it is postulated that by improving free fatty acid transport into 
mitochondria, and supporting aerobic glycolysis 246-248, in preference to the less efficient 
pentose-phosphate pathway 305,306, then regeneration will be facilitated. The effect of LAC 
treatment to increase neuronal NGF binding capacity 297, and responsiveness 244,245 may 




L-acetyl-camitine may therefore improve peripheral nerve regeneration 
independently of its effect upon the number of surviving neurons, although further 
electrophysiological studies and the demonstration of target organ reinnervation would be 
required to conclude that the increased regeneration is of functional benefit. The 
regenerative capacity of individual neurons may be enhanced either by a direct effect to 
support axonal growth, or by a more facilitative effect whereby LAC treatment enhances 
the regenerative response to physiological neurotropic cues. 
This might suggest that LAC treatment should be continued until target organ 
reinnervation has occurred after peripheral nerve repair, and that it may also be of benefit 
even after nerve repairs which have been delayed for several months. Furthermore, LAC is 
likely to be of benefit in causing peripheral nerve regeneration in chronic neuropathic 
conditions where impaired regenerative capacity, rather than sensory neuronal death, is the 
principal pathogenetic mechanism. 
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Chapter 8. L-acetyl-carnitine: a Pathogenesis Based Treatment 
for HIV -Associated Distal Symmetrical Polyneuropathy 
8.1 Introduction 
In the previous two chapters it has been proposed that L-acetyl-carnitine (LAC) 
treatment may be neuroprotective, possibly acting via the promotion of mitochondrial 
bioenergetic function, or its NGF agonist activity. Results also suggested that LAC may be 
of benefit in promoting nerve regeneration in chronic conditions where there is a 
continuing metabolic insult to the neurons, for example in diabetic neuropathy. However 
the pathogenesis of diabetic neuropathy is complicated by microvascular changes, and so a 
neuropathy whose pathogenesis is more identifiably due to impaired mitochondrial 
function, and loss of target derived NGF 229 was chosen for testing the clinical efficacy of 
LAC. 
illV -associated peripheral neuropathies (PN) 204 are a cause of significant 
morbidity in 10-35% ofillV positive patients 26,312,313, and distal symmetrical 
polyneuropathy (DSP) is the commonest form. It is a chronic condition that affects 11-
66% of patients on nucleoside analogue reverse transcriptase inhibitor (NRTI) drug 
therapy 204,314, and the dideoxynucleotide analogue agents stavudine (D4T), zalcitabine 
(ddC), and didanosine (ddI) are particularly implicated in its pathogenesis 26,204,315. A 
striking feature of illV -associated DSP is the development of severe dysaesthetic pain 26 
which may be unresponsive to analgesia, even in combination with anticonvulsants 204, 
tricyclic antidepressants 316, mexiletine 316, or Peptide T 317. Accordingly, withdrawal of 
certain NRTI's often becomes necessary 26,204 since no effective therapies for DSP are 
currently available, despite the recent promise shown by recombinant nerve growth factor 
(rhNGF) 229, and changes in the prescribing pattern of these drugs have led to a reduction 
in the incidence ofPN 26. As a result there is a need for a pathogenesis-based treatment for 
DSP which would allow patients to remain upon NRTI therapy, which remains the 
keystone of current highly active antiretroviral therapy (HAART) regimes 318. 
DSP is currently thought to be a result of disrupted mitochondrial oxidative 
metabolism 203,315 secondary to a reduction in neuronal mitochondrial DNA content 
202,315,319, which makes the neurons unable to maintain long peripheral axons, resulting in 
the glove and stocking distribution ofDSP 204 (cf. 1.4). In keeping with this die-back 
hypothesis, epidermal innervation is known to be reduced in DSP 320, although the 
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innervation of the dermis and sweat glands remains to be formally quantified. The 
development of an abnormal sweating pattern in DSP suggests that an autonomic 
neuropathy also develops, and this may also be a factor in the nocturnal sweating common 
in HIV disease 321. 
Since DSP is a chronic condition that involves axonal die-back, there are 
considerable similarities with the situation found after chronic peripheral nerve transection 
as a result of trauma. In both conditions the target organs and distal segments of peripheral 
nerve are chronically denervated, and axonal regeneration is the key to restoring normal 
sensory function and target derived neurotrophic support. Although there is a persistent 
insult to the neurons in DSP, unlike chronic nerve transection, both conditions are likely to 
involve disruption of mitochondrial energy metabolism. In nerve transection this leads to 
significant sensory neuronal death, whereas in DSP the effect is more subtle, making 
neurons unable to sustain long peripheral axons. A therapy that could induce peripheral 
nerve regeneration in DSP may therefore be of benefit in the setting of peripheral nerve 
trauma, and regeneration after repair. 
L-Acetyl-Carnitine (LAC) has been proposed as a therapeutic agent for DSP. The 
acetyl ester ofL-carnitine, LAC is vital for normal mitochondrial function, being a 
physiological transport molecule for free fatty acids, and an important acetyl-group donor 
in high energy metabolism and ~-oxidation of free fatty acids 246,247. In addition, LAC 
potentiates the actions ofNGF 244,245,297, promotes peripheral nerve regeneration 298, and 
has been shown to be neuroprotective both in vitro 244,248 and in animal models of diabetic 
neuropathy 322. LAC has analgesic properties, possibly mediated by increasing ACTH and 
~-endorphin levels 323, whilst its non-acetylated form, L-carnitine, also has favourable 
immunological benefits 324 in HIV infection. Furthermore, short term LAC treatment 301 
has shown symptomatic benefits in DSP, although it is not known if this effect is long-
lasting, or whether it is due to neuronal regeneration, or merely to an analgesic effect. 
This study was therefore designed to determine the effect of long term LAC 
therapy upon symptoms and cutaneous innervation in patients with DSP, by using 
quantitative immunohistochemistry with fibre-type specific antisera, a technique that has 




This study was performed in agreement with the terms of the Helsinki Declaration, 
after appropriate review by the local research ethics committee. Five asymptomatic HIV 
negative controls, and an open observational cohort of 5 patients with established NRTI 
therapy related DSP (Grade 2-414 by analgesic requirement) were recruited. Selection 
criteria included anyone aged 20-50 years, of either sex, with a documented positive 
licensed HIV-antibody ELISA test [Roche v1.5, or Cobas v1.5], and a diagnosis of stable 
DSP (onset within 6-12 months of commencing NRTI therapy, symptoms stable for >3 
months, and no other neuropathic aetiological factors or therapies associated with DSP). 
The median age ofthe neuropathic patients at recruitment was 34 years (range 30-44), and 
was 32 years (range 29-53) for controls. The controls had tested negative for HIV 
antibodies within the previous 3-12 months, had no neuropathic symptoms or signs, and 
had no history of diabetes, metabolic disorders, alcohol abuse, or treatment with potentially 
neurotoxic agents. 
Patients received six months of treatment with oral LAC capsules [Sigma-Tau, 
Italia] at a dose of 1500mg b.d., and all other medications were managed on a clinical 
basis. 
As an outpatient procedure under local anaesthesia lcm x 0.5cm skin biopsies were 
excised from an anatomically standardised point in the lower third of whichever leg was 
felt to be more symptomatic by the patient (cf. 2.3.4). Biopsies were taken prior to 
commencing LAC therapy ("pre-treatment"), and again from a neighbouring site in the 
same leg after 6 months of treatment ("post-treatment"). A single biopsy was taken from 
an equivalent site in each control. 
All staining and quantification (cf. 2.4.5, 2.5.3) was performed by one masked 
individual to eliminate inter-observer error, and both pre- and post-treatment biopsies were 
processed together in order to eliminate minor variabilities between staining runs. A 
systematic random sample of 15 J.lm vertical cryosections 325 from each biopsy was 
collected (cf. 2.4.1a & 2.4.2c), and stained (cf. 2.4.5) by indirect immunohistochemistry 
using primary antisera against protein gene product 9.5 (PGP9.5.), calcitonin gene related 
peptide (CGRP), and vasoactive intestinal polypeptide (VIP). Antisera against PGP9.5 
bind to all fibre-types, since PGP9.5 is a constitutive component of all nerve fibres, 
whereas antisera against the peptide neurotransmitter CGRP are specific for the C, Ao 
fibres of small sensory neurons, and antisera against VIP are specific for cholinergic, 
sympathetic postganglionic efferent fibres. Staining was visualised using a fluorescein 
conjugated secondary antibody (FITC-conjugated goat anti-rabbit serum,). 
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The area of immunostaining with each antibody, approximates closely to the actual 
area of each type of nerve fibre present, was then quantified (cf. 2.5.3) in a systematic 
random sample of 6 visual fields including both epidermis and dermis (PGP9.5 & CGRP), 
or subcutaneous sweat glands alone (PGP9.5 & VIP). Innervation was then expressed 
either as a total area (Jlm2), or as a fraction of the total area of interest, whether that was 
epidermis, dermis, or sweat gland ("fractional area of immunostaining"). The pre-treatment 
level of innervation could then be compared to that found after treatment with LAC (i.e. 
change in fractional area of immunostaining, expressed as a percentage of the pre-
treatment value), and both results compared to the level of innervation found in non-
neuropathic HIV negative controls. Statistical comparison was performed using the 
techniques described previously (cf. 2.5.7). 
8.3 Results 
8.3.1 Clinical and Immunological Parameters 
In the patients with established DSP the mean duration of neuropathy prior to recruitment 
was 34 (standard deviation 42) months, and none had a history of diabetes, or metabolic 
disorders. Patient 1 had persistent NRTI induced DSP, which had remained constant 
despite withdrawal of ddI therapy 8 years prior to recruitment, whilst the other 4 patients 
remained on NR TI therapy during the full course of the study (patient 2, lamivudine 
(3TC); patient 3, 3TC & D4T; patients 4 & 5, D4T & ddI). Only patient 5 had a previous 
history of alcohol excess, but had no alcohol related illness and had stopped drinking three 
years before recruitment (18 months prior to onset of neuropathy). Similarly, only patient 
3 had received treatment with another potentially neurotoxic agent, having taken a course 
of dapsone 100mgl day several years prior to the onset of his neuropathy. 
Clinical grade of neuropathic pain fell significantly from a median of3 (range 2-4) 
at recruitment, to 2 (range 1-2) after six months of LAC treatment (p=0.016), and patients 
also described an improvement in general well-being and quality of life, although this was 
not formally assessed. Viral load (pre-treatment 204650 copies/ml (cpm), SD 311517; 
post-treatment 192550cpm, SD 284473; p=O.923), CD4 positive T-cell count (pre-
treatment 232/JlI, SD 127; post-treatment 264/JlI, SD 244; p=l.OO), and CD4 count as 
percentage of total T-cell count (pre-treatment 13.0%, SD 4.90; post-treatment 17.4%, SD 
11.6; p=0.457) did not alter significantly over the study period, however the CD4/CD8 
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ratio did increase (pre-treatment 0.20, SD 0.094; post-treatment 0.43, SD 0.68; p=0.008). 
LAC treatment was well tolerated; no side effects were described, and no adverse events, 
or wound complications at biopsy sites occurred. 
8.3.2 Immunohistochemistry - Morphology of Cutaneous Innervation 
Representative photomicrographs are shown in Figures 8.1-8.4. 
A normal pattern of cutaneous innervation was present in the control biopsies. The 
cutaneous innervation derived from a plexus of fibres in the reticular dermis which fed 
either into plexi enveloping individual sweat glands, or into the plexus of finer sub-
epidermal fibres which ran parallel to the surface of the skin within the papillary dermis 
(Figures 8.IC, 8.2C). These fibres either terminated in sensory organs lying in the region 
of the dermo-epidermal junction, or sent branches up the dermal papillae to enter the 
epidermis as free-end terminals. Within the epidermis fibres either ran perpendicular to the 
surface of the skin, or ended in fine branches lying parallel to the base of the stratum 
corneum. PGP9.5 immunoreactive fibres predominated in all regions of the skin, whilst 
CGRP positive fibres lay principally in the sub-epidermal plexus (Figure 8.3C), and deeper 
layers of the epidermis, and VIP positive fibres enveloped the sweat glands (Figure 8.4C). 
In the skin of patients with established DSP there was an almost complete absence 
of fibres within the epidermis, and both the sub-epidermal plexus, and the plexi 
surrounding individual sweat glands were atrophied (Figures 8.IA & 8.2A), as were the 
sweat glands themselves. LAC treatment was associated with a general normalisation of 
morphology, although epidermal fibres remained less evident than in the skin of controls 
(Figures 8.IB, 8.2B). 
8.3.3 Immunohistochemical Quantification - All Fibre Types (PGP9.5) 
The effect of LAC treatment upon cutaneous innervation in each of the patients 
with established DSP, as determined by quantitative immunohistochemistry is given in 
Table 8.1, where positive values reflect an increase in innervation after treatment and 
negative values reflect a decrease. Table 8.2 shows the cutaneous innervation of the DSP 
cohort as a whole, compared to that of the asymptomatic controls. 
In summary, the data presented in these tables show that when compared to 
controls, patients with established DSP exhibited reduced innervation of the epidermis 
(51 % of control), dermis (49%) and, most markedly, of the sweat glands (25%) (Table 
8.2). LAC treatment subsequently caused a significant (p<0.05) overall increase in 
innervation within the epidermis and dermis, and a highly significant (p<0. 00 1) increase 
within the sweat glands (Table 8.1), although Patient 4 exhibited insignificant reductions in 
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Figure 8.1: Effect of LAC Treatment Upon Cutaneous Innervation by All Fibre Types 
Photomicrographs ofverfical sections through skin biopsies stained by indirect immunofluorescence 
using a primary antiserum to PGP 9.5. Nerve fibres show as green fluorescence, against the red of the 
non-specific stain Pontamine Sky Blue. Cutaneous nerve fibres are scarce, and atrophic in established 
DSP [A], but after 6 months of LAC treatment (lS00mg b.d.) [B] innervation increases to normal levels 
in the dermis, although epidermal innervation remains less than that found in normal controls [C]. Six 
months after stopping LAC treatment innervation is reduced [D]. Scale bar equals 40J.1m. 
Figure 8.2: Effect of LAC Treatment Upon Sweat Gland Innervation by All Fibre 
Types 
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Photomicrographs of sections through skin biopsies stained by indirect immunofluorescence using a 
primary antiserum to PGP 9.5, and showing the innervation of the dermal sweat glands. Nerve fibres 
show as green fluorescence, against the red of the non-specific stain Pontamine Sky Blue. Nerve fibres 
are scarce, and atrophic in established DSP [A], but after 6 months of LAC treatment (1500mg b.d.) [B] 
innervation by all fibre types increases to normal levels [C]. Six months after stopping LAC treatment 
innervation is reduced [D]. Scale bar equals 40Jlm. 
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Figure 8.3: Effect of LAC Treatment Upon Cutaneous Innervation by Small Sensory 
Fibres 
Photomicrographs of vertical sections through skin biopsies stained by indirect immunofluorescence 
using a primary antiserum to CGRP. Small sensory nerve fibres show as green fluorescence, against the 
red non-specific staining of Pontamine Sky Blue. Cutaneous fibres are almost entirely absent in 
established DSP [A], but after 6 months of LAC treatment (1500mg b.d.) [B] innervation by small 
sensory (C,Ao) fibres increases to supranormallevels in the dermis, although epidermal innervation 
remains sparse compared to HIV negative, non-neuropathic controls [C]. Six months after stopping 
LAC treatment innervation is reduced [D]. Scale bar equals 40~m. 
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Figure 8.4: Effect of LAC Treatment Upon Sweat Gland Innervation by Cholinergic 
Sympathetic Fibres 
Photomicrographs of sections through dermal sweat glands stained by indirect immunofluorescence 
using a primary antiserum to VIP. Cholinergic sympathetic efferent nerve fibres show as green 
fluorescence, against the red of the non-specific stain Pontamine Sky Blue. Fibres are scarce, and 
atrophic in established DSP [A), but after 6 months of LAC treatment (1500mg b.d.) [B) innervation 
increases to normal levels [C]. Six months after stopping LAC treatment innervation is reduced [D). 















Epidermis Dermis Sweat Glands 
PGP CGRP PGP CGRP PGP VIP 
223%* 41 % 5117%* 12401%* 212%* 133%* 
69% 1363% 61 %* 294% 328%* 71 % 
96% 359% -21 %* 111 % 44% 67% 
-65% 750332% -42% 109% 737%* 5109% 
222%* 1639%** 241 % 1407% 373%* 272%* 
60%* 599%** 123%* 445%** 309%** 295%** 
Percentage change for each individual equals the difference between the pre- and post-treatment 
fractional areas of immunostaining, expressed as a percentage of the pre-treatment value (positive 
values reflect an increase in innervation, whilst negative values reflect a decrease). 
* P value < 0.05, ** P value <0.001 post-treatment innervation compared to pre-treatment. 
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Table 8.2: Effect of LAC Treatment Upon Cutaneous Innervation in DSP 
Patients Compared to Non-Neuropathic HIV Negative Controls 
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Controls Pre-Treatment Post -Treatment 
Antiserum: 
Total Area Fractional Total Area Fractional Total Area Fractional 
(Jlm2) Area (Jlm2) Area (Jlm2) Area 





0.0000557* ~ CGRP 33.46 0.00109 3.83* 20.39 0.000539 (69.81) (0.00200) (13.33) (0.000199) (27.25) (0.000689) 
PGP 690.87 0.00764 344.43** 0.00375** 692.14 0.00780 
~ (376.53) (0.00471) (331.08) (0.00348) (699.12) (0.00838) 
.... 
S! 
'" ~ ~ 142.21 0.00159 56.49** 0.000629* 303.67* 0.00343* CGRP (125.56) (0.00153) (78.67) (0.000968) (288.20) (0.00360) 
~ 2492.23 0.0436 768.90** 0.0110** 3462.55* 0.0454 
"'CI PGP 




= ~ 2236.73 0.0358 990.96** 0.0140** 2527.47 0.0383 ~ VIP 
00 (1983.50) (0.0157) (1155.32) (0.0163) (2103.26) (0.0207) 
Values stated are the mean (SD) total area of immunostaining (2 decimal places), and fractional area of 
immunostaining (3 significant figures) for each antibody in each anatomical area of interest 
(epidermis, dermis, or sweat glands) within the skin. 
* P value < 0.05, ** P value <0.001 compared to control. 
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epidermal and dermal innervation, and Patient 3 showed a significant fall in dermal 
innervation (21 %, p=0.025). Whilst epidermal innervation remained reduced after LAC 
treatment (73% of control), innervation of both the dermis (102% of control) and sweat 
glands (104%) normalised completely (Table 8.2). 
8.3.4 Immunohistochemical Quantification - Small Sensory (C, Ao) Fibres (CGRP) 
Dermal innervation with CGRP positive fibres was significantly reduced (40% of 
control) in established DSP, whilst epidermal innervation was almost absent (5% of 
control). Highly significant increases occurred in both epidermal (mean 599%) and dermal 
(mean 445%) innervation after 6 months of LAC treatment (Table 8.2). Innervation 
increased in every patient (Table 8.1), such that the mean fractional area of 
immunostaining reached 49% of control in the epidermis, and 216% of control in the 
dermis. 
LAC treatment was also found to increase the proportion of all nerves (PGP 9.5 
positive) which displayed CGRP immunoreactivity in both the epidermis (pre-treatment 
4%; post-treatment 29%; control 43%), and the dermis (pre-treatment 17%; post-treatment 
44%; control 21 %). 
8.3.5 Immunohistochemical Quantification - Sympathetic Sudomotor Fibres (VIP) 
The reduction in sympathetic efferent innervation of the sweat glands (VIP positive 
fibres, 39% of control) which was found in patients with established DSP was less than the 
reduction in their total innervation (PGP9.5 positive fibres, 25% of control) (Table 8.2). 
This was matched by atrophy of the sweat glands themselves, since the total area of sweat 
gland present within the sections examined was only 68% of control (p=0.039). 
Innervation increased in every patient after LAC treatment (Table 8.1), with the result that 
the mean fractional area of staining reached the same level as that found in controls (107% 
of control), as did the area of the sweat glands themselves (117% of control, p=0.322). 
The proportion of the total innervation (PGP9.5 positive) which was due to VIP 
immunoreactive fibres also returned to normal (pre-treatment 127%; post-treatment 84%; 
control 82%). 
8.3.6 Effect o(WithdrawingLAC Treatment 
All patients continued to be followed in clinic after the second biopsy. Patients 
who discontinued LAC treatment after the initial 6 months have described a worsening of 
neuropathic symptoms or a reduction in their sense of well-being, in some cases beginning 
within days of ceasing treatment. Those who have remained on LAC treatment have 
continued to show symptomatic improvement. 
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A third skin biopsy was obtained from Patient 1 six months after discontinuing 
LAC treatment, by which time he was suffering from Grade 4 neuropathic pain. 
Quantification of this biopsy revealed a decrease in the innervation of all areas of the skin 
examined, by all fibre types assessed (Table 8.3, Figures 8.1D-8.4D). Small sensory fibres 
showed the greatest overall reduction, and although innervation generally remained better 
than that found prior to commencing LAC treatment, CGRP immunoreactivity in the 
epidermis was less than in the initial baseline biopsy. 
8.4 Discussion 
8.4.1 Methodology 
In the patient cohort NRTI induced DSP was diagnosed by a neurologist. All 
patients had stable DSP prior to recruitment, making spontaneous resolution unlikely to 
have accounted for the changes in symptoms and innervation that were found. 
Immunohistochemical quantification (lC) of cutaneous innervation has previously 
been found to correlate with clinical tests of sensory function in leprosy 326, and in diabetic 
neuropathy 327, where during the course of the disease IC changes precede those of sensory 
testing 25. The morphology of cutaneous innervation in DSP has previously been described 
qualitatively, and the density of epidermal fibres shown to be reduced along a proximal to 
distal gradient 320. However fibre counts do not assess the health of surviving fibres, whose 
atrophy or regeneration can be quantified by determination of the area ofimmunostaining, 
as used in this study. 
8.4.2 Cutaneous Innervation is Decreased in Established Distal Symmetrical 
Polyneuropathy (DSP) 
Since PGP9.5 is a constitutive component of peripheral nerve fibres any decrease in 
immunoreactivity will reflect actual loss or atrophy of fibres rather than a reduction in 
function of surviving fibres, which is an additional cause of decreased immunoreactivity 
for fibre-type specific neuropeptide transmitters (e.g. CGRP, or VIP). It is therefore 
evident that in established DSP symptoms do reflect a reduction in the cutaneous 
innervation of the lower leg. Epidermal innervation is most affected, in keeping with the 
die back hypothesis of sensory neuropathy 26, although there is also marked atrophy of the 
dermal and sweat gland plexi. This cutaneous denervation may explain the finding that 
neuropathic symptoms frequently do not begin to resolve for some weeks after starting 
Table 8.3: Effect of Withdrawal of LAC Treatment Upon Cutaneous 
Innervation in a Patient with DSP 
Pre-Treatment Post-Treatment Final Biopsy 
Antiserum: 
Fractional Area Fractional Area Fractional Area 
Vol 0.000481 0.00156 0.000886 .... PGP E (0.000544) (0.000583) (0.00143) 
Q,I 
"0 
0.000227 0.000010 .... 0.000161 c. CGRP ~ (0.000391) (0.000447) (0.000025) 
PGP 0.000355 0.0185 0.00155 Vol (0.000313) (0.0111) (0.00114) .... S 
... 
Q,I 
0.000045 0.00563 0.000398 Q CGRP (0.000050) (0.00321) (0.000408) 
PGP 0.0149 0.0464 0.0252 
..... Vol (0.00557) (0.0112) (0.00557) ~"O 
Q,I = ~.! 












Values stated are the mean (SD) fractional area ofimmunostaining (3 significant figures) for each 
antibody in each anatomical area of interest (epidermis, dermis, or sweat glands) within the skin. 
Percentage reduction after stopping LAC treatment equals the fractional area of immunostaining 
found after 6 months of LAC treatment ("Post-Treatment") minus that found 6 months after ceasing 
LAC treatment ("Final Biopsy"), expressed as a percentage of the "post-treatment" value. 
* P value < 0.05, ** P value <0.001 compared to control. 
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LAC treatment, and may then continue to improve for many months, since this timeframe 
matches the slow rate at which peripheral nerves regenerate. 
As might be expected from the dysaesthetic algesic symptomatology ofDSP, it is 
the small sensory (C, AD) fibres that are most affected, since this fibre type shows the 
greatest reduction in area of immunostaining when compared to normal controls. 
Furthermore, since the proportion of all fibre staining (PGP9.5) that was due to CGRP 
immunoreactivity was also markedly reduced in the epidermis (DSP 4%; control 43%), 
there is not only a loss of epidermal fibres, but also a reduction in function of the small 
sensory fibres that do survive. In contrast, the preservation ofthe CGRP:PGP9.5 ratio 
(DSP 17%; control 21 %) in the dermis suggests that fibre loss or atrophy predominates, as 
also seems to be the case in the sweat glands where the VIP:PGP9.5 ratio remained 
unchanged (DSP 82%; control 84%). 
8.4.3 L-acetyl-carnitine (LAC) Treatment Improves Cutaneous Innervation and 
Symptoms in Distal Symmetrical Polyneuropathy (DSP) 
Six months of oral treatment with LAC resulted in significant increases in the 
innervation of the epidermis, dermis, and sweat glands. The PGP 9.5 results demonstrate 
that cutaneous nerve fibres did actually regenerate sufficiently that both dermal and sweat 
gland innervation reached the level found in normal skin. Intra-epidermal fibres also 
regenerated, although epidermal innervation did not reach a normal level either because 
epidermal innervation is reduced in non-neuropathic patients with HIV 320, or because 
reinnervation occurs more slowly in the epidermis than in other tissues 328, implying a need 
for greater than 6 months of LAC treatment. A study comparing the epidermal innervation 
of patients with DSP after prolonged LAC treatment (> 12 months), to that of non-
neuropathic HIV positive individuals is underway to address this question. 
The increased ratio of CGRP and VIP to PGP9.5 immunostaining which was found 
after LAC treatment is a feature of regenerating nerve fibres, and also suggests that the 
reinnervating fibres were functional, although electrophysiological and sensory testing will 
be required to confirm this. The increase in dermal CGRP immunoreactivity to 
supranormallevels is likely to reflect the fact that regeneration into the epidermis was not 
complete, with the result that anterogradely transported CGRP accumulated in the dermal 
part of the fibres due to a distal "damming" effect, as has been described in early diabetic 
neuropathy 25. 
Although LAC treatment resulted in a significant reduction in the grade of 
neuropathic pain experienced by subjects in this study, randomised controlled trial (RCT) 
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data utilising a validated visual analogue pain scale will be required to conclusively 
demonstrate a symptomatic benefit. A RCT is now underway which will provide this data, 
along with formal electrophysiology and thermal threshold testing to determine the 
functional effect of LAC treatment in DSP, 
Whilst there was no placebo arm to this study, the natural history of untreated DSP, 
plus the return of symptoms and worsening of cutaneous innervation after cessation of 
LAC treatment in patient 1, suggests that the beneficial effects found in the patient cohort 
were a result of LAC treatment. Consideration of the mechanism by which LAC treatment 
may have effected such an improvement first requires an explanation of the pathogenesis 
ofNRTI therapy associated DSP, 
8.4.4 Mechanism o(Action 
Although the pathogenesis ofDSP has not been entirely clarified, the DNA 
polymerase-y hypothesis remains the most powerful explanation 202, In eukaryote cells 
DNA is polymerised from individual deoxynucleotide triphosphates (dNTP) by DNA 
polymerase, the y and P-isoforms of which are significantly inhibited by the 
dideoxynucleotide triphosphate (ddNTP) NRTI's 315, Unlike nuclear DNA (nDNA) 
replication, mitochondrial DNA (mtDNA) replication is solely dependent upon the y-
isoform, inhibition of which is greatest in non-mitogenic cells where only mtDNA is 
replicated 202,315, Due to its proximity to the free radical species generated by the 
respiratory chain complexes mtDNA is particularly liable to damage, and since there are no 
mtDNA repair mechanisms overall oxidative metabolic function must be maintained by 
replication 315, Hence by impairing mtDNA replication, NRTI's reduce the cell's capacity 
for oxidative phosphorylation, which is the critical energy pathway in neurons, As a result 
neurons may apoptose 310, or fail to meet the metabolic requirements for maintaining long 
peripheral axons resulting in a die-back, glove and stocking neuropathy, 
LAC treatment may therefore counteract ddNTP NRTI toxicity by several 
mechanisms, Firstly, it may reduce mtDNA damage by a direct antioxidant effect 295,296, 
Secondly, LAC facilitates mitochondrial homeostasis of acetyl-CoA, promotes long-chain 
free fatty acid transport across mitochondrial membranes 247, and via regulation of 
malonyl-CoA promotes cytosolic FF A oxidation 294, By promoting glucose utilisation and 
high-energy substrate oxidative metabolism, LAC thereby improves neuronal metabolic 
capacity 329, In addition LAC may facilitate distal neurotrophic support, particularly of 
small myelinated and unmyelinated (C, A5) nociceptive neurons, since it increases NGF 
binding capacity 297, enhances the response to NGF 245, and promotes neurite extension in 
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response to NGF 244. Furthermore, LAC promotes peripheral nerve regeneration 298 and 
function 249,304,330,331 independently ofNRTI toxicity. Also, patients with NRTI associated 
peripheral neuropathy have reduced serum LAC levels, but asymptomatic HIV positive 
controls do not 332. LAC penetrates the blood-brain barrier 302, and serum levels can be 
increased by oral or parenteral administration of LAC 303,333, which also reverses the 
depletion of LAC content that occurs in the peripheral nerves of diabetic rats 322. 
8.4.5 Other Potential Benefits ofL-acetyl-carnitine (LAC) Treatment 
LAC may offer additional benefits in the management of HI V infection since the 
mitochondrial pathogenesis of DSP shares similarities with that of the lipodystrophy 
syndrome 334 that is associated with highly active antiretroviral therapy (HAART) 335. 
Lipodystrophy may therefore be responsive to LAC treatment. Furthermore, the related 
compound L-camitine (with which LAC equilibrates in-vivo) improves CD4 positive T-
cell counts by limiting ceramide production and apoptosis 336-339 and by promoting 
mononuclear cell proliferation 336; serum lipid profiles 337, and exercise capacity 340 may 
also improve. In this study an oral dose of 1500mg b.d. of LAC was safe, well tolerated, 
and unlike rhNGF treatment 324 no side effects occurred. LAC treatment was not 
associated with any progression of HI V infection; in fact the viral load fell, small increases 
in both absolute and percentage CD4 counts were found, and the CD4/CD8 ratio doubled 
(p=O.008). 
8.4.6 Implications 
Although nucleoside analogue antiretroviral agents have been partly superceded by 
other agents such as the protease inhibitors, they remain fundamental elements of 
combination therapy 26,318 and are likely to remain important components in the 
management of HI V for the foreseeable future 26. Peripheral neuropathy has been the 
principal complication limiting the use of several of these agents 26,204, and LAC may now 
offer an effective, pathogenesis based approach to management, which can allow patients 
to remain on NRTI therapy. A full randomised controlled trial is now underway to attempt 
to validate the results of this study, and to determine the required duration of LAC 
treatment. 
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Chapter 9. Discussion 
An estimated 300,000 peripheral nerve injuries occur each year in Europe alone, 
and yet even after optimal surgical repair sensory outcome remains disappointingly poor 
5,6,9, such that "no adult with a major nerve transection has ever attained normal 
sensibility" 10. That is the case even after primary repair of clean injuries, and it is 
accepted that outcome is even worse in the case of chronic nerve injuries, and those 
requiring nerve grafting 5,6. Sensory outcome also impacts adversely upon motor outcome 
due to loss of normal proprioceptive feedback for motor control IS, and peripheral nerve 
injuries are therefore a major cause of morbidity, healthcare expenditure, and social 
disruption 6. 
Quality of sensation depends upon the number of innervating neurons, so it is likely 
that the single most important determinant of poor sensory outcome after surgical repair of 
peripheral nerve injuries is the death of a large proportion of the sensory neuronal pool 19, 
although various other factors are also implicated 5,17,18. Sensory neuronal death after 
peripheral nerve injury was fIrst reported in the early 20th century, and subsequent studies 
have demonstrated that up to 50% neuronal loss occurs 55,96-98,102,107,108,1ll,1l8, that a similar 
magnitude of neuronal death does occur clinically 115, and that DNA fragmentation occurs 
92,98,100,102. Although sensory neuronal death was well recognised, it was not known how 
soon after nerve injury neuronal death begins, how long the period of neuronal death lasts 
for, and what effect peripheral nerve repair, and its timing after injury, had upon the 
magnitude of neuronal death. Administration of exogenous neurotrophic factors was 
known to reduce neuronal death in an experimental setting 47, but its immediate clinical 
applicability was questionable 7 (cf. 1.6) and so a pressing need existed for alternative 
strategies with more immediate clinical potential. 
The initial aim of this project was therefore to describe the timecourse of primary 
sensory neuronal death (cf. Chapter 3) in order to identify logical timepoints at which to 
test neuroprotective strategies, and to defme a therapeutic window for the future clinical 
application of any successful strategies. Consideration of the pathogenetic events 
underlying neuronal death then led to the hypothesis that early surgical repair (cf. Chapter 
4), and N-acetyl-cysteine (cf. Chapter 5) would reduce sensory neuronal death. Finally, 
the similarities between the effects of peripheral axotomy and the pathogenesis of distal 
symmetrical polyneuropathy neuropathy in mv disease lead to the investigation of L-
acetyl-carnitine (cf. Chapters 6-8) as a clinically applicable treatment which might 
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improve peripheral nerve regeneration and reduce sensory neuronal death after peripheral 
nerve injury. 
Death of individual neurons was identified by TUNEL (cf. 1.4,2.4.3,2.5.1), and 
the magnitude of neuronal loss was quantified from statistically unbiased stereological 
neuron counts obtained using the optical disector technique (cf. 1.4, 2.4.3, 2.5.2). Sensory 
neuronal death within axotomised L4&5 dorsal root ganglia (DRG) began within 24 hours 
of injury, although this did not translate into actual neuron loss until 7 days after axotomy, 
reflecting the time taken for individual neurons to progress from DNA fragmentation to 
eventual involution and loss (cf. 3.4.4). Neuronal death peaked 2 weeks after axotomy, as 
shown by TUNEL, and neuronal loss was virtually complete by 2 months after axotomy. 
Although neurons were still dying 6 months after injury, as shown by the presence of 
occasional TUNEL positive neurons, death occurred at a sufficiently low rate that the 
neuronal loss at 4 & 6 months after injury was not significantly different to that found at 2 
months (cf. 3.4.4). Around 40% of the entire sensory neuronal pool died by a process that 
did not exclusively involve apoptotic morphological features, and this was accompanied by 
a secondary wave of satellite cell death, which reached a peak 2 months after sciatic nerve 
transection (cf. 3.4.7). 
The experimental timepoints of 2 weeks and 2 months after injury were therefore 
adopted as reflecting the peaks of both neuronal death (TUNEL) and neuronal loss. Of 
more clinical relevance, it would appear that strategies to reduce neuronal death should 
ideally be implemented within 24 hours of injury, although intervention within 2 weeks of 
injury should still cause a significant reduction in neuronal death, and up to 2 months after 
injury some benefit may be accrued. However interventions later than this are unlikely to 
have any significant neuroprotective benefit. How precisely these results from a well-
defined rat model can be applied to the more diverse clinical situation found in man is not 
certain, although it is likely that the overall pattern will be similar. Repeating this study in 
another animal model, such as the rabbit, and using lesions at different distances from the 
DRG may help to answer this question. Alternatively it may be possible to adapt in-vivo 
clinical techniques such as functional magnetic resonance imaging (tMRI) 341 and 
magnetic resonance neurography 342 for the estimation of sensory neuronal death, or to 
estimate DRG volume by high resolution MRI scanning, since changes in DRG volume 
were related to neuronal loss (cf. 3.4.6). 
Sensory neuronal death is reduced by exogenous growth factor administration after 
peripheral nerve injury 47,105,106,109,148,167,217 • Surgical nerve repair involves co-apting the 
axons in the proximal stump to the neurotrophic factory that is the distal nerve stump 
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47,48,69, and may therefore be the simplest way to restore neurotrophic support and limit 
neuronal death. Despite prolonged debate over the optimal timing of surgical repair 6,11,13,42 
the effect upon neuronal death has not been given due consideration, and although early 
repair is now generally recommended for most nerve injuries 5,6,11, nerve transections still 
do not have priority for access to theatre facilities. As a result they are frequently not 
repaired for some days, and closed injuries are generally left for a diagnostic period of 
several months prior to exploration 6. 
Nerve repair has now been demonstrated to markedly reduce sensory neuronal 
death, and the principle that the neuroprotective benefit is greater the earlier repair is 
performed has been established (cf. 4.4.2). It would therefore seem that where there is no 
contraindication, it is inadvisable to delay nerve repair even by 24 hours, and that early 
secondary nerve repairs II should be performed within two weeks of injury, and late 
secondary nerve repairs 11 within two months (cf. 4.4.3). Since immediate repair will 
never be clinically feasible for the majority of injuries, further studies using larger 
experimental groups are now needed to determine the effect of short delays (6-48 hours) 
upon neuronal death. Alternatively, retrospective clinical studies could seek differences in 
sensory outcome between patients who underwent nerve repair at different times after 
injury, although it would be difficult to obtain sufficient numbers of patients with 
adequately standardised injuries to reliably detect any difference given the relative 
insensitivity of current clinical sensory tests. 
Despite the reduction in sensory neuronal death that can be achieved by early 
peripheral nerve repair, there is still a clinical need for an adjuvant neuroprotective 
therapy. Neuronal death was not entirely eliminated even by immediate nerve repair (cf. 
4.3), and yet many patients are unlikely to undergo surgical repair within 8-12 hours of 
injury in even the best organised of trauma services. There is also a need to reduce the 
neuronal death that occurs after closed injuries, since these may not be explored until after 
several months of diagnostic delay 6 and may represent simple crush injuries 
(axonometsis). Nerve repair would not benefit these latter injuries, but significant sensory 
neuronal death may still occur 107. Clinically applicable pharmaceutical agents were 
therefore sought which might reduce sensory neuronal death. 
The mechanism by which axotomy effects neuronal death is thought to involve loss 
of distal neurotrophic support 17,47, increased generation of nitric oxide (NO) 196-198, 
mitochondrial dysruption (cf. 3.4.5) and bio-energetic dysfunction 53,185,19l, reactive 
oxygen species (ROS) 53,166, and possibly also abortive entry into the cell cycle 160,293 (cf. 
1.5). In neurons the principal means of defence against reactive oxygen species is 
glutathione 242,270, but synthetic capacity is limited and intramitochondrial glutathione is 
rapidly depleted by oxidative stress, and the disruptive effects ofROS and nitric oxide 
(NO) upon energy metabolism are then potentiated 197,270,280,283 (cf. 5.4.3). 
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N-acetyl-cysteine (NAC) has demonstrated antioxidant effects which are mediated 
via glutathione synthesis at low-doses, has anti-mitotic effects in neuronal cell lines, and 
has been shown to be neuroprotective in response to various neurotoxic stimuli in vitro (cf. 
1.6 & 5.4.3). NAC is already in clinical use as a glutathione precursor in the treatment of 
paracetamol overdose 241, and was therefore thought to offer potential as a neuroprotective 
agent after peripheral axotomy. After sciatic nerve transection NAC treatment resulted in a 
significant dose-related decrease in the number of TUNEL positive neurons found 2 weeks 
after injury (p<0.05), and in a significant decrease in the neuronal loss found 2 months 
later (control 35% loss; NAC treatment 3% loss, p=0.002) (cf. 5.4.2). NAC did not entirely 
prevent sensory neuronal death, but over 10,000 neurons were protected by treatment. 
NAC therefore has considerable clinical potential for the adjuvant treatment of peripheral 
nerve trauma (cf. 5.4.4), although further research will initially be required to establish 
what effect NAC has upon nerve regeneration. 
The mechanism by which axotomy effects neuronal death is similar to that 
underlying the NRTI antiretroviral therapy associated neuropathy that affects around 20% 
of patients with HIV (cf. 8.1), since both are postulated to involve mitochondrial 
dysfunction, failed oxidative metabolism, free radical generation, and loss of distal 
neurotrophic support (cf. 1.5 & 8.4.4). L-acetyl-camitine (LAC) has essential 
physiological roles in free fatty acid transport and mitochondrial energy metabolism 
246,247,294. It has antioxidant properties 295,296, facilitates the actions ofNGF 244,245,297, and is 
neuroprotective in-vitro 244,245,248 (cf. 1.6 & 6.4.3). LAC was known to stimulate peripheral 
nerve regeneration after sciatic nerve injury in the rat 298,299, and to improve symptoms in 
HIV infected patients with DSP after short-term therapy 301. 
When LAC was administered to rats after sciatic nerve transection a significant 
dose-related decrease, of up to 91 %, was found in the number ofTUNEL positive neurons 
2 weeks after axotomy (p<0.01) (cf. 6.4.2). Sensory neuronal death was decreased to the 
extent that no neuron loss was found 2 months after injury (control 35% loss; LAC 
treatment -4% loss, p<O.OOl), and this represents the salvage of over 10,000 neurons, and 
the protection of almost the entire sensory neuronal pool of the sciatic nerve (cf. 6.4.2). 
LAC treatment also a caused significant increase in the peripheral nerve regeneration 
found 6 weeks after late secondary repair, suggesting that not only is LAC neuroprotective, 
but that it also stimulates the regenerative capacity of individual neurons (cf. 7.4.2). In 
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keeping with this, 6 months of oral LAC treatment (1500mg b.d.) not only improved 
symptoms in HIV infected patients with NRTI related DSP, but caused peripheral nerve 
regeneration back into target tissues (cf. 8.4.3). Epidermal innervation increased, and both 
total dermal, and sudomotor innervation returned to normal control levels, with the NGF 
dependent small sensory C, A8 fibres exhibiting the greatest response to treatment (cf. 
8.4.3). 
The physiological peptide LAC has therefore been demonstrated to almost entirely 
eliminate sensory neuronal death after peripheral nerve transection (cf. 6.4.2), and to 
promote peripheral nerve regeneration after nerve injury 298,299, even independently of its 
neuroprotective effect (cf. 7.4.2). LAC has also now been demonstrated to cause 
peripheral nerve regeneration in a clinical setting of chronic nerve injury (cf. 8.4.3), and to 
be safe and easy to administer clinically. LAC therefore has the potential not only to be 
the first pathogenesis based treatment for NR TI therapy associated DSP in HIV disease (cf. 
8.4.6), but also to be the first clinically applicable agent for the adjuvant pharmacotherapy 
of peripheral nerve injuries (cf. 6.4.4 & 7.4.4). Further research is now required to 
determine the exact neuroprotective mechanism of LAC, and to establish how great a delay 
between injury and commencing LAC treatment is acceptable without losing the 
neuroprotective benefit of treatment. However, given the data presented to date, and the 
extensive clinical safety data available for LAC, clinical trials to establish the effect of 
LAC treatment upon the sensory outcome after major nerve injuries in the upper limb and 
brachial plexus are currently being scheduled. 
Further studies are also needed to confirm whether or not the reduction in sensory 
neuronal death found after treatment with NAC & LAC will actually improve sensory 
function after nerve repair. This could either be determined experimentally by 
electrophysiological studies and by immunohistochemical quantification of cutaneous 
innervation at suitable timepoints after peripheral nerve repair, or by randomised 
prospective clinical trials of sensory outcome. It also remains to be determined whether 
these agents will show equal promise in preventing neuronal death after other forms of 
nervous system injury, and their effect upon motorneuron survival is currently under 
investigation in a model of brachial plexus injury. The applicability of LAC & NAC in 
limiting secondary neuronal death after traumatic brain and spinal cord injury should also 
be investigated. In the wider setting of neuronal death in general, mitochondrial bio-
energetic, and oxidative stress mechanisms have been postulated for conditions as varied 
as ischaemia reperfusion injury, Alzheimers disease, Huntingdon's disease, Parkinson's 
disease, amyotrophic lateral sclerosis, and the neurodegeneration associated with ageing 
166,185,233-237,343 
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Both LAC and NAC might therefore offer potential either as investigative 
tools in further eliciting the pathogenesis of these conditions, or possibly even as 
therapeutic agents. 
In summary, this project has defmed the time course of primary sensory neuronal 
death after peripheral nerve injury, thereby setting a logical time frame for subsequent 
research and identifying a potential therapeutic window for interventions to reduce 
neuronal death. The principle that the timing of surgical nerve repair affects sensory 
neuronal death has been established, and this potentially has profound implications for the 
organisation of peripheral nerve surgery services. Two clinically safe pharmaceutical 
agents (NAC & LAC) have been demonstrated to almost eliminate sensory neuronal death 
after peripheral nerve injury, and L-acetyl-camitine has also been demonstrated to enhance 
peripheral nerve regeneration in both an animal model of late secondary nerve repair, and 
in the clinical setting of HI V-associated distal symmetrical polyneuropathy (DSP). Further 
research into these drugs is underway, and the results of two randomised controlled clinical 




Appendix 1 (Materials (or Nerve Conduits & Caps): 
Material Source Product Code 
Polyhydroxybutyrate (PHB) Sheet Astra, Astra Tech AB, Box 14, S-431 21 18000 Molndal, Sweden 
Low Vicosity, High Mannuronic Acid Pronova Biomedical, N-0371 Oslo, LVM Content Ultrapure Sodium Alginate Norway (LVM) 
0.1 % Fibronectin (Fn) Solution from Sigma-Aldrich Ltd., Poole, Dorset, U.K. Fl141 Bovine Plasma 
Recombinant Murine Leukaemia Autogen Bioclear UK Ltd., Holly Ditch ABC156 Inhibitory Factor (LIF) Farm, Mile Elm, CaIne, Wiltshire, U.K. (Specific Activity> 1x108 U/mg) 
Recombinant Human Glial Growth Cambridge Neurosciences, U.S.A. Factor II (GGF) 
High-Grade Silicone Rubber Tubing Philip Harris International, Lichfield, T88-5420 (lmm internal diameter) Staffordshire, U.K. 
White Air Inlet Needle Avon Medicals, SIMS Portex Ltd., A81 Redditch, Worcestershire, U.K. 
Sherwood Davis & Geck, Northern 1100601630 Monoject 1ml Syringe Ireland 
Dulbecco's Modified Eagle's Medium Gibco Life Technologies, Glasgow, U.K. 21885 (DMEM) 
10% Foetal Calf Serum Imperial Laboratories, London, U.K. 
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Appendix 2 (N-Acetyl-Cysteine & L-Acetyl-Carnitine Treatment): 
Material Source Product Code 
L-acetyl-carnitine (anhydrous powder) Sigma-Tau Farmaceutiche, 00144 Roma, 5012300 Italia 
L-acetyl-carnitine (capsules) Sigma-Tau Farmaceutiche, 00144 Roma, Italia 
N-acetyl-cysteine ("Parvolex®") Evans Medical Ltd., Leatherhead, U.K. Ll067BEVA 
Sterile Normal Saline for Injection Maco Pharma, Southampton House, London, U.K. 
Sterile 5% Glucose for Injection Maco Pharma, Southampton House, London, U.K. 
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Appendix 2 (Surgical Materials): 
Material Manufacturer Product Code 
18 Gauge Abbocath®-T Venisystems, Abbott Ireland, Sligo, G7154535-18 Ireland 
Betadine 2% in alcohol Royal Free Hospital Pharmacy, London 
9/0 Ethilon® Sutures Ethicon Ltd., Bankhead Avenue, W2898 Edinburgh, U.K. 
10/0 Ethilon® Sutures Ethicon Ltd., Bankhead Avenue, W2850 Edinburgh, U.K. 
Halothane BP May & Baker Ltd., Dagenham, UK 
Halothane Regulator (Series 5 T.C.V.) International Market Supply, Congleton, Cheshire, UK 
Hydrex® (Chlorhexidene Gluconate 0.5% Adams Healthcare, Lotherton Way, 
w/v in 70% IMS) Leeds, U.K. 
25 Gauge Kendall Monoject® Sherwood Medical, Northern Ireland 1100-255312 Hypodermic Needles 
Xylocaine (Lignocaine HCl) 2% with Astra Pharmaceuticals Ltd., Kings PL 0017/5030R Adrenaline Langley, England 
Melolin Smith & Nephew Medical Ltd., Hull, ART6696491 England 
4/0 Polydioxanone (PDS®II) Sutures Ethicon Ltd., Bankhead Avenue, W9734 Edinburgh, UK 
3/0 Prolene® Sutures Ethicon Ltd., Bankhead Avenue, W8878 Edinburgh, UK 
6/0 Prolene® Sutures Ethicon Ltd., Bankhead Avenue, W8718 Edinburgh, U.K. 
Sagattal™ Rhone Merieux Ltd., Harlow, Essex, VP A 0040/2111 VSO (sodium pentobarbitone 60mglml) U.K. 
#15 Surgical Blade Swan-Morton Ltd., Sheffield, UK 0205 
Temgesic® (300l-lg buprenorphine/ml) Schering-Plough, Shire Park, 108499 Hertfordshire, U.K. 
4/0 Vicryl® Sutures Ethicon Ltd., Bankhead Avenue, W9825 Edinburgh, U.K. 
_ .. _---_ .. _--_ .. _---
- ---- --
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Appendix 3 (Antibodies & Staining Reagents): 
Antibody / Stain / Reagent Abbreviation Working Source Catalogue Dilution Number 
Bovine Serum Albumin BSA 1:1000 Sigma-Aldrich Ltd., Poole, Dorset, A-2153 
u.K. 
Rabbit Polyclonal Antibody Affiniti Research Products Ltd., 
to Calcitonin Gene Related CGRP 1:3000 CA 1134 
Peptide Marnhead, Exexter, U.K. 
FluorolinkTM CyTM-3 Amersham Pharmacia Biotech UK 
Labelled Goat Anti-Mouse Cy-3 1:100 Ltd., Little Chalfont, PA43002 
IgG (H+L) Buckinghamshire, U.K. 
FITC Labelled Goat Anti- FITC 1:100 Vector Laboratories Inc., J0813 Rabbit Burlingame, CA 94010, U.S.A. FI-1000 
Hoechst 33342 H33342 1:1000 Sigma-Aldrich Ltd., Poole, Dorset, B-2261 U.K. 
Normal Goat Serum NGS 1:100 Sigma-Aldrich Ltd., Poole, Dorset, G-9023 U.K. 
Normal Horse Serum NHS 1:100 Sigma-Aldrich Ltd., Poole, Dorset, H-0146 UK 
Normal Rat Serum NRS 1:100 DAKO, DK-2600 Glostrup, X0912 Denmark 
Mouse Monoclonal Antibody Affiniti Research Products Ltd., Cocktail to Phosphorylated PAMNF 1:1000 Mamhead, Exexter, U.K. NA 1299 Neurofilaments 
Rabbit Polyclonal 
Antiserum to Ubiquitin C- PGP9.5 1:1500 Affiniti Research Products Ltd., PG 9500 Terminal Hydroxylase Marnhead, Exexter, U.K. 
(Protein Gene Product 9.5) 
Propidium Iodide PI 1:1000 Sigma-Aldrich Ltd., Poole, Dorset, P-4170 UK 
Rabbit Anti-Cow S-1 00 S-100 1:1000 DAKO, DK-2600 Glostrup, Z 0311 Denmark 
Promega Apoptosis TUNEL Promega Corporation, Madison, Detection System Staining Kit WI 53711-5399, U.S.A. G3250 Fluorescein 
Polyclonal Rabbit Antiserum Hammersmith Hospital, London, 
to Vasoactive Intestinal VIP 1:2000 (VIPI5) 
Polypeptide U.K. 
Monoclonal Mouse Anti- DAKO, DK-2600 Glostrup, Human Von Willebrand VWF 1:1000 Denmark M0616 Factor 
! 
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Appendix 4 (Miscellaneous Laboratorv Materials & Equipment): 
Item / Material Manufacturer Product Code 
3.5X Magnification Surgical Loupes Carl Zeiss, Postfach 1865, D-73408, Aalen, Germany 
50mm Glass Coverslips Chance Propper Ltd., West Midlands, B66 INZ, U.K. 
62mm Glass Coverslips Chance Propper Ltd., West Midlands, B66 INZ, U.K. 
BioRad H2500 Microwave Oven Energy Beam Sciences Inc., Agawam, H2500 Massachusetts, U.S.A. 
Boxer Autoclave Borolabs, U.K. 
Cryostat Bright Instruments Ltd., Huntingdon, ModelOTF U.K. 
DAKO Pen for Immunohistochemistry DAKO, DK-2600 Glostrup, Denmark S 2002 
Fluid Cooled Digital Spot Camera Diagnostic Instruments, U.S.A. Model 1.3.0 
Fluorescent Lamp Burner Unit Olympus Optical Co. Ltd., Japan U-RFL-T 
Gold Star Glass Slides (76x26mm) Chance Propper Ltd., West Midlands, B66 INZ, U.K. 
Optical Microscope Olympus Optical Co. Ltd., Japan BX60 
Optical Microscope Olympus Optical Co. Ltd., Japan BX50 
Paraformaldehyde (PF A) Sigma-Aldrich Ltd., Poole, Dorset, U.K. P-6148 
Peristaltic Pump Watson-Marlow Ltd., Falmouth, 505SIRL Cornwall, U.K. 
Sodium Azide Sigma-Aldrich Ltd., Poole, Dorset, U.K. S-2002 
Sodium Citrate Sigma-Aldrich Ltd., Poole, Dorset, U.K. S-464l 
Sucrose Sigma-Aldrich Ltd., Poole, Dorset, u.K. S-9378 
Triton X-I 00 BDH Laboratory Supplies, Poole, BH15 306324N lTD, U.K. 
Vectabond® 
Vector Laboratories Inc., Burlingame, SP-1800 CA 94010, U.S.A. 
Appendix 5 (Triple Staining Protocol): 
1) Fix sections onto slides by drying on hotplate overnight & DAKO pen around edges. 
2) Stain ganglia in runs of3 animals (12 ganglia, 24 slides) at a time. Use a testes slide as a 
positive control, and a normal DRG slide as a -TdT control, giving a total of 26 slides per 
staining run. 
3) Rehydration: PBS 10 minutes 
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-at this point get out 4 phials of equilibration buffer, 4 of Nucleotide (FITC-dUTP) & 3 of 
TdT to thaw. 
3) Permeabilise: 
-microwave in 250ml ofO.01M Na Citrate for 1.5 minutes, set at total time & control 
override, with a 1.51 water load (2 beakers of 750ml). Use 2 sets of slides together. 
-testing the power level of the microwave showed it to be 478W. 
4) Rapid Cooling: immediately place slides into iced PBS for 5min. 
5) Equilibrate: 1 00~1 equilibration buffer per slide. 
Carefully cover with plastic coverslip (fold a comer up before applying it). 
Incubate for 8 min at room temperature. 
Prepare Nucleotide mixture (protect from light): 
-require 50~1 per slide. 
-Mix: 45~1 equilibration buffer + 5~1 nucleotide mix + 1~1 TdT enzyme. 
-so require: 1170~1 equilibration buffer + 130~1 nucleotide mix + 26~1 TdT 
enzyme. 
-negative control: 45~1 equilibration buffer + 5~1 nucleotide mix + 1~1 distilled 
water. 
6) TdT Reaction (protect from light): 
-carefully peel off coverslips, blot excess liquid & apply nucleotide mix (50~1 per slide). 
-replace plastic coverslips. 
-incubate in humid chamber for 60 minutes at 37°C (protected from light). 
7) Terminate TdT reaction: 
-dilute 20x SSC 1 Of old to give 2xSSC (use 60ml of20xSSC into 600ml distilled water, 
into 2 staining jars. For second run top this up with remaining 10ml 20xSSC diluted to 
100ml, and split between jars). 
-soak slides in jars for 15 minutes at room temperature in a humid chamber. 
8) Wash: PBS 5 minutes. 
9) Apply l~g/ml Propridium Iodide + l~glml Hoechst 33342 in PBS 
-apply onto slide (~300~1 / slide), incubate for 10 minutes at room temperature. 
10) Wash: 
-distilled water 8 minutes. 
-PBS 4 minutes. 
13) Mount Glass Coverslips (50mm / 64mm): 
-PBS/Glycerine mountant with glass coverslip. Seal with DPX. 
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Appendix 6 ammunohistochemistry Protocol for Skin Biopsies): 
1. Fix sections onto slides by drying on hotplate overnight & DAKO pen around edges. 
2. Permeabilise: 0.2% Triton-X in PBS for 1hour. 
3. Wash: PBS 3 min. 
4. Counterstain: Pontamine Sky Blue 30min. 
5. Wash: PBS 3min x 2. 
6. Primary Antibody Incubation: 
-apply primary antibody & incubate overnight at 4°C in a humid chamber: 
-appropriate dilution of primary antisera diluted in antibody diluent + blocking 
antiserum (normal goat serum) 1: 1 00: 
PGP 9.5 1:1500 CGRP 1:3000 VIP 1:2000 
7. Wash: PBS 3min x 2. 
8. Secondary Antibody Incubation: 
-Apply FITC-conjugated goat anti-rabbit antiserum (1 :100 dilution in antibody diluent) & 
incubate for 1 hour at room temperature in humid chamber. 
9. Wash: PBS 3min x 3. 
10. Mount Glass Coverslips (50mm /64mm): mount with PBS/Glycerine, store slides at 4°C. 
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Appendix 7 (Immunohistochemistry Protocol tor Nerve Repairs): 
1. Fix sections onto slides by drying on hotplate overnight & DAKO pen around edges. 
2. Permeabilise: 1 hour in 0.1 % Trition-X in PBS at room temperature. 
3. Wash: 2 x 5 minute rinses in PBS. 
4. Block: incubate for 1 hour at room temperature with 1: 100 Normal Goat & Horse 
Serum in antibody diluent (~250I-tJ per slide). 
5. Primary Antibody Incubation: 
1 hour incubation at room temperature with primary Ab in antibody 
diluent: P AMNF (monoclonal) 1: 1 000 + S-100 (polyclonal) 1: 1000 
6. Wash: 2 x 5 minute rinses in PBS. 
7. Secondary Antibody Incubation: 
8. Wash: 
2 hour incubation at room temperature with secondary Ab in antibody 
diluent: 
1: 100 Cy-3 anti-mouse + 1: 100 FITC anti-rabbit + 1: 1 00 normal rat 
serum. 
2 x 5 minute rinses in PBS. 
9. Mount Glass Coverslips (50mm /64mm): mount with PBS/Glycerine, store slides at 4°C. 
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Appendix 8: Preparation & Storage of Reagents & Solutions 
8.1 Phosphate Buffered Saline (PBS) 
Phosphate buffered saline was prepared by dissolving 87.9g NaCI + 2.72g KH2P04 + 11.35g 
Na2HP04 into 5 litres of distilled water. A further 5 litres of distilled water was then added, and then at least 
8.5 hours later the pH was tested, and adjusted to pH7.3 by addition ofNaOh, or HCI as required. 
8.2 Paraformaldehyde (PF A) 
A stock 20% solution was prepared by dissolving 300g anhydrous PFA (Sigma-Aldrich, U.K.) in 
1.5 Htres of PBS, using a magnetic stirrer and a warming plate to maintain the solution at 35-45°C, The 
resulting solution was then aliquotted, and stored at -40°C. The day before use, an aliquot of 20% PF A 
was thawed and diluted to five times the volume with PBS, giving a fmal solution of 4% PF A in PBS. This 
solution was stored at 4°C prior to use within 24 hours. 
8.3 Solution of Sucrose in Phosphate Buffered Saline (PBS Sucrose) 
150g of sucrose and Ig of sodium azide (Sigma-Aldrich, u.K.) was dissolved into 1 litre of PBS. 
8.4 Zamboni's Fluid (Tissue Fixative) 
Zamboni's fluid was prepared in 1 litre aliquots by mixing 150ml of saturated picric acid solution 
with 850ml ofa solution of2% paraformaldehyde (PFA) in PBS (pH7.4). The fluid was stored at 4°C prior 
to use. 
8.5 PBS - Glycerine Mountant 
Glycerine slide mountant was prepared by dissolving 19 of antifade compound 
(1 ,4Dia20Bicyclo2.2.20ctane) in 4ml of PBS, and adding the resulting solution to 36ml of glycerine. The 
mountant was stored at 4°C prior to use. 
8.6 Antibody Diluent Solution 
All antibodies were diluted prior to application in a solution of 0.03% Triton-X + 0.1 % Bovine 
Serum Albumin (BSA) + 0.1 % Sodium Azide (Sigma-Aldrich, U.K.) in PBS. Aliquots of diluent solution 
were prepared by dissolving O.lg sodium BSA, O.lg sodium azide, and 301-11 of Triton-X into 100mlofPBS. 
Diluent solution was stored at 4°C prior to use. 
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Appendix 9 (Frequently Used Abbreviations): 
Abbreviation Full Name Abbreviation Full Name 
AIF's Apoptosis Inducing Factors IL-l~ Interleukin-l ~ 
ASPA Animals (Scientific Procedures) Act iNOS Inducible Nitric Oxide Synthase 
BDNF Brain Derived Neurotrophic Factor ISEL In-Situ End Labelling 
C.A.S.T. Computer Assisted Stereo logy JNK c-Jun Kinase Toolbox 
L-acetyl-carnitine (also termed 
CGRP Calcitonin Gene Related Polypeptide LAC cetyl-L-carnitine (ALCAR) by other 
authors) 
CNTF Ciliary Derived LIF Leukaemia Inhibitory Factor Neurotrophic Factor 
Cy-3 Cyanine-3 NAC N -acetyl-cysteine 
D4T Stavudine NGF Nerve Growth Factor 
ddC Zalcitabine NGS Normal Goat Serum 
ddI Didanosine NHS Normal Horse Serum 
DRG Dorsal Root Ganglion NO Nitric Oxide 
DRG's Dorsal Root Ganglia NOS Nitric Oxide Synthase 
DNA Deoxyribonucleotidyl Acid nNOS Neuronal (constitutive) Nitric Oxide Synthase 
DSP Distal Symmetrical Polyneuropathy NRTI Nucleoside-Analogue Reverse Transcriptase Inhibitor 
FITC Fluorescein Isothiocyanate NT-3 /-4 Neurotrophin-3 / -4 
GAP-43 Growth Associated Protein-43 NTF Neurotrophic Factor 
GGF Glial Growth Factor MAPK Mitogen Activated Protein Kinase 
GDNF Glial Derived Neurotrophic Factor MMP Mitochondrial Membrane Potential 
H33342 Hoechst 33342 mRNA Messenger Ribonucleotidyal Acid 
HIV Human Immunodeficiency Virus mtDNA Mitochondrial Deoxyribonucleotidyl Acid 
ICE Interleukin Converting Enzyme 
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Appendix 9 Continued (Frequently Used Abbreviations): 
Abbreviation Full Name Abbreviation Full Name 
PAMNF Pan-Axonal Marker ROS Reactive Oxygen Species 
of Neurofilament 
PBS Phosphate Buffered Saline SD Standard Deviation 
PDS Polydioxanone SOD Superoxide Dismutase 
PFA Paraformaldehyde TdT Terminal deoxyribonucleotidyl 
transferase 
PGP9.5 Protein Gene Product 9.5 TNFo: Tumour Necrosis Factor 0: 
Terminal deoxyribonucleotidyl 
PI Propidium Iodide TIJNEL transferase Uptake Nick-End 
Labelling 
PTFE polytetrafluoroethylene VIP Vasoactive Intestinal Polypeptide 
Appendix 10 (Stereological Abbreviations): 
Abbreviation Full Name Abbreviation Full Name 
a Area Ny Numerical Volume 
-
a Mean Area Npar Number of Particles 
t Thickness s Number of Sections 
-
t Mean Thickness Vdis Disector Volume 
Ndis Number of Disectors Vref Reference Volume 
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